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The lipid phosphatase PTEN is most well-known for its role in dephosphorylating PIP₃ to 
negatively regulate the Akt pathway. This pathway is important in tumour suppression, and 
has more recently been shown to be involved in synaptic plasticity. PTEN is mutated in 
various cancers and dysregulated in Alzheimer’s Disease, suggesting it may be a useful 
therapeutic target. 
 
PTEN activity is controlled by a range of post-translational modifications (PTMs) including 
SUMOylation, which has been reported to regulate the localisation, function, stability and 
coupling to the Akt pathway. 
 
The initial aim of this study was to assess if, and how, PTEN SUMOylation affects its 
reported functions. To achieve this, I optimised protocols to detect SUMOylation and 
characterise a novel “PTEN-3KR” mutant, in which all three known SUMO acceptor lysine 
residues are substituted to arginine. 
 
Unexpectedly, PTEN-3KR displayed both enhanced SUMOylation and ubiquitination. While 
surprising, this provided an interesting tool to investigate the consequences of these 
increased levels of PTEN modification. I found that PTEN-3KR is unable to supress the Akt 
pathway, but its turnover and ability to dimerize were unaffected. I also investigated how 
PTEN-3KR impacted on AMPAR trafficking and retromer function. PTEN-WT, but not PTEN- 
3KR, overexpression upregulated total protein levels of retromer components SNX27 and 
VPS26. Compared to PTEN-WT, PTEN-3KR also bound less to SNX27 and decreased 
surface expression of a prototypic retromer cargo GluT1. 
 
These results confirm the importance of SUMOylation and/or ubiquitination in the regulation 
of PTEN activity. Moreover, they demonstrate a novel role for SUMOylation of PTEN in 
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1 General Introduction 
1.1 Synaptic Plasticity 
1.1.1 Overview- PTEN, Plasticity, Post Translational Modifications and Retromer 
 
Alterations to synaptic transmission in response to activity or experience are referred to as 
synaptic plasticity (Citri and Malenka 2008; Larrabee 1947; Hughes 1958). This process is 
reliant on changes to the biophysical properties of the synapse, including alternations in the 
trafficking of neuronal receptors; this fundamental process underlies mechanisms of learning 
and memory (Collingridge et al. 2004; Beattie et al. 2000). Post translational modifications 
(PTMs) such as SUMOylation of neuronal proteins have been shown to influence plasticity 
(Jaafari et al. 2013). Phosphatase and Tensin Homolog (PTEN) is critical in plasticity (Jurado 
2017), and is reported to play a role in Alzheimer’s disease-related pathology (Knafo et al. 
2016). PTEN can also be SUMOylated and ubiquitinated (Trotman et al. 2007; Huang et al. 
2012), however, the role of PTEN SUMOylation in neurons and plasticity has not been 
assessed. Therefore, this thesis aims to further examine the role of PTEN in plasticity with a 
focus on receptor trafficking, and establish whether SUMOylation plays a role. I will also 
assess the influence of PTEN on the retromer complex, a trafficking complex which regulates 
endosome to cell surface trafficking of membrane proteins including neurotransmitter 
receptors (Vagnozzi and Pratico 2019; Temkin et al. 2017; Seaman 2007; Gallon and Cullen 
2015). It has been reported that PTEN can interrupt retromer formation and influence 
membrane protein trafficking in cell lines, but this is not well characterised (Shinde and 
Maddika 2017). The introduction of this thesis will outline the fundamental cell biology behind 
plasticity, PTEN, SUMOylation and retromer, then explain their involvement to relevant 
diseases. 
 
1.1.2 The Synapse 
 
Neurotransmitters are passed between a neuron and its neighbouring cell at a specialised 
junction called a synapse (Harris and Littleton, 2015). Chemical synaptic transmission 
involves the delivery of neurotransmitters from the pre-synapse, facilitated by calcium influx 
after an action potential (Katz and Miledi 1968, 1967b; Sudhof et al. 2012; Sheffler 2020). 
This causes neurotransmitter-containing vesicles to fuse with the membrane of the pre-
synapse and release the neurotransmitters into the synaptic cleft and detection by receptors 
at the postsynaptic membrane (Sheffler 2020; Sudhof et al. 2012) (Figure 1.1.2.1). There are 
many kinds of neurotransmitter including dopamine, serotonin, acetylcholine and glutamate 







neurotransmitter found most abundantly in the brain, and underpins various mechanisms of 
learning and memory (Zhou and Danbolt 2014; Barco et al. 2006). Approximately 80% of 
glutamate found in neurons in synthesized by an enzyme called Phosphate-Activated 
Glutaminase (PAG), which converts glutamine into glutamate by removing its amido group 
(Nadler, 2012; Schousboe et al. 2014). In astroglia, glutamate is converted back into 
glutamine by condensation of glutamate and ammonia by Glutamine Synthetase (GS) 
(Martinez-Hernandez, 1997; Shen, 2013). 
 
Figure 1.1.2.1. The Synapse. 
This schematic depicts hippocampal neurons and a chemical synapse, adapted from (Lodish 
2000; Mabb and Ehlers 2010). The diagram on the left shows two neurons, with the axon, 
soma (cell body), synapse and dendrite labelled. Dendrites form synapses with other 
neurons, enabling them to receive signals released by axons which conduct the electrical 
impulse (Lodish 2000). On the right, the diagram shows a chemical synapse. When an action 
potential causes depolarisation, calcium floods the cell, causing vesicles to fuse with the 
presynaptic membrane and exocytose neurotransmitters into the synaptic cleft, which are 
picked up by receptors at the post-synapse (Katz and Miledi 1967a; Sudhof 2012). 
Schematic created in Biorender.com, using premade neuron and synapse shapes. 
 
 
1.1.3 Glutamate Signalling 
 
Glutamate receptors are able to mediate glutamate signals in processes involved in learning 
and memory (Barco, Bailey, and Kandel 2006). Glutamate signalling provides the majority of 
fast, excitatory transmission in the brain, and is mediated by four kinds of glutamate 
receptors: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), N- 





(Hollmann and Heinemann 1994; Zhou and Danbolt 2014; Fleming and England 2010). 
AMPARS, NMDARs and Kainate receptors are known as ionotropic receptors, which are 
ligated-coupled ion channels that pick-up glutamate signals released from the pre-synapse 
(Martinez-Lozada et al. 2015; Greger et al. 2017). Changes to AMPAR receptor levels at the 







1.1.4 AMPAR Subunits 
 
AMPARs function as heteromers, with different combinations of four primary subunits GluA1- 
4 (Wenthold et al. 1992; Dingledine et al. 1999; Hollmann and Heinemann 1994) (See Figure 
1.1.5.1. for schematic of AMPAR topology). Each subunit has a different role in ion selectivity 
and trafficking properties, so the ability of AMPARs to heterodimerize leads them to have 
functional variation (Lu et al. 2009; Greger et al. 2017). For example, different combinations 
of these subunits give them different cation channel properties; the presence of the GluA2 
subunit causes Na+ permeability, AMPARs are not Na+ permeable unless they have this 
subunit (Sommer et al. 1991; Martinez-Lozada and Ortega 2015). Lu et al. (2009) found the 
dominant heteromers are GluA1 and GluA2 at CA1 synapses in the hippocampus, making 
up about 80% of the population of AMPARs. In pyramidal neurons in CA1, all surface 
AMPARs contain GluA2. Lu et al. (2009) also found cells in which GluA1, A2 and A3 are 
knocked out do not have AMPAR EPSCs at synapses, but NMDARs EPSCs are unchanged. 
In CA1, the majority of synaptic transmission is regulated by GluA1/2 heteromers; GluA2 KO 
in mice leads to a 50% loss of AMPAR mEPSCs and causes a dramatic change in 
frequency, without an effect on amplitude. Therefore, Lu et al. (2009) suggest around half of 
the synapses have no AMPAR mediated activity under GluA2 KO, and some AMPARs 
containing GluA2 are gradually replaced by AMPARs without GluA2. This suggests there are 
two populations of synapses which vary depending on whether they are able to engage 
GluA2 lacking receptors (Lu et al. 2009). Deleting GluA3 simultaneously with GluA2 had little 
extra effect, suggesting GluA3 is more dispensable for transmission (Lu et al. 2009). 
 
1.1.5 AMPAR Q/R Editing Site 
 
The majority of AMPARs in the adult brain are calcium-impermeable, due to replacement of 
Q607 with an arginine through RNA editing in the pore loop of the GluA2 subunit (Henley and 
Wilkinson 2016; Greger et al. 2003; Sommer et al. 1991) (see Figure 1.1.5.1. for schematic 
of channel conductance after AMPAR Q/R editing). This RNA editing also regulates exit from 
the endoplasmic reticulum (ER) and tetramerization; unedited subunits tetramerise and are 
trafficked to the cell surface, while subunits which have been edited to arginine localise 









Figure 1.1.5.1. AMPA Receptor Topology and Q/R Editing. 
This schematic on the left depicts an AMPAR subunit, showing its intracellular re-entrant loop 
with Q/R editing site (in GluA2 subunit), transmembrane domains and glutamate binding site. 
Schematic on the right shows three states of AMPARs in regards to calcium conductance. 
Unedited and GluA2 lacking AMPARs allow calcium to flow into the cell, those with the Q607 
site in the pore loop edited to arginine through RNA editing do not allow calcium entry 
(Henley and Wilkinson 2016; Greger et al. 2003; Sommer et al. 1991). Schematic adapted 
from Henley and Wilkinson (2016), Widagdo et al. (2017) and Wright and Vissel (2012) and 
created in biorender.com with premade shapes. 
 
1.1.6 Short Term Synaptic Plasticity 
 
The mechanism by which synapses change their properties in response to the level of 
stimulation they experience is termed synaptic plasticity (Larrabee 1947; Citri and Malenka 
2008; Hughes 1958). Broadly speaking, synaptic plasticity can refer to synaptic pruning, 
neurogenesis, or activity-Dependent changes in synaptic strength (Barco, Bailey, and 
Kandel 2006); this thesis will focus on the latter. 
The history of activation of the synapse can affect the probability/magnitude of the 
neurotransmission at the next stimulation, which is referred to as paired-pulse facilitation 
(PPF) or depression depending on the direction of the probability of release (Jackman and 
Regehr 2017; Citri and Malenka 2008; Katz and Miledi 1968). After stimulation of excitatory 
synapses, the chance of a second neurotransmission event is initially enhanced, up to a 
point at which the probability of release drops off (Citri and Malenka 2008; Katz and Miledi 
1967b, 1968). This is because the activity temporarily increases calcium in the presynapse, 
which can facilitate the next potential (Citri and Malenka 2008; Katz and Miledi 1968; 
Dobrunz and Stevens 1997). Specifically, the probability of PPF at the synapse is inversely 
related to the probability of the starting release probability and directly correlates with the 










Figure 1.1.6.1 AMPA Receptor Trafficking in Long Term Depression and Long Term 
Potentiation. 
This schematic depicts an unstimulated synapse on the left; AMPARs will be constitutively 
trafficking to and from the membrane in these conditions (Henley and Wilkinson 2013; Chen 
and Maghsoodi 2007). The central panel shows increased AMPAR endocytosis in response 
to low frequency stimulation, leading to a decrease in synaptic strength; the right-hand panel 
shows increased AMPAR trafficking to the synapse after high frequency stimulation, 
increasing synaptic strength (Citri and Malenka 2008; Beattie et al. 2000; Collingridge, Isaac, 
and Wang 2004; Fleming and England 2010; Carroll et al. 1999; Chen and Maghsoodi 2007). 
This schematic is adapted from Chen and Maghsoodi (2007), Citri and Malenka (2008), and 
OpenstaxCNX (2016) and created in biorender.com using premade shapes. 
 
 
1.1.7 Long Term Synaptic Plasticity 
 
There are two opposite processes which coordinate long-term synaptic response to different 
types of stimulation. The first is termed Long Term Potentiation (LTP), where synapse 
response probability is increased following high-frequency stimulation (Bliss and Lomo 1973; 
Ho 2011). The second is called Long Term Depression (LTD), which occurs following low 
frequency stimulation and is characterised by weakening of synaptic responses (Lynch, 
Dunwiddie, and Gribkoff 1977; Ho 2011; Dudek and Bear 1992). These processes can be 
measured by electrophysiological recordings in mouse brain hippocampal slices; synaptic 







increase or decrease after high or low stimulation (Ho 2011). LTP was first discovered in the 
rabbit hippocampus, where following stimulation, synaptic responses were potentiated for up 
to 10 hours (Bliss and Lomo 1973). 
There are two main mechanisms by which these changes in synaptic strength are created; 
changes to level of neurotransmitter release from the pre-synapse to the post synapse, and 
changes in the amount and activity of receptors which detect the neurotransmitters (Fleming 
and England 2010). Regarding changes to receptors, this is partly due to changes in AMPAR 
levels at synapses; LTD leads to removal of AMPARs and subsequent synaptic depression, 
while LTP leads to insertion of more AMPARs and therefore increased excitability (Beattie et 
al. 2000; Collingridge et al. 2004; Fleming and England 2010; Carroll et al.1999) (See Figure 
1.1.2.1.). 
 
1.1.8 NMDAR-Dependent Plasticity 
 
Synaptic plasticity is often studied in the hippocampus, an area of the brain where 
information flows in a loop (Neves et al. 2008). NMDAR-dependent LTD and LTP are most 
well characterised in the hippocampus; this area has a high level of NMDAR expression 
and is critical for spatial learning and memory (Nakazawa et al. 2004; Malenka and Bear, 
2004). AMPARs and NMDARs are colocalised at excitatory hippocampal synapses; 
approximately 70% of synapses contain both kinds of receptor (Bekkers and Stevens, 
1989). 
NMDARs and AMPARs are ligand-gated ion channels; NMDARs require both transmitter 
release and depolarisation for activation, they are calcium permeable and mediate calcium 
influx needed for LTP induction when activated (Ho, 2011). When AMPARs are activated by 
glutamate binding, there is partial depolarisation of the neuron due to sodium influx through 
AMPARs, leading to the removal of the voltage-Dependent magnesium block from co- 
localised NMDARs (Bekkers and Stevens 1989; Greger et al. 2017; Watson 2012; Luscher 
and Malenka 2012; Mayer 1984; Nowak et al. 1984; Nakazawa et al. 2004; Molnar 2019). 
This allows calcium influx through voltage gated calcium channels and NMDARs and 
increased depolarisation, leading to changes in the level of AMPARs at the membrane and 
modulation of synaptic strength (Bliss and Collingridge 1993; Watson 2012; Mayer 1984; 
Nowak et al. 1984; Greger et al. 2003; Greger et al. 2017; Hunt and Castillo 2012; Luscher 
and Malenka 2012). 
Synaptic NMDAR activation increases both AMPAR and NMDAR surface expression, but 







2009). Through this mechanism, NMDARs can regulate plasticity through regulation of 
AMPAR postsynaptic expression, this is one of the main processes underpinning learning 
and memory (Collingridge et al. 1983; Morris et al. 1986; Dudek and Bear 1992; Li et al. 
2009; Bashir et al. 1991). NMDARs are critical in LTP; since the NMDAR antagonist AP5 
blocks LTP without effecting basal synaptic transmission (Collingridge, et al. 1983). 
Specifically, AP5 application leads to selective inhibition of hippocampal-dependent place 
learning, without effecting retention of spatial information already learnt, suggesting 




Figure 1.1.8.1 NMDAR-Dependent LTP. 
When AMPARs are activated by glutamate binding, sodium ions flow into the post synapse, 
causing partial depolarisation and removal of the magnesium block from NMDARs (Watson 
2012; Mayer 1984; Nowak et al. 1984; Luscher and Malenka 2012). This causes calcium 
influx and increased depolarisation, leading to changes in the level of AMPARs at the 
membrane and modulation of synaptic strength (Bliss and Collingridge 1993; Watson 2012; 
Nakazawa et al. 2004; Molnar 2019; Luscher and Malenka 2012). Schematic adapted from 








1.1.9 AMPAR Trafficking 
 
AMPARs are subject to both constitutive and activity-dependent movement to and from 
synapses, referred to as AMPAR trafficking (Henley and Wilkinson 2013). Trafficking of 
AMPARs is important for maintaining synaptic efficacy (Shi et al. 2001). AMPAR trafficking is 
regulated by transport via molecular motor proteins such as dynein, which is a cytoskeletal 
motor protein that moves cellular cargoes around the cell (He et al. 2005; Levy and Holzbaur 
2006; Kapitein et al. 2010). For example, dynein motors drive axonal transport and move 
AMPARs into dendrites (Kapitein et al. 2010). Inactivation of dynein reduces AMPAR 
EPSCs, again suggesting the role of dynamin in AMPAR transport (Kim and Lisman 2001). 
Variation in which subunits AMPARs contain gives rise to differences in the way they are 
trafficked (Shi et al. 2001). During stimulation, GluA1 and 2 are inserted into synapses, while 
heteromers containing GluA2 and 3 are constitutively trafficked to synapses (Shi et al. 2001; 
Passafaro et al. 2001). Local trafficking to and away from the surface occurs via recycling 
endosomes and sustains AMPARs at synapses which is critical in plasticity; blocking this 
movement though endosomes inhibits LTP (Park et al. 2004). 
AMPAR trafficking is also influenced by various post-translational modifications including 
phosphorylation, palmitoylation and ubiquitination (Boehm et al. 2006; Henley and Wilkinson 
2013; Lin et al. 2009; Widagdo et al. 2015). Phosphorylation plays a key role in regulating 
AMPAR insertion and removal; for example, phosphorylation of AMPAR subunit GluA1 at 
serine 818 by Protein Kinase C (PKC) controls AMPAR insertion during LTP (Boehm et al. 
2006; Henley and Wilkinson 2013). Blocking phosphorylation at this site limits LTP and 
inhibits PKC-induced membrane insertion of GluA1 (Boehm et al. 2006) GluA1 
dephosphorylation is generally associated with endocytosis and LTD (Henley and Wilkinson 
2013). 
 
1.1.10 AMPARs, TARPs and Scaffolding Proteins 
 
Scaffolding proteins play a crucial role in synaptic transmission through tethering receptors, 
stabilising them and building signalling complexes (Elias and Nicoll 2007; Garbett and 
Bretscher 2014). Transmembrane AMPA Receptor Regulatory Proteins (TARPs) are proteins 
which associate with AMPARs and regulate their expression, anchoring at the synapse, 
conformation and activity (Carbone and Plested 2016; Chen et al. 2000; Priel et al. 2005; 
Schnell et al. 2002; Bats et al. 2007). 
Stargazin, a suggested auxiliary subunit of AMPARs (Vandenberghe et al. 2005), can 







surface (Chen et al. 2000). Stargazer mice, which do not express Stargazin, express 
AMPARs but these localise at synapses dramatically less than in Stargazin heterozygous 
mice (Chen et al. 2000; Hashimoto et al. 1999). Stargazer mice also cannot produce AMPAR 
EPSCs under basal conditions and show ataxia (Chen et al. 2000; Hashimoto et al. 1999). 
The ability for Stargazin to interact with AMPARs is critical for surface delivery of AMPARs, 
while Stargazin interactions with postsynaptic density protein of 95 kDa (PSD-95) is critical 
for AMPAR targeting to synapses (Chen et al. 2000). Rescue of Stargazin expression in 
Stargazin knockout granule cells rescues AMPAR currents; this is mediated by Stargazin 
binding to PSD-95, as expression of Stargazin mutant which lacks its amino-terminal PSD- 
95, Disc-large and ZO-1 (PDZ) binding domain does not rescue AMPAR currents (Chen et 
al. 2000). Expression of this mutant, which cannot localise at synapses in hippocampal 
neurons, also reduces hippocampal AMPAR miniature EPSCs compared to untransfected 
neurons (Chen et al. 2000). Other work has confirmed that interactions between PSD-95 and 
Stargazin regulate movement of AMPARs between synaptic and extra synaptic sites, and 
disruption this interaction destabilises AMPARs, reducing AMPAR clustering at the post- 
synapse (Bats et al. 2007). In addition to surface expression, Stargazin can also module 
AMPAR conductance (Carbone and Plested 2016). Stargazin can exist in two states: an 
inactive state during basal conditions, and an active state which increases the channel 
conductance of AMPARs, driven by AMPAR channel opening (Carbone and Plested 2016). 
Expression of a mutant of an endosomal scaffolding protein, Eps15–homology domain 
protein EHD1/Rme1 (Rme1-G429R) (known to act as dominant negative) causes slowing of 
receptor recycling from endosomes towards the plasma membrane (Park et al. 2004; Lin et 
al. 2001; Grant and Caplan 2008). When trafficking from endosomes to the plasma 
membrane was prevented by expression of this mutant, AMPARs accumulated 
intracellularly. There was a re-localisation of the total population of AMPARs from spines to 
endosomal compartments in dendritic shafts (Park et al. 2004). This mutant was also able to 
block LTP induction, evidenced by a lack of AMPAR insertion after glycine stimulation (Park 
et al. 2004). Park et al. (2004) discovered that AMPARs inserted during LTP are not newly 
synthesised, but come from a recycled pool, highlighting the importance of the endosomal 







1.1.11 Glutamate Receptor-Interacting Proteins (GRIPs) 
 
GRIPs can interact with AMPARs through their PDZ domain and are involved in AMPAR 
trafficking and clustering at synapses (Bissen et al. 2019; Dong et al. 1997). GRIP1 is an 
adaptor protein which links AMPARs to other proteins involved in transport such as E-
cadherin and motor protein kinesin superfamily (KIF) protein, promoting AMPAR transport to 
dendrites (Heisler et al. 2014; Dong et al. 1997). GRIP1 is described by Heisler et al. (2014) 
as a “multilink interface”, which is used by KIF5 to promote N- cadherin/GluA2 transport to 
dendrites, a process involved in stabilisation of excitatory synapses and dendritic spine 
structure. GRIP1 is reported to regulate both insertion and removal of AMPARs into the 
synaptic membrane (Bissen et al. 2019; Osten et al. 2000; Hirbec et al. 2003). GRIP1 binding 
to AMPARs is also negatively regulated by phosphorylation by PKC (Matsuda et al. 1999). 
These studies show that various neuronal proteins such as PSD-95, GRIP1 and Stargazin 
and their interactions with AMPARs are necessary for correct synaptic function and reflect 





1.2.1  Overview-PTEN 
Phosphatase and Tensin Homolog (PTEN), is a phosphatase with tumour suppressive 
activity, encoded by the PTEN gene (Steck et al. 1997). PTEN’s main mechanism of action is 
via its phosphatase activity in dephosphorylating the phosphoinositide phosphatidylinositol 
(3,4,5) trisphosphate (PIP₃) into phosphatidylinositol 4,5-bisphosphate (PIP₂ ) (Maehama and 
Dixon 1998) (Figure 1.2.1.1). This activity negatively regulates activation of RAC-alpha 
serine/threonine-protein kinase (Akt) (Stambolic et al. 1998; Myers et al. 1998). PTEN works 
in opposition to class I phosphatidylinositol- 3 kinase (PI3K), which phosphorylates 
phosphoinositides, increasing levels of PIP₃, which positively regulates Akt (Fruman et al. 
1998; Denley et al. 2009; Vivanco and Sawyers 2002; Cantley and Neel 1999; Georgescu 
2010). PTEN is known as a dual phosphatase, as it also has protein phosphatase activity 
which can dephosphorylate substrate proteins including Akt via direct interactions; both of 
these functions have a role in PTEN’s tumour suppression activity (Furnari et al. 1998; 
Phadngam et al. 2016; Lee et al. 1999; Gildea et al. 2004). PTEN loss/mutation is found 







and glioblastoma, and even small alternations to the level of PTEN can encourage tumour 
growth (Alimonti et al. 2010; Morani et al. 2014; Steck et al. 1997; Ali et al.1999; Li et al. 
1997). PTEN has additional important roles in neurons and plasticity; PTEN is reported to be 
essential in LTD, and is also involved in neuronal development and AMPAR trafficking (Moult 
et al. 2010; Jurado et al. 2010; Kwon et al. 2003). 
 
 
Figure 1.2.1.1. Schematic of PTEN/PI3K/AKT pathway. 
PTEN dephosphorylates PIP₃, removing a D3 phosphate, recreating PIP₂. PI3K works in the 
opposite direction by adding a phosphate (this schematic is adapted from Sansal and Sellers 
(2004) and Carnero and Paramio (2014), and based on work by Maehama and Dixon (1998); 
Fruman et al. (1998), Denley et al. (2009); Vivanco and Sawyers et al. (2002); Cantley and 
Neel (1999); Georgescu (2010). Created on BioRender.com using premade shapes. 
 
1.2.2 PTEN Signalling - Lipid Phosphatase Activity 
 
PTEN’s lipid phosphatase activity is critical in its role as a tumour suppressor; the 
dephosphorylation of PIP₃ limits activation of Akt, a major kinase which has over 100 known 
substrates including proteins involved in plasticity including Glycogen Synthase Kinase 3 
(GSK3) and BCL2 associated agonist of cell death (BAD) (Manning and Cantley 2007; Cross 
et al. 1995; Datta et al. 1997). Akt has effects on many aspects of cellular homeostasis 
including cell survival, cell metabolism and protein synthesis, as well as synaptic plasticity 
(Myers et al. 1998; Manning and Cantley 2007; Datta et al. 1997; Levenga et al. 2017; Kohn 







lowered sensitivity to apoptosis and enhanced proliferation through the Akt pathway 
(Stambolic et al. 1998). 
PIP₃ is rare and therefore very difficult to detect under unstimulated growth conditions, due to 
the necessary tight regulation of PI3K and activity of PTEN and other lipid phosphatases 
(Vivanco and Sawyers 2002). PIP₃ generation and subsequent Akt activation are strongly 
implicated in tumorigenesis (Stambolic et al. 1998; Miao et al. 2010; Denley et al. 2009), so it 
is not surprising that somatic and germline mutations in PTEN found in cancer mostly involve 
the phosphatase domain (Ali et al. 1999). 
 
1.2.3 Phosphoinositide Activation of Akt 
 
Although PIP₂ can bind Akt and partially activate it (Franke et al. 1997), PIP₃ binding has a 
stronger effect on activating Akt through allowing it to localise at the membrane, where it can 
then be phosphorylated at Thr308 by PIP₃-dependent protein kinase-1 (PDK1), in a PIP₃ 
Dependent reaction (Andjelkovic et al.1997; Stokoe et al. 1997; James et al. 1996; Alessi et 
al. 1997; Vivanco and Sawyers 2002). PIP₃ primes Akt for activation (Alessi et al. 1996; 
Andjelkovic et al. 1997). When PIP₃ binds Akt, it does not directly activate it, but causes its 
translocation from the cytosol to the membrane, and undergoes a change in conformation 
which allows PDK1 to activate it (James et al. 1996; Stokoe et al. 1997; Andjelkovic et al. 
1997; Alessi et al. 1996; Milburn et al. 2003; Vivanco and Sawyers 2002). Although this 
phosphorylation of Akt at Thr308 is sufficient and critical to activate it, further activation can 
come from additional phosphorylation at Ser473 by PDK2 (Alessi et al. 1996; Alessi et al. 
1997). Blocking PIP₃ binding to Akt using a nonphosphoinositide small molecule antagonist, 
which is able to block PIP₃–PH domain interactions (but not PIP₂ interactions), was able to 
supresses PI3K-PDK1- Akt pathway, and had downstream effects on inhibiting tumour 
growth and apoptosis (Miao et al. 2010). This shows PIP₃ binding to Akt can positively 
regulate it, and blocking this interaction can stop upstream kinases such as PDK1 from 
activating it (Miao et al. 2010). 
 
1.2.4 PTEN Signalling - Protein Phosphatase Activity 
 
Aside from lipid phosphatase activity, PTEN also has tyrosine, serine and threonine 
phosphatase ability (Myers et al. 1997). PTEN can directly dephosphorylate various 







Response Element-Binding Protein (CREB) (Tamura et al. 1998; Park et al. 2002; Gu et al. 
2011; Phadngam et al. 2016; Shinde and Maddika 2016). This protein phosphatase activity 
plays a role in tumour suppression, as well as neuronal stem cell differentiation and gene 
expression (Tibarewal et al. 2012; Lyu et al. 2015). CREB phosphorylation is also relevant in 
synaptic plasticity, fear memory and adult hippocampal neurogenesis (Ortega-Martínez 
2015; Zhou et al. 2009; Suzuki et al. 2011). Increasing CREB-mediated transcription can 
enhance short and long term memory storage via regulation of Brain-Derived Neurotrophic 
Factor (Suzuki et al. 2011). 
In an ovarian cancer cell line (OVCAR3), PTEN-WT and PTEN with intact protein 
phosphatase (but not lipid phosphatase) activity can limit Glucose Transporter 1 (GluT1) 
surface expression and glucose uptake, which has a role in cancer (Zambrano et al. 2019; 
Phadngam et al. 2016). It is suggested that this is because PTEN physically interacts with 
Akt, and through its protein phosphatase activity can directly dephosphorylate it (Phadngam 
et al. 2016). Akt activation is known to regulate GluT1 expression (Barthel et al. 1999), so it 
was concluded that through protein phosphatase activity, PTEN can reduce Akt 
phosphorylation and have a downstream effect of limiting surface GluT1 expression 
(Phadngam et al. 2016). PTEN protein phosphatase activity can also dephosphorylate and 
subsequently deactivate FAK, reducing cell invasion in glioma cells (Tamura et al. 1998; 
Park et al. 2002). Recent work has also shown phosphoglycerate kinase 1 (PGK1), is a 
PTEN protein phosphatase target; its dephosphorylation by PTEN inhibits its 
autophosphorylation and subsequently activation (Qian et al. 2019). Through this pathway, 
PTEN is able to supress glycolysis and brain tumour formation (Qian et al. 2019). 
 
1.2.5 PTEN Structure – N Terminus 
 
PTEN’s N terminus has a PIP2 binding domain which is able to bind PIP and PIP2; the 
binding of PIP2 increases PTEN’s phosphatase activity (Campbell, Liu, and Ross 2003; Liu et 
al. 2019). The N terminus is also involved in membrane anchoring; full length PTEN has a 30 
times stronger affinity for artificial plasma membrane vesicles than the C2 domain alone, 
suggesting this area is critical for membrane localisation (Liu et al. 2019; Das, Dixon, and 
Cho 2003). The N terminus also contains lysine K13, which has been shown to be 
ubiquitinated, and is involved with nuclear localisation (Trotman et al. 2007; Liu et al. 2019). 
Next to this, a cytoplasmic localisation signal is also found (amino acids 19–25), mutations of 
which can also induce nuclear import (Denning et al. 2007). Mutation of this site can also 
reduce the ability of PTEN to supress growth and regulate phosphorylation of Akt at Ser473 







1.2.6 PTEN Structure – Catalytic Domain 
 
Next to the N terminus is the catalytic domain, with a large active site which can allow access 
for PIP3 and other phosphorylated substrates; mutation of G129E in the site blocks PIP3 
access, but does not stop binding from protein substrates, meaning this PTEN “G” mutant 
has intact protein phosphatase activity, but no lipid phosphatase activity (Liu et al. 2019; 
Furnari et al. 1998). This mutation can inhibit PTEN’s growth suppression activity, thus 
increasing cell proliferation (Furnari et al. 1998). The COOH terminal region forms a 
conserved domain (C2) in the C terminal which binds phospholipids (Lee et al. 1999) and is 
partially responsible for electrostatic membrane binding (Lee et al. 1999; Shenoy, Nanda, 
and Losche 2012; Das et al. 2003). The crystal structure shows the C2 domain contains a 
CRB3 loop which has five lysines with positive charge (Lee et al. 1999); Shenoy et al. (2012) 
have shown through MD simulations that this CRB3 loop is in contact with the membrane, 
and the C-tail is repelled away. Mutations in the CBR3 and Cα2 loops alter the tumour 
suppressor and membrane anchoring function of PTEN, without effecting its stability (Lee et 
al. 2019; Rahdar et al. 2009). 
 
1.2.7 PTEN Structure – C-tail and PDZ Ligand 
 
There are also four sites in the C-tail that can be phosphorylated: S380, T382, T383, and 
S385 (Das, Dixon, and Cho 2003; Rahdar et al. 2009; Vazquez et al. 2000) and this 
phosphorylation effects stability and activity (Vazquez et al. 2000). The relevance of these 
sites will be discussed in section 1.2.9. 
At the end of PTEN then is a class I PDZ binding motif (Lee, Chen, and Pandolfi 2018). This 
sequence enables protein-protein interactions and regulates PTEN binding to proteins which 
contain a PDZ domain (Liu et al. 2019). Such proteins which can bind PTEN’s PDZ bind 
motif include PSD-95 and MAGI2 (Jurado et al. 2010; Vazquez et al. 2001). PTEN-PDZ 
interactions are important in an array of processes in the cell including stability of PTEN and 
synaptic plasticity events in neurons (Valiente et al. 2005; Jurado et al. 2010). PDZ binding 
with MAGI-2 stabilises PTEN and PDZ binding with microtubule-associated serine/threonine 
(MAST) kinases enables phosphorylation of the C terminus of PTEN by these kinases 
(Valiente et al. 2005). PTEN mutants that had an intact PDZ domain, but mutations in the C 
terminal tail had differential PDZ binding with other proteins, showing it is not the PDZ 
binding motif alone that regulates PDZ binding; specific C terminal tail regions are also 
involved in PDZ domain recognition (Valiente et al. 2005). Acetylation of Lys402 regulates 







PTEN-PDZ association with PSD-95 is essential for LTD, as it helps PTEN to anchor in the 
presynaptic terminal (Jurado et al. 2010). PTEN’s role in plasticity will be discussed in 1.2.14. 
 
1.2.8 PTEN Localisation in Cell Lines 
 
Localization of PTEN is important, as binding at the membrane is essential for its activity 
against PIP₃, and even low PTEN levels at the membrane can regulate PIP₃ levels (Nguyen 
et al. 2014; Vazquez et al. 2006). However, most PTEN is not membrane bound, it is in fact 
difficult to detect at the membrane without specialist microscopy (Nguyen et al. 2014; 
Vazquez et al. 2006). The process of PTEN membrane binding is highly dynamic, as PTEN 
only remains at the membrane for <400 ms (Vazquez et al. 2006). Because the cytosolic and 
membrane pools of PTEN change rapidly, there is no specific pool that is localised in one 
place, it is more likely that all PTEN is capable of membrane binding (Vazquez et al. 2006). 
Through molecular simulation data, it has also been shown that the mobility of nearby lipids 
is reduced in the presence of PTEN even if they don’t directly interact with it, suggesting 
PTEN is able to regulate diffusive movement of lipids (Shenoy et al. 2012). 
Phosphoinositide binding events are lower than PIP₃ turnover rate, so it is suggested that 
each time PTEN binds lipids, there are several catalytic cycles (Vazquez et al. 2006). 
As Yasui et al. (2014) note, several regions of PTEN are involved in membrane localisation 
and/or association with phospholipids including PIP2 binding motif in the N-terminus, and this 
CRB3 loop and Cα2 helix in the C2 domain (Rahdar et al. 2009; Lee et al. 1999). The C2 
domain binds phosphatidylserine in the CRB3 loop, helping to anchor at the membrane (Lee 
et al. 1999; Shenoy et al. 2012). Rahdar et al. (2009) confirmed PIP2 binding is also critical in 
membrane binding; expression of a phosphatase specific to PIP2 called inositol 
polyphosphate-5-phosphatase inhibited membrane binding. Non-specific electrostatic 
interactions at the membrane also enable membrane localisation (Das et al. 2003). 
 
1.2.9 PTEN Conformation- Open/ Closed Model 
 
PTEN has four phosphorylation sites (Ser380/ Thr382/ Thr383/ Ser385) which are close to 
each other on the C-terminal tail, and phosphorylation at these sites reduce its ability to 
localise at the plasma membrane and tapers its catalytic activity (see Figure 1.2.9.1. for 
schematic) (Das et al. 2003; Vazquez et al. 2000; Vazquez et al. 2001; Odriozola et al. 2007; 
Rahdar et al. 2009; Bolduc et al. 2013). It has been reported that phosphorylation at these 
sites causes PTEN to “switch” between an open or closed conformation (Odriozola et al. 







Bolduc et al. (2013) made a tetra-phosphorylated PTEN mutant, at the four known 
phosphorylation sites in the C-tail. When compared to the unphosphorylated, PTEN-WT, this 
phospho-mimetic PTEN has a more compact conformation where the C-tail and C2 domain 
interact with each other. This phosphorylated, “closed” PTEN has reduced catalytic activity 
and membrane affinity, while dephosphorylated PTEN is in an “open” conformation, where 
its C-tail is not interacting with the C2 domain, leaving it able to associate with the 
membrane and carry out its lipid phosphatase activity (Bolduc et al. 2013; Rahdar et al. 
2009; Das et al. 2003; Odriozola et al. 2007; Vazquez et al. 2000; Shenoy et al. 2012). 
Phospho-mimetic C-tail mutants are reported to have 80% lower affinity for membrane 
association (Das et al. 2003). Dephosphorylation triggers a conformational change, allowing 
nonspecific electrostatic interactions at the membrane; the association with the membrane is 
then strengthened by PIP2 binding to the PIP2 binding domain, and phosphoserine binding to 
the C2 domain (Das et al. 2003; Ross and Gericke 2009; Bolduc et al. 2013; Lee et al. 1999; 
Shenoy et al. 2012; Iijima et al. 2004). 
The open/closed model was confirmed and expanded by Rahdar et al. (2009) N- and C- 
terminal fragments can be co-immunoprecipitated, whether expressed together or separately 
then mixed, demonstrating an intramolecular interaction. By mutating the phosphorylation 
sites in the C-terminal so that it was non-phosphorylatable, the PTEN fragments could then 
not associate, showing phosphorylation is necessary for this binding and the “closed” 
conformation (Rahdar et al. 2009). These mutations also increased membrane localisation. 
Mutation of the catalytic pocket or CRB3 loop also reduced intramolecular interactions; this 
site is where the C-tail is thought to interact (Rahdar et al. 2009). This provides further 
evidence of the intramolecular interactions of PTEN and how phosphorylation is involved. 
Furthermore, although the C-tail is needed to stabilise PTEN, without its C-tail can bind the 
membrane more easily and is actually more active, shown by its increase ability to facilitate 
G1 arrest (Rahdar et al. 2009; Vazquez et al. 2000). This confirms the notion that the C- 
terminal can have an inhibitory effect on membrane binding, as can phosphorylation of the C- 
tail. 
There is some controversy surrounding exactly how PTEN switches conformation. As noted 
by Rahdar et al. (2009), they found an effect of mutation of charged residues K260, K263, 
K266, K267 and K269 in the CRB3 loop affected C-tail binding, while Odriozola (2007) did 
not see this effect. It is worth noting that the groups used slightly different constructs: 








Rahdar et al. (2009) essentially cut PTEN in half. Both looked at how these pieces 
then associated with each other. 
It has been reported that PTEN moves from the open to the closed conformation through a 
sequence of salt-bridge formations, where interactions move along the protein towards the 
C-terminal end; this happens extremely fast, within 100 nanoseconds (Shenoy, Nanda, and 
Losche 2012). Phosphorylated, closed PTEN is also less able to bind to PDZ-domain 
containing proteins such as MAGI-2, whereas in the “open” conformation it is more able to 
bind PDZ-domain proteins (Vazquez et al. 2001). 
Figure 1.2.9.2. PTEN Open/ Closed Model. 
When PTEN is phosphorylated at sites S380, T382, T383, and S385, it is in the closed 
conformation, with the C-tail wrapped around it, unable to bind the membrane (Das, Dixon, 
and Cho 2003; Rahdar et al. 2009; Vazquez et al. 2000; Bolduc et al. 2013). As explained by 
Ross and Gericke (2009), dephosphorylation causes its conformation to change and initially 
allows non-specific interactions at the membrane, this encourages the PIP₂ binding domain 
to bind PIP₂, and the C2 domain to bind phosphoserine, strengthening membrane 
association (Ross and Gericke 2009; Das et al. 2003; Lee et al. 1999; Iijima et al. 2004). 
This schematic from Ross and Gericke (2009) and based on work by Iijima et al. 2004; Lee 







1.2.10 PTEN Auto-Dephosphorylation 
 
Raftapolou et al. (2004) discovered PTEN uses its own protein phosphatase ability to auto- 
dephosphorylate its T383 phosphorylation site in the C terminal, which is involved in enabling 
it to open and reveal its C2 domain. This enables the C2 domain to inhibit cell migration. 
Catalytically dead PTEN is more phosphorylated at T383 than PTEN-WT, so its own 
phosphatase activity plays a role in this regulation (Raftopoulou et al. 2004). 
 
1.2.11 PTEN Orientation and Conformation 
 
To further study the conformation of PTEN and compare the membrane bound and cytosolic 
differences in the protein, Shenoy et al. (2012) used neutron reflectometry and molecular 
dynamic simulations of PTEN; this technique can be used to analyse the composition of 
membranes, and conformation and orientation of proteins at the membrane (Wacklin 2010). 
When bound to the membrane, the structure of PTEN essentially flattened against the 
membrane (Shenoy et al. 2012). The C-terminal tail is in a different shape depending on 
whether PTEN is membrane bound or in solution; while PTEN is membrane bound it forms a 
peptide coil, which is stabilised by fluctuating hydrogen bonds, and its tail is repelled away 
from the membrane electrostatically by the membrane’s acidic lipids (Shenoy et al. 2012). 
This enables PTEN to localise in the correct position at the membrane, with the lipid binding 
area towards the membrane, where phospholipids can anchor it in place (Shenoy et al. 
2012). However, in solution, the C-terminal tail is wrapped around the C2 domain, which 
causes the end of the C-tail to block the membrane binding pocket (Shenoy et al. 2012). This 
study gives some insight into how the open/closed conformations are created, and why 
PTEN is inactive in its closed, non-membrane bound state and how PTEN positions at the 
membrane. 
 
1.2.12 Summary- PTEN in Cell Lines 
 
These studies together show that PTEN is a highly dynamic protein, which is regulated by 
phosphorylation, binding of phospholipids and phosphoserine and electrostatic interactions 
(Lee et al. 1999; Vazquez et al. 2000; Redfern et al. 2008; Das et al. 2003). Its localisation, 
conformation, interactions, stability and activity depend on these events, and this has 
downstream effects on cell cycle arrest, transcription and p-Akt signalling (Vazquez et al. 
2001; Vazquez et al. 2000; Das et al. 2003; Bolduc et al. 2013; Rahdar et al. 2009). Higher 
levels of PTEN are membrane bound when cells are highly polarized after nutrient starvation, 
and membrane localisation may become asymmetrical (Vazquez et al. 2006). Therefore, the 







to allow specificity during certain physiological situations, which may have an impact on 
tumour suppressor function (Vazquez et al. 2006). The ability of groups of PTEN molecules 
to be in this essentially inactive, cytosolic state allows for PI3K signalling and PTEN activity 
to balance PIP₃ levels (Vazquez et al. 2006). 
 
1.2.13 PTEN in Neurons and Brain Development 
 
PTEN is present in the pre and post-synapse in neurons (Weston et al. 2012; Takeuchi et 
al. 2013; Jurado et al. 2010). In hippocampal neurons, PTEN and phosphorylated PTEN 
localize at separate subcellular compartments; a T366 phosphomimetic mutant of PTEN is 
restricted to submembrane regions in the cytoplasm within the dendrites and cell body and 
mostly localised to the Golgi, whereas PTEN-WT localises more with synaptic and axonal 
markers and is more diffuse (Moult et al. 2010). 
Some evidence of PTEN’s importance in the brain comes from developmental studies. 
Neurons from conditional PTEN KO mice show enhanced neuronal projections and spine 
density, as well as defective synaptic structures in the cerebellum and cortex (Fraser et al. 
2008). Myelination abnormalities were also present such as thickened axonal myelination, as 
well as weakening of synaptic transmission and plasticity in the hippocampus, compared to 
PTEN heterozygous or WT mice (Fraser et al. 2008). PTEN deletion also causes progressive 
macrocephaly in the mouse brain and increased phosphorylated Akt levels are observed 
(Kwon et al. 2003; Kwon et al. 2001). Mice with PTEN deletion also have neuronal 
hypertrophy with increased numbers of synapses, as well as ectopic dendrites in the cortex 
and hippocampus (Kwon et al. 2006). These mice displayed abnormal responses to stimuli 
and disrupted social learning and interaction. Furthermore, PTEN-deleted spines have a 
mushroom shape in comparison to spiny wild-types in granule neurons in the dentate gyrus, 
again showing a tendency towards enlargement during PTEN KO (Haws et al. 2014). These 
morphological differences are accompanied by increased Akt phosphorylation (Kwon et al. 
2003), as well as changes to downstream Akt targets such as GSK3B (Kwon et al. 2006; 
Cross et al. 1995). These studies together show that PTEN has an important role in neuronal 
development in terms of regulating growth and synaptic transmission; and modulations to 
PTEN during development can have downstream effects on mouse behaviour (Kwon et al. 
2003; Kwon et al. 2001; Fraser et al. 2008; Moult et al. 2010). 
 
1.2.14 PTEN in Synaptic Plasticity- LTD 
 
Despite being widely known for its role in tumour suppression, there is evidence that PTEN 







process by which after low frequency stimulation, synaptic responses are depressed (Lynch 
et al. 1977). It has been reported that PTEN is essential in this process (Wang et al. 2006; 
Jurado et al. 2010). When NMDA receptors are activated, PTEN is redistributed and 
recruited to the postsynaptic terminal where it binds PSD-95 (Jurado et al. 2010). When this 
mechanism is blocked in hippocampal slices using bpV(HO)pic, (a bis-peroxivanadium 
derivative and pharmacological inhibitor of PTEN), the magnitude of LTD involving AMPA 
receptors is greatly reduced in comparison to control slices, according to electrophysiological 
recordings (Jurado et al. 2010). Overexpression of a lipid and protein phosphatase-inactive 
PTEN mutant (PTEN-C124S) and a lipid phosphatase-inactive mutant which retains its 
protein phosphatase activity (PTEN-G129E) (Myers et al. 1998; Weng et al. 2001), both 
produced the same effects in blocking LTD; both mutants showed a reduction in sustained 
EPSCs up to 40 minutes after stimulation, suggesting the lipid phosphatase activity of PTEN 
is critical for its function in NMDAR-dependent, hippocampal LTD (Jurado et al. 2010). These 
manipulations of PTEN did not affect LTP, or hippocampal mGluR-dependent LTD in this 
study (Jurado et al. 2010). 
Mechanistically, PTEN associates with PSD-95 through its PDZ ligand; Jurado et al. (2010) 
suggest that this interaction is critical in LTD, as expression of a PTEN mutant, which lacks 
the PDZ-binding motif (GFP-PTEN-ΔPDZ) blocks LTD (Jurado et al. 2010). Furthermore, 
overexpression of PTEN had an effect of depressing basal AMPAR transmission, but did not 
alter LTD. Interestingly, the amount of PSD-95 actually associated with PTEN under basal 
conditions is low at around 1%, which roughly doubles after NMDAR stimulation (Jurado et 
al. 2010). Therefore, even a low level of interactions of PTEN is significant in terms of 
plasticity events. Jurado et al. (2010) propose several potential mechanisms for how the 
PSD-95-PTEN interaction regulates plasticity. It could be that this interaction allows PTEN to 
localise by the membrane at activated synapses, which would improve its catalytic activity by 
allowing access to PIP₃, which is critical in AMPAR clustering at the membrane (Arendt et al. 
2010). The group also suggest PTEN may regulate plasticity through GSK-3β, which is 
activated by PIP₃ (Cross et al. 1995) (See section 1.2.17). 
This study suggests the phosphatase activity of PTEN, as well as its PDZ interaction ability 
is critical to NMDAR-Dependent LTD, and that PTEN expression can have a dampening 
effect on transmission (Jurado et al. 2010). Wang et al. (2006) also demonstrate the critical 
role of PTEN in LTD. They report that PTEN-deficient mice display LTP, but not LTD. It is 
suggested that this is due to the role of PTEN in PI3K suppression; PI3K pharmacological 
inhibition rescues LTD in PTEN-deficient mice. This study again highlights the importance of 







1.2.15 PIP₃ and Plasticity 
 
Exactly how PTEN mechanistically regulates LTD is not clear, but due to the importance of 
its phosphatase activity (Jurado et al. 2010), it is possible that it may be through the 
regulation of PIP₃ (Arendt et al. 2010). Arendt et al. (2010) report that PIP₃ levels are 
implicated in the correct functioning of synaptic AMPARs. The exact location of AMPARs in 
the spine membrane is important, as around 15% of the spine surface area is considered 
the postsynaptic density (PSD), where neurotransmission occurs (Harris, Jensen, and Tsao 
1992). 
PIP₃ affects AMPAR distribution; depletion of PIP₃ causes an increase in the proportion of 
AMPARs that can cycle between the dendrite and spine (Arendt et al. 2010). This is because 
PIP₃ is necessary for PSD-95 localisation in spines; as PSD-95 is essential for AMPAR 
targeting to synapses, PIP₃ depletion causes AMPARs to detach from the PSD, and move 
away from this area, causing synaptic depression (Arendt et al. 2010; Chen et al. 2000). 
Inhibition of PIP₃ in neurons by quenching with Pleckstrin Homology domain from General 
Receptor for Phosphoinositides (PH-GRP1), which binds with PIP₃ with high affinity, causes 
depression of AMPAR-mediated EPSCs without effecting NMDAR EPSCs (Arendt et al. 
2010; Corbin, Dirkx, and Falke 2004). The effect was then reversed when PIP₃ levels were 
restored by expression of a constitutively active PI3K. 
Post-embedding immunogold electron microscopy was used in this study to establish 
precisely where AMPARs were localised (Arendt et al. 2010). It was reported that PIP₃ limits 
AMPAR surface expression; AMPARs localise to spines and accumulate at the plasma 
membrane during PIP₃ depletion (Arendt et al. 2010). In slices, PIP₃ synthesis inhibition with 
LY294002 caused GluA2 to localise in the extra-synaptic membrane next to the PSD, but 
GluA2 in the PSD was decreased (Arendt et al. 2010). Thus, PIP₃ levels control movement of 
AMPARs between the PSD and extra-synaptic compartment. Arendt et al. (2010) conclude 
that PIP₃ reduction causes local translocation of AMPARs in the spine surface, which leads 
to increased extra-synaptic AMPAR accumulation, and reduction of AMPARs at the synaptic 
membrane, which is congruent with depression of AMPAR-mediated transmission caused by 
PI3K inhibitor LY294002 or PH-GRP1 expression. 
Mechanistically, PIP₃ may regulate the PSD-95 synaptic complex, which is critical for 
AMPAR clustering at the membrane (Arendt et al. 2010; Jurado 2017; Elias and Nicoll 2007; 
Bats et al. 2007). PIP₃ quenching through PH-GRP1 expression significantly decreased 
PSD-95 accumulation in spines (Arendt et al. 2010). Therefore, PIP₃ Dependent interactions 







PSD-95 to anchor AMPARs at synapses, reducing clustering at the membrane (Arendt et 
al. 2010; Elias and Nicoll 2007; Bats et al. 2007). 
This supports Jurado et al. (2010) who reported that suppression of PIP₃ levels via PTEN 
overexpression can reduce AMPAR synaptic responses, which they suggest may be due to 
reduced AMPAR clustering at the membrane. It is surprising that PTEN phosphatase 
inhibition can block LTD; (Jurado et al. (2010) give two potential explanations for this. They 
suggest that either overexpressed PTEN may act on a separate population of AMPARs from 
the group that are removed during LTD, or, synaptic depression induced by PTEN 
overexpression is not sufficient to saturate LTD expression (Jurado et al. 2010). 
In support of Arendt et al. (2010), other work has demonstrated the involvement of PIP₃ and 
kinases in the PIP₃ pathway in AMPAR regulation; PI3K inhibition can reduce AMPAR 
membrane insertion and block LTP (Man et al. 2003; Jurado 2017). PIP₃ depletion could 
influence plasticity through inhibition of GSK3β (see 1.2.17) (Peineau et al. 2007; Jurado 
2017; Cross et al. 1995). Additionally, PIP₃ may regulate AMPAR trafficking by driving 
AMPAR phosphorylation (Qin et al. 2005). GluA1 phosphorylation at S831 can occur via 
Ras–Pi3K–Akt pathway signalling, which drives its insertion into synapses (Qin et al. 2005). 
PIP₃ levels can also regulate the localisation of a variety of PIP₃-sensing proteins involved in 
AMPAR localisation including Sorting Nexin 27 (SNX27), Pleckstrin Homology Like Domain 
Family B Member 2 (PHLDB2) (McMillan et al. 2020; Cai et al. 2011; Hussain et al. 2014; 
Levi et al. 1993; Xie et al. 2019) (See General Discussion). 
 
1.2.16 Evidence of PTEN Influence in Plasticity through PIP₃ Regulation 
 
Following their work on PIP₃, Arendt et al. (2014) directly showed that PTEN counteracts 
PIP₃ signalling and shifts plasticity events towards depression. Under basal conditions, PIP₃ 
is being rapidly turned over in spines. NMDAR-Dependent LTP and LTD both upregulate 
PIP₃ levels, and during LTP, Akt phosphorylation at S473 and T308 was also increased 
(Arendt et al. 2014). PTEN is able to counteract PIP₃ increase during LTD, blocking the net 
change in PIP₃ (Arendt et al. 2014). Pharmacological inhibition of PTEN with bpV(HOpic) 
during LTD induction enhances PIP₃ levels in spines and the dendritic shaft compared to 
baseline (in addition to the initial increase seen after PTEN inhibition) (Arendt et al. 2014). In 
contrast, PTEN inhibition does not alter changes in PIP₃ levels seen after LTP. PTEN 
therefore functions as switch during plasticity which determines effects of PIP₃ upregulation, 
with a preference for LTD (Arendt et al. 2014). This study confirms the involvement of PTEN 







towards synaptic depression, an effect seen in other studies (Jurado et al. 2010; Knafo et al. 
2016). 
 
1.2.17 Plasticity Regulation through PTEN and GSK-3β 
 
GSK-3β has a critical role in plasticity; conditional KO in mice leads to synaptic transmission 
defects, reduced NMDAR and AMPAR subunit and PSD-95 levels and impaired fear memory 
(Liu et al. 2018). Jurado et al. (2017) postulate that PTEN may enable LTD through its action 
of positively regulating GSK-3β. GSK-3β is reported to be activated during LTD; this 
activation is critical for LTD as GSK-3β inhibition blocks LTD (Peineau et al. 2007). GSK-3β 
is negatively regulated by AKT (Cross et al. 1995). Therefore, by reducing PIP₃ levels and 
subsequent Akt activation via its lipid phosphatase action (Maehama and Dixon 1998), PTEN 
can enhance GSK-3β activation (Sharma et al. 2002). This has been demonstrated in 
neurons; PTEN degradation is associated with increased GSK-3β phosphorylation (Kwak et 
al. 2010). It is suggested that during LTD, the translocation of PTEN to synapses has 
downstream effects through the PIP₃ pathway, with a result of activating GSK-3β at 
necessary synapses (Arendt et al. 2014; Jurado et al. 2010; Peineau et al. 2007). 
 
1.2.18 PTEN in Synaptic Plasticity- LTP 
 
While Jurado et al. (2010) have shown that PTEN is not a critical component in LTP, other 
groups have published contradictory results. Takeuchi et al. (2013) used theta burst-induced 
(TBS)-LTP a protocol of stimulation patterns involving short, high frequency bursts which can 
induce LTP in hippocampal neurons (Capocchi, Zampolini, and Larson 1992), to test the 
effect of PTEN KO on plasticity. The group found that in PTEN KO mice, TBS-LTP was 
dysregulated, this was in an age Dependent manner; TBS-LTP was increased in young KO 
mice and significant impairment was seen only when mice were middle-aged. In these 
middle-aged mice, synaptic transmission under basal conditions in dentate granule cells was 
enhanced (Takeuchi et al. 2013). There were also deficits in hippocampal-Dependent 
cognitive/social behaviour. As plasticity deficits are present at an earlier stage than 
morphological defects, it was suggested that PTEN KO effects on plasticity are not purely 
due to morphological defects (Takeuchi et al. 2013). Therefore, PTEN seems to have 
different roles/ relevance in different kinds of plasticity, possibly due to differences in 
methodology between studies (KO vs pharmacological inhibition and expression of PTEN 
mutants). PTEN has also been shown to robustly rescue synaptic deficits in Alzheimer’s 







1.2.19 PTEN and AMPAR trafficking 
 
In addition to the mechanism discussed above, PTEN has been shown to regulate AMPAR 
trafficking via leptin, a hormone released from fat cells shown to be involved in NMDAR- 
dependent plasticity (Moult et al. 2010; Shanley, Irving, and Harvey 2001). Leptin has an 
inhibitory effect on PTEN though increasing its phosphorylation, and is also able to increase 
GluA1 surface expression in hippocampal neurons. This process also correlated with PIP₃ 
increase, and requires NMDAR activation (Moult et al. 2010). It was also shown that 
pharmacological PTEN inhibition with bisperoxovanadium (bpV) showed similar effects to 
those of leptin; GluA1 trafficking as well as excitatory synaptic strength were enhanced 
(Moult et al. 2010). When two dominant negative, catalytically dead forms of PTEN were 
expressed (G129E or C124S), basal mEPSCs amplitudes were increased and leptin 
application failed to produce further increases in EPSC’s, further suggesting that a lack of 
PTEN activity influences basal EPSCs, and it is the phosphatase activity of PTEN that 
underlies this (Moult et al. 2010). This study suggests that inhibition of PTEN via leptin can 
enhance synaptic function in the hippocampus and influence AMPAR trafficking (Moult et al. 
2010). 
In summary, PTEN is an important regulator of PIP₃ in the context of plasticity, possibly 
through effects of PIP₃ on AMPAR trafficking and stability at the synapse, or through 
downstream effects on kinases such as GSK-3β (Arendt et al. 2010; Arendt et al. 2014; 
Jurado et al. 2010; Jurado 2017). The localisation of PTEN is relevant in this system, as 
PTEN is recruited to the post synaptic terminal during NMDA receptor stimulation, blocking 
its binding to PSD-95 reduces AMPAR mediated synaptic transmission (Jurado et al. 2010). 
 
 
1.3 Post Translational Modifications 
1.3.1 PTEN, Post Translational Modifications and Plasticity 
 
PTEN can be modified by various Post Translational Modifications (PTMs) including 
SUMOylation, ubiquitination, phosphorylation and S-nitrosylation (Huang et al. 2012; 
Trotman et al. 2007; Kwak et al. 2010; Vazquez et al. 2000). Due to the relevance of both 
SUMOylation and ubiquitination in synaptic plasticity, and a role for PTEN (Jurado et al. 
2010; Jaafari et al. 2013) this thesis aims to explore how these PTMs regulate PTEN and the 
relevance of this in plasticity, with a focus on protein trafficking (see Aims Section 2.). This is 
of interest given the evidence that S-nitrosylation and ubiquitination of PTEN have a role in 







(Knafo et al. 2016; Kwak et al. 2010), PTMs relevant to PTEN and how they influence PTEN 




SUMOylation is the post-translational modification process whereby Small Ubiquitin-like 
Modifier (SUMO) protein is conjugated to a substrate (Matunis et al. 1996; Wilkinson and 
Henley 2010). SUMO can form covalent, reversible associations with substrate proteins, 
which can have a wide range of effects on cellular processes including inducing nuclear 
import of substrates, transcription, tumour necrosis factor-induced cell death and 
modulation of ubiquitin- mediated degradation (Shen et al. 1996; Matunis et al. 1996; Wang 
et al. 2014; Yang and Sharrocks 2004; Okura et al. 1996; Henley et al. 2020). SUMO was 
first identified in the 1990’s and is critical for the function of eukaryotic cells (Wilkinson and 
Henley 2010; Shen et al. 1996; Matunis et al. 1996). SUMOylation is also important in 
many aspects of neuronal regulation (Henley et al. 2020). 
Ran-GTPase-activating protein 1 (RanGAP1), a nucleotide guanosine triphosphate 
(GTP)ase which is involved in nuclear pore complex transport processes, was the first 
protein shown to be covalently modified by SUMO1 (Wilkinson and Henley 2010; Matunis, 
et al. 1996). It was shown that SUMOylation was able to influence target protein 
localisation: unmodified RanGAP1 localised in the cytoplasm, whereas SUMOylated 
RanGAP1 was enriched in the cytoplasmic fibres of the nuclear pore complex (Matunis et 
al. 1996; Mahajan et al. 1997). SUMO shares 18% of its sequence with ubiquitin, but differs 
in that it is not generally associated with subsequent degradation of substrates (Matunis et 
al. 1996; Matunis and Guzzo 2012; Gill 2004). 
 
1.3.3 The SUMOylation Cycle 
 
Before conjugation, the translated SUMO precursor must first be cleaved by SUMO specific 
proteases (SENPs), which reveals its carboxy-terminal Gly-Gly motif, enables adenylation by 
an E1 enzyme, enabling the formation of a E1SUMO thioester (Gareau and Lima 2010; 
Liebelt and Vertegaal 2016; Wilkinson and Henley 2010). SUMO is activated in an ATP- 
Dependent reaction, attaching it to the E1 enzyme, which is a heterodimer of SUMO- 
activating enzyme subunit 1 (SAE1) and SAE2; it is then transferred to an E2 enzyme 
(Ubc9), which enables conjugation to substrates by identifying SUMO consensus motifs 
(Desterro et al. 1999; Gong et al. 1999; Wilkinson and Henley 2010; Schwarz et al. 1998; 







and the substrate (Gupta et al. 2014). Around 75% of SUMO substrates contain consensus 
sequence “ψKX(D/E)”, where ψ is a hydrophobic residue, which can directly interact with 
Ubc9 (Gareau and Lima 2010; Xu et al. 2008; Gong et al. 1997; Sampson et al. 2001; 
Rodriguez, Dargemont, and Hay 2001). The ability of a substrate to interact with Ubc9 
correlates with SUMOylation (Sampson et al. 2001). Ubc9 interactions with SUMO are 
much stronger than with ubiquitin (Gong et al. 1997). 
E3 ligases, while not always essential for SUMOylation, can facilitate SUMO binding to 
substrates through assembling a complex consisting of an E2SUMO thioester with a 
substrate, or strengthening Ubc9 interactions with target proteins (Gareau and Lima 2010; 
Liebelt and Vertegaal 2016; Desterro et al. 1999). An example of an E3 ligase is Ran-binding 
protein 2 (RanBP2) which binds SUMO and Ubc9, and increases nuclear antigen SP100 
SUMOylation (Pichler et al. 2002). In neurons, an E3 ligase called protein inhibitor of 
activated STAT (signal transducer and activator of transcription), PIASx, increases 
SUMOylation of transcription factor myocyte enhancer factor 2A (MEF2A) (Shalizi et al. 
2007; Shalizi et al. 2006). Overexpression of PIASx enhances dendrite differentiation in the 
rat brain in vivo, which is suggested to be via increasing MEF2A SUMOylation (Shalizi et al. 
2007). PIASx is therefore important for neuronal development and may be involved in 
neuronal connectivity (Shalizi et al. 2007). 
SUMO can also bind non-covalently to substrates via SUMO-interacting motifs (SIMs), which 
are sites which vary in sequences, but often contain a hydrophobic core and aspartic flanking 









Figure 1.3.3.1. The SUMO cycle in mammals. 
First, SUMO is cleaved by SENP, exposing its Gly-Gly motif, then activated in an ATP 
Dependent reaction, attaching it to the E1 activating enzyme (SAE1/2) (Guo and Henley 
2014; Gareau and Lima 2010; Liebelt and Vertegaal 2016; Wilkinson and Henley 2010; 
Desterro et al. 1999; Gong et al. 1999). SUMO is then transferred to the E2 conjugating 
enzyme (Ubc9), which catalyses its conjugation to target proteins, in a reaction that is often 
facilitated by an E3 ligase (Gong et al. 1997; Gong et al. 1999; Wilkinson and Henley 2010; 
Schwarz et al. 1998; Gareau and Lima 2010). Finally, SENP can deconjugate SUMO from 
the target protein (Hickey, Wilson, and Hochstrasser 2012). This schematic is adapted from 
CytoskeletonNews, Xu et al. (2014), Meulmeester and Melchior (2008) and Chanda et al. 
(2018), and based on work by Desterro et al. (1999); Gong et al. (1999); Schwarz et al. 
(1998) and Sampson et al. (2001). 
 
 
1.3.4 SUMO Paralogues and Chain Formation 
 
One or more SUMO precursor proteins are found in all eukaryotes tested so far (Flotho and 
Melchior 2013). There are five paralogues of SUMO in mammals: SUMO1-5. SUMO2 is 
expressed in most tissues and ~46% identical to SUMO1 (Kamitani et al. 1998; Henley et al. 
2020). SUMO 2 and 3 share the same sequence except for three N-terminal residues, so for 
simplicity, SUMO2 and SUMO3 with therefore be referred to as SUMO2/3 (Wilkinson and 
Henley 2010). Many target proteins can be SUMOylated by either isoform, while some are 







residue which blocks its maturation and therefore cannot SUMOylate target proteins, but may 
be able to form non-covalent interactions (Owerbach et al. 2005). 
An important quality of SUMO its ability to form chains, SUMO 2 and 3 contain an internal 
SUMOylatable lysine, meaning they can form chains through isopeptide bonds between this 
lysine on one molecule and the glycine residue on the C-terminal of another molecule 
(Vertegaal 2010; Xu, Plechanovova, et al. 2014; Tatham et al. 2001). SUMO1 lacks this site 
so it cannot form chains; it can however attach to SUMO 2/3 chains and act as a chain 
terminator (Vertegaal 2010; Matic et al. 2008; Tatham et al. 2001). SUMO 2 and 3 can also 




SUMOylation of substrates can be reversed by the same enzymes which cleave precursor 
SUMO, causing its maturation (Guo and Henley 2014; Wilkinson and Henley 2010). These 
enzymes are called SENPs, and can also cleave the isopeptide bond between the substrate 
and glycine of the attached SUMO, removing it from the substrate (Hickey, Wilson, and 
Hochstrasser 2012). SENPs fit into three categories as explained by Yeh (2009). The first 
contains SENP1 and 2, which are specific to mono-SUMO1, 2 and 3 (Guo and Henley 2014; 
Zhang, Saitoh, and Matunis 2002; Gong and Yeh 2006; Yeh 2009). 
The next category includes SENP3 and 5, which preferential deSUMOylate mono-SUMO2/3, 
and to a lesser extent, SUMO1 (Guo and Henley 2014; Gong and Yeh 2006; Yeh 2009). 
SENP6 and 7 are in the final category and also prefer SUMO2/3; they preferentially 
deSUMOylate chains and have limited ability to cleave precursor SUMO (Guo and Henley 
2014; Bekes et al. 2011; Mukhopadhyay et al. 2006; Yeh 2009). SENP cleavage of SUMO is 
reported to be rapid and stochastic, and blocking deSUMOylation results in slow growth and 
sensitizes cells to replication stress (Bekes et al. 2011). 
 
1.3.6 Roles of SUMOylation in Non-Neuronal Cells 
 
SUMO target proteins seem to be involved in nearly all aspects of cellular homeostasis and 
can be found widely in the cell, including on cell surface and mitochondrial proteins (Flotho 
and Melchior 2013; Zitti et al. 2017; Paasch et al. 2018). SUMOylation of substrates can 
have diverse effects, including modulation of DNA repair, antiviral response and ubiquitin- 
mediated degradation (González-Santamaría et al. 2012; Maccario et al. 2010; Huang et al. 







SUMOylation has also been shown to be critical in development; when SUMOylation is 
totally inhibited via KO of Ubc9 in mice, they die before E7.5 (Nacerddine et al. 2005). Cells 
deficient in Ubc9 also have severe deficits in nuclear organisation (Nacerddine et al. 2005). 
Specifically, SUMO1 absence is associated with cleft-pallet phenotype, although it is not 
essential for survival (Alkuraya et al. 2006), however, SUMO2 KO mice were not viable and 
died at E10.5 (Wang et al. 2014). SUMOylation also plays a role in ocular lens cell 
differentiation; SUMO1 binding to the transcription factor specificity protein 1 (Sp1) positively 
regulated it, increasing expression of β-crystallins (a marker of lens cell differentiation (Gong 
et al. 2014; Piatigorsky 1981). SUMO1 was present in complexes with Sp1 at both early and 
late developmental stages of mouse lens development (Gong et al. 2014). 
 
SUMOylation is strongly implicated in the recruitment of proteasomal proteins to 
promyelocytic leukaemia nuclear bodies (PML-NBs); increasing accumulation of 
SUMOylated protein by using the proteasome inhibitor MG132 application induced 20S 
proteasome subunit translocation from the cytoplasm to the nucleus, where it showed higher 
levels of co-localisation with PMLs (Lamoliatte et al. 2017). Mutation of the SIM site in PML 
blocked this recruitment (Lamoliatte et al. 2017). Various proteins involved in SUMO 
regulation are also SUMOylated including Ubc9 and SAE1, as well as ubiquitin E3 ligases 
such as WWP2 (Lamoliatte et al. 2017; Bawa-Khalfe et al. 2017). 
 
1.3.7 The SUMO Enigma 
 
The SUMO system is highly dynamic; SUMO is continuously conjugated and deconjugated 
from substrates (Bekes et al. 2011), Due to the fact that generally there are low levels of 
SUMOylation of most substrates under basal conditions, but SUMOylation effects seem to 
persist after deconjugation (Wilkinson and Henley 2010), Hay (2005) suggests SUMOylation 
of a protein may have effects even after the SUMO has been deconjugated. This is referred 
to as the “SUMO enigma” (Hay 2005). For example, as explained by Henley and Wilkinson 
(2010), SUMOylation of kainite receptor subunit 6 (GluR6), induces its plasma membrane 
endocytosis (Martin et al. 2007). However, despite only a small fraction of GluR6 being 
SUMOylated under basal conditions, once endocytosed the subunit can be deSUMOylated 
and remain internalised – thus the effects of SUMOylation persist after its removal (Martin et 
al. 2007; Wilkinson and Henley 2010). This means that a previously SUMOylated protein 
may have a different localisation than a protein which has never been SUMOylated (Hay 









Ubiquitin can covalently conjugate substrates and act as a signal for internalisation, 
proteasomal degradation or recruitment of other proteins, depending on which sites are 
ubiquitinated (Ciehanover, Hod, and Hershko 1978; Ciechanover et al. 1982; Varshavsky 
2006; Komander 2009). There are three stages to ubiquitin conjugation. The first is carried 
out by an E1 enzyme which attaches to and activates ubiquitin, next the E1 ligase covalently 
links ubiquitin to an E2 ligase, then finally an E3 enzyme interacts with the E2 and substrate 
and is able to transfer ubiquitin to the substrate (Stewart et al. 2016; Suresh et al. 2016; 
Pickart and Eddins 2004). However, in some cases, E3 ligases can directly form a thioester 
with ubiquitin and transfer it to the substrate, without the need for an E2 ligase; one such E3 
ligase is Homologous to E6AP C-Terminus (HECT) (Weber et al. 2019). HECT contains a 
catalytic cystine residue that can conjugate to ubiquitin (Weber et al. 2019). There are 
approximately 40 E2 enzymes in humans, but around 600–700 E3 ligases (Stewart et al. 
2016; George et al. 2018). 
Ubiquitin can conjugate to substrates in three formations: monoubiquitination, where one 
ubiquitin molecule binds a substrate, multi-monoubiquitination, where several molecules 
conjugate to a substrate at different sites, or polyubiquitination, where ubiquitin self- 
ubiquitinates on a substrate, forming chains (Komander 2009) (Figure 1.3.8.1.). Ubiquitin 
contains seven lysines which can accept ubiquitin which enable it to form chains (Komander 
2009). Generally speaking, monoubiquitination of cell surface proteins leads to internalisation 
and lysosomal degradation or recycling, while polyubiquitin chains at Lys48 lead to 
proteasomal degradation (Kawadler and Yang 2006; Hershko and Ciechanover 1998; 
Haglund et al. 2003; Hicke and Riezman 1996; Komander 2009). Polyubiquitination at lys63 
can induce signal cascade activation (Kawadler and Yang 2006). Alternatively, substrates 
can have their ubiquitin removed by deubiquitinating enzymes (DUBs), which deconjugate 
ubiquitin, which is then recycled through the ubiquitin-proteasome system (Suresh et al. 
2016). Ubiquitin can form also mixed chains with SUMO (Nie and Boddy 2016), discussed 









Figure 1.3.8.2. Ubiquitination Formations. 
Ubiquitin can attach to target proteins in three formations; monoubiquitination, multi- 
monoubiquitination or polyubiquitination (Komander 2009). SUMO2/3 and ubiquitin can also 
form mixed chains on target proteins (Nie and Boddy 2016; Guzzo et al. 2012). This 
schematic is adapted from Sadowski and Sarcevic (2010) and Swatek and Komander (2016) 




1.3.9 Ubiquitination in Neurons and Plasticity 
 
Ubiquitination has also been reported to be relevant in plasticity, including through regulation 
of AMPARs and AMPAR scaffolding proteins (Widagdo et al. 2015; Mabb and Ehlers 2010; 
Colledge et al. 2003). PSD-95 is ubiquitinated by E3 ubiquitin ligase Mouse Double Minute 2 
Homolog (MDM2) (Colledge et al. 2003). This is triggered by NMDAR activation, and leads to 
PSD-95 degradation through the proteasome. By blocking PSD-95 ubiquitination through 
mutations of its PEST sequence, or treatment with proteasomal inhibitor MG132, NMDAR- 
induced AMPAR endocytosis is inhibited. LTD is also blocked by another proteasomal 
inhibitor Lactacystin, and significantly attenuated by MG132 (Colledge et al. 2003). This 
study highlights the role of ubiquitination in mediating PSD-95 regulation of AMPARs at 
synapses; PSD-95 ubiquitination via MDM2 is essential in regulation of AMPAR surface 
expression during plasticity (Colledge et al. 2003). 
Lee et al. (2008) used contextual memory retrieval which involves conditioning mice with a 







proteins. After contextual memory retrieval, two PSD proteins, guanylate kinase associated 
protein (GKAP) and Shank are polyubiquitinated, and Shank is subsequently degraded (Lee 
et al. 2008). Mice fear-memory deficits caused by protein synthesis inhibitor anisomycin were 
rescued by proteasomal inhibition with clasto-lactacystin-β-lactone (βlac) in CA1 after 
retrieval. βlac also blocked the degradation of Shank after memory retrieval, keeping it up to 
basal levels. It was concluded that ubiquitin-Dependent degradation is part of the mechanism 
by which synapses are reorganised through protein degradation and synthesis in memory 
retrieval, and protein synthesis can rescue retrieval-induced degradation (Lee et al. 2008). 
Ubiquitination is therefore highly relevant to plasticity, through regulation of AMPAR 
endocytosis and synaptic reorganisation through protein degradation (Colledge et al. 2003; 
Lee et al. 2008). 
 
1.3.10 SUMO and Ubiquitin Cross-regulation 
 
There is a high level of overlap between proteins that are SUMOylated and ubiquitinated; 
many proteins are modified by both PTMs (Lamoliatte et al. 2017). SUMO and ubiquitin can 
also combine signals via a SUMO-targeted ubiquitin ligase (STUbL), which are ubiquitin E3 
ligases which contains a SIM sites that allow it to bind SUMO chains and ubiquitinate them, 
forming mixed chains (Nie and Boddy 2016). An example is RING Finger Protein 4 (RNF4), 
which can tag SUMOylated proteins with ubiquitin (Nie and Boddy 2016; Xu, Plechanovova, 
et al. 2014). These mixed chains are recognised by proteins which have a SIM and ubiquitin 
interacting motif (UIM), which can have a range of effects including degradation, or 
recognition by proteins involved in DNA repair (Nie and Boddy 2016; Xu, Plechanovova, et 
al. 2014; Guzzo et al. 2012). The capping of chains by SUMO1 can increase binding to 
RNF4 (Xu, Plechanovova, et al. 2014). 
 
1.3.11 Neuronal SUMOylation and Ubiquitination and Effects on Plasticity 
 
SUMOylation of neuronal proteins can be increased by AMPA and potassium chloride 
stimulation (Feligioni et al. 2009). Increasing SUMOylation in the synapse is able to reduce 
potassium chloride-induced glutamate release, and reducing SUMOylation has the opposite 
effect (Feligioni et al. 2009). SENP1 increased potassium chloride-induced calcium influx 
and glutamate release. Interestingly, these effects were reversed when release was evoked 
with Kainate. It was concluded that SUMOylation of neuronal proteins can regulate 







At the post synapse, AMPARs are modulated by several kinds of PTMs including 
ubiquitination, phosphorylation and glycosylation (Diering and Huganir 2018; Widagdo et al. 
2015). GluA1 and 2 are ubiquitinated near the end of their C-terminus when activated by 
AMPA, and this is critical for their ligand-induced degradation (Widagdo et al. 2015). This 
ubiquitination is necessary for AMPAR trafficking to late endosomes, where they undergo 
lysosomal degradation (Widagdo et al. 2015). Mutation of AMPAR ubiquitination sites 
(Lys868 in GluA1 and Lys870 or Lys882 in GluA2), reduced retrograde trafficking of the 
subunits to late endosomes and subsequently their degradation, without affecting surface 
levels (Widagdo et al. 2015). 
Although AMPARs are not directly SUMOylated, their trafficking is regulated by global 
SUMOylation in neurons (Jaafari et al. 2013). This is required for insertion of GluA1 at the 
surface after glycine-induced LTP. This method of LTP induction also increases SUMO1 and 
Ubc9 mRNA in dendrites, as well as colocalization between SUMO1 and Ubc9 and PSD-95. 
SENP1 overexpression or dominant negative Ubc9 expression is able to inhibit LTP, shown 
by lack of increases in AMPAR surface expression, as well as lack of dendritic SUMO1 
mRNA increase (Jaafari et al. 2013). It was shown that SUMO1 mRNA increases in spines 
are likely due to SUMO1 translocation, as mRNA binding protein: Cytoplasmic 
polyadenylation element binding protein (CPEB), was also increased after ChemLTP. This 
study suggests SUMOylation is critical for plasticity-mediated increases in AMPAR surface 
expression (Jaafari et al. 2013). 
 
1.3.12 PTEN SUMOylation 
 
SUMOylation of PTEN was first identified at two sites: K266 and K254 by Huang et al. 
(2012), who reported that K266R, K254R and K266R/K254R double PTEN point mutants are 
less SUMOylated than PTEN-WT in immunoprecipitation experiments. (See Figure 1.3.12.1. 
for schematic of PTEN SUMO sites). SUMOylation at K289 was also later discovered; in 
HEK cells, K266A mutation, and double mutation K266A/K289A either greatly reduced or 
almost abolished His-SUMO1 conjugation respectively compared to WT, and K266A and or 
K266A/K289A showed a similar effect for His-SUMO2 on greatly reducing conjugation 
(González-Santamaría et al. 2012). In that study, PTEN SUMOylation was examined in in 
vitro SUMOylation assays, where purified proteins are mixed together in a tube and 
immunoprecipitated. Wang et al. (2014) showed double mutant K266R/K254R had totally 
inhibited SUMOylation capacity, and single mutants were partially SUMOylated in vitro by 
SUMO1. They did not see a band shift between single and double mutants, which they 





at the other site. Huang et al. also saw this lack of band shift. Other than K254, K266 and 
K289 discussed, no other sites on PTEN have been proven to be SUMOylated, although 
SUMO Interacting Motif (SIM) sites have been found and non-covalent interactions between 
PTEN and SUMO1 are reported (Bawa-Khalfe et al. 2017). Bassi et al. (2013) report the 
dominant site to be K254, and (Wang et al. 2014) and Huang et al. (2012) showed double 
mutant K266R/K254R entirely blocks SUMOylation, however Gonzales-Santamaria et al. 
(2012) showed combined K266A/K289A mutation greatly reduced SUMOylation, so the 
dominant site cannot be unequivocally concluded. 
 
Figure 1.3.12.1. PTEN Predicted and Identified SUMO Sites. This schematic shows 
identified SUMO sites on PTEN in green (Huang et al. 2012; González-Santamaría et al. 
2012). Predicted SUMO sites, according to SUMOplot software, are shown in yellow and red 
(sites with scores below 0.5 are omitted) (Abcepta, 2021). Created in Biorender.com using 
premade shapes. 
An important point to note is that all studies except one on PTEN SUMOylation have tested 
the SUMOylation level of PTEN mutants using tagged, recombinant SUMO overexpression. 
An issue is that tagged proteins can behave differently to their endogenous counterparts 
(Skube et al. 2010), and overexpression of recombinant SUMO has been suggested to lead 
to artefacts if it is not controlled (Eifler and Vertegaal 2015). This will be discussed further in 
the general discussion. The only paper to test endogenous SUMO in cells did so by using 
SENP knockout cell lines (Bawa-Khalfe et al. 2017), which can confound results as it also 
causes changes to the global SUMOylation system. Therefore, although it is likely PTEN is 
SUMOylated, research in this area is still in the early stages and is perhaps confounded by 
overexpression and changes to global SUMOylation, especially taken with the lack of 
agreement in terms of which is the main SUMO site and how PTEN influences location, 






1.3.13 Functional and Localisation Effects of PTEN SUMOylation - K254 Site 
 
SUMOylation of PTEN has been found to have a range of effects on PTEN including effects 
on localisation, ubiquitination, antiviral response, DNA repair, ability to limit Akt pathway and 
tumorigenesis (González-Santamaría et al. 2012; Maccario et al. 2010; Bassi et al. 2013; 
Huang et al. 2012; Bawa-Khalfe et al. 2017). SUMOylation at K254, but not K289, was also 
found to enhance nuclear retention of PTEN, and is associated with response to genotoxic 
stress and DNA repair (Bassi et al. 2013). PTEN KD rescue with WT, but not lipid- 
phosphatase null or K254R mutants, was able to rescue response to ionizing radiation, 
shown by ability to recruit RAD51 to DNA damage sites which the mutants lacked. These 
mutants were also unable to resolve Breast cancer gene 1, early onset (BRCA1) expression 
compared to WT expressing cells (Bassi et al. 2013). K254R had equal phosphatase activity 






1.3.14 PTEN K266 SUMOylation Controls Membrane Binding and Tumour 
Suppression 
 
Huang et al. (2012) propose that SUMOylation of PTEN at K266 facilitates membrane 
binding, and this is necessary for its phosphatase activity. They postulate that this happens 
due to an increase in electrostatic interactions between PTEN and the electronegative 
membrane, which are increased by the addition of SUMO, as molecular dynamics 
simulations showed it to have several positively charged sites (Huang et al. 2012). They 
report disruption of SUMOylation at this site reduce PTEN’s ability to regulate the P-Akt 
pathway and downstream effects on tumour growth and cell proliferation. Reduced- 
SUMOylation capacity PTEN mutants (K266R and K254R mutants) had impaired ability to 
supress p-Akt pathway. In PC-3 cells, which contain a homozygous PTEN exon deletion, 
transfection with PTEN-WT reduced AKT phosphorylation at T308 and S473 by around 68% 
compared to control transfection cells (Vlietstra et al. 1998; Huang et al. 2012). In cells 
transfected with PTEN-K266R mutant, there was no significant change in Akt 
phosphorylation. In PTEN K254R mutant transfected cells, Akt phosphorylation was 
decreased by 38-39% compared to controls (Huang et al. 2012). When PC-3 cells 
expressing empty vector control or K266R PTEN were injected into immunodeficient mice, 
K266R mice had faster tumour growth than control mice, suggesting K266R mutation inhibits 
the tumour suppression ability of PTEN. Furthermore, Huang et al. (2012) saw a correlation 
between PTEN-SUMOylation-dependent Akt phosphorylation level and tumour growth. They 
also showed that K266 has a more cytosolic than membrane localisation compared to WT. 
Therefore, the integrity of K266 is necessary for PTEN’s localisation and ability to regulate 
the Akt pathway. Blocking SUMO1 modification at these sites by mutating the lysine residues 
inhibits PTEN’s ability to regulate the Akt pathway, thus promoting cell proliferation and 
tumorigenesis (Huang et al. 2012). Huang et al. (2012) postulate that SUMO modification of 
PTEN enables its activity independently of a conformational change, according to molecular 
dynamic simulations which were used to model the conformation of PTEN K266R, K266A 
and K266Q mutants. 
Another study has reported the role of SUMOylation in PTEN membrane localisation 
(González-Santamaría et al. 2012). Imaging of MCF-7 cells showed PTEN mutants with 
reduced SUMOylation capacity (K266A, K289A and K266A/K289A mutants) localised 
predominantly in the cytoplasm, whereas PTEN-WT localised mainly in the nucleus. This 
effect was confirmed by subcellular fractionation and subsequent Western blot, which 
showed mutation at these sites alone or combined, switched PTEN localisation from nucleus 







a model of viral infection, infection with Vesicular Stomatitis Virus induces PTEN 
translocation from cytosol to membrane, where it localises with SUMO1 and SUMO2 
(González-Santamaría et al. 2012). Gonzales Santamaria et al. (2012) conclude that 
SUMOylation of lysines in the C2 domain of PTEN reduce the ability of the C2 domain to 
associate with C-terminus on PTEN, thus encouraging an open conformation, and 
increasing interaction with the plasma membrane. This differs from the view of Huang et al. 
(2012), who suggest SUMOylation effects PTEN independently of a conformation change. 
Conversely, Bawa-Khalfe et al. (2017) report that SUMOylated PTEN sequesters in the 
cytosol (although membrane localisation was not analysed specifically). 
In summary, SUMOylation and PTEN localisation seem to be linked, although the 
mechanism by which SUMOylation facilitates membrane localisation is in dispute. The 
SUMOylation level of PTEN mutants has only been tested with endogenous SUMO in one 
paper, in which only SUMO1 modification (and not SUMO2/3) was detectable (Bawa-Khalfe 
et al. 2017). The role (or presence) of PTEN SUMOylation in neurons has not yet been 
examined; given the importance of both SUMOylation and PTEN in plasticity (Jurado et al. 
2010; Jaafari et al. 2013), examining PTEN SUMOylation in neurons may further 







Table 1. Literature Review of Previous Work on PTEN Mutants in SUMOylation Studies 
 
Mutant Effect on 
SUMOylation 
Effect on Location Effect on Activity Effect on Stability & 
Ubiquitination (Ub) 
K254R Reduces SUMOylation 
(Huang et al. 2012; 
Bassi et al. 2013; 
Wang et al. 2014) 
Inhibits nuclear retention 
(Bassi et al. 2013), 
Slightly reduces 
membrane binding 
(Huang et al. 2012) 
Defective in P-Akt 
suppression 
(Huang et al. 2012) 
 
K266R Reduces SUMOylation 
(Huang et al. 2012, 
Wang et al. 2014) 
Inhibits membrane 
binding (Huang et al. 
2012) 
Can’t supress P-Akt 
or tumour growth 





(Huang et al. 2012; 
Wang et al. 2014) 
  Increases Ub, reduces 
stability (Wang et al. 
2014) 
K266A Reduces SUMOylation 
(Gonzales-Santamaria 
et al. 2012) 
Increases cytoplasmic 
localisation (Gonzales- 
Santamaria et al. 2012) 
Can’t supress P-Akt 
(Huang et al. 2012) 
Reduces Ub 
(Gonzales-Santamaria 





et al. 2012) 
Increases cytoplasmic 
localisation (Gonzales- 
Santamaria et al. 2012) 
 Reduces Ub 
(Gonzales-Santamaria 
et al. 2012) 
K289A  Increases cytoplasmic 
localisation (Gonzales- 
Santamaria et al. 2012) 
 Reduces Ub 
(Gonzales-Santamaria 








Khalfe et al. 2017) 
 Increases stability 




1.3.15 Ubiquitination of PTEN 
 
Of the three SUMO sites mentioned (K266, K289 and K254), two are also known to be 
ubiquitination sites, K266 and K289 (González-Santamaría et al. 2012; Trotman et al. 2007; 
Wu et al. 2016). K13 and K66 are also reported to be ubiquitinated (Gupta and Leslie 2016; 
Trotman et al. 2007). K13 and K289 are functionally relevant as mutations at these sites 







mutated in some forms of cancer (Duerr et al. 1998) and nuclear PTEN is reduced in late 
stage colon cancer (Trotman et al. 2007), K66 is thought to be the dominant ubiquitination 
site; combined K13R, K80R and K289R mutation reduced PTEN poly-ubiquitination levels 
somewhat compared to WT, but K66R alone greatly reduced FLAG ubiquitin 
immunoprecipitation by PTEN, suggesting this is the main site (Gupta and Leslie 2016). 
 
1.3.16 Functional Consequences of PTEN Ubiquitination 
 
Arguably, the most important consequence of PTEN ubiquitination is its subsequent 
degradation (Gupta and Leslie 2016). PTEN is downregulated in AD, and PTEN 
ubiquitination may regulate this PTEN loss (Griffin et al. 2005; Kwak et al. 2010) see 
‘Diseases’ section for more information). 
PTEN K66R mutation increases PTEN stability by reducing ubiquitination, which has 
downstream effects on reducing Akt activation and cell proliferation (Gupta and Leslie 2016). 
Trotman et al. (2007) reported that PTEN nuclear import is mediated by monoubiqutination, 
while degradation is mediated by polyubiquitination. Monoubiquitination-defective PTEN 
K289E mutant showed inhibited nuclear import; PTEN ubiquitination has important 
consequences as nuclear PTEN is more stable and there was a significant correlation 
between dominant nuclear (versus cytoplasmic) PTEN localization and low tumour stage in 
colon cancer (Trotman et al. 2007). 
Maccario et al. (2010) also showed that PTEN’s localisation at the membrane enhances 
its polyubiquitination, leading to destabilisation through enhanced degradation. Maccario 
et al. (2010) used N-terminal myristoylation of PTEN, which can be used to artificially 
induce membrane localisation (McIlhinney 1998). This artificially increased membrane 
targeting caused increased ubiquitination of PTEN (Maccario et al. 2010). This shows that 
the localisation of PTEN is also important in terms of regulating its level of ubiquitination 
and subsequent degradation. 
Akt activation can also reduce PTEN stability through ubiquitination and degradation, which 
is dependent on the E3 ligase Makorin Ring Finger Protein 1 (MKRN1), which is stabilised 
through phosphorylation by Akt (Lee et al. 2015). It was concluded that there is a positive 
feedback loop whereby a reduction of PTEN activity increases Akt signalling, which promotes 
PTEN ubiquitination and degradation (Lee et al. 2015). Therefore, the relationship between 
PTEN, ubiquitination and PTEN activity is complex and bi-directional (Lee et al. 2015). 
There is some debate about the role of PTEN ubiquitination on its catalytic activity. Akt 







attributed to enhanced stability and subsequent increased levels of PTEN, rather than a 
change in its activity (Gupta and Leslie 2016). In contrast, Maccario et al. (2010) used a 
Ubiquitin “K all R” mutant, in which all seven lysines in ubiquitin are mutated, leaving it 
unable to form chains, to block poly-ubiquitination of PTEN (Li and Ye, 2008). This mutant 
blocked catalytical activity against PIP₃ (Maccario et al. 2010). It was concluded by Maccario 
et al. (2010) that ubiquitination reduces catalytic activity, and does so even before 
degradation, which is in contrast to Gupta and Leslie (2016) who suggest it is through 
enhanced degradation and subsequent reduced levels that catalytic activity is diminished. 
 
1.3.17 SUMO/ Ubiquitin Crosstalk and PTEN 
 
As described in Section 1.3.9, SUMO can recruit ubiquitin via a STUbL, forming mixed 
SUMO/Ubiquitin chains on a substrate which can act as a signal for degradation (Nie and 
Boddy, 2016; Xu et al. 2014). Bawa-Khalfe et al. (2016) demonstrated that SUMOylation of 
PTEN increases its association with WW Domain Containing E3 Ubiquitin Protein Ligase 2 
(WWP2), an E3 ligase which facilitates PTEN ubiquitination and subsequent degradation. 
SENP1 deSUMOylates PTEN and WWP2, reducing WWP2-PTEN interaction and blocking 
ubiquitin mediated degradation (Bawa-Khalfe et al. 2016). 
Conversely, SUMOylation can negatively regulate ubiquitination of PTEN (Wang, Chen, et al. 
2014). Both SUMO1 overexpression, or overexpression of SUMO E3 ligase PIASxα reduced 
ubiquitination of PTEN, with a result of promoting PTEN stability. SiRNA KD of PIASxα had 
the opposite effect of reducing stability shown by reduced half-life of PTEN. Mutating two 
SUMO acceptor sites (K254 and K266) on PTEN, had an effect of ablating this PIASxα 
driven increase in stability through increasing ubiquitination (Wang et al. 2014). PIASxα also 
negatively regulated Akt phosphorylation by stabilising PTEN, and PIASxα overexpression 
induced cell cycle arrest, blocking proliferation and tumour suppression. Interestingly, in both 
PTEN null PC-3 cells and PTEN shRNA HeLa stable cell line, PIASxα overexpression did not 
have this effect of decreasing Akt phosphorylation, suggesting that this effect is PTEN 
Dependent. Furthermore, overexpression of PIASxα reduced the rate of cell proliferation in 
U2OS cells and HeLa cells, but there was no effect in PC-3 or shPTEN-HeLa stable cell line 
compared with control cells. It was concluded that PIASxα is a SUMO E3 ligase, and through 
its ability to increase PTEN SUMO1 modification, it can reduce PTEN ubiquitination and 
increase PTEN stability (Wang et al. 2014). This also suggests that SUMO and ubiquitin 
compete for the same sites on PTEN (Wang et al. 2014). Negative regulation of 







There is therefore conflicting evidence surrounding the order of SUMO and ubiquitin 
conjugation, and how they regulate each other. 
 
1.4 The Retromer Complex 
1.4.1 Retromer and PTEN Overview 
 
A role for PTEN in the regulation of the trafficking complex “retromer” has recently been 
discovered (Shinde and Maddika, 2017). Retromer is important in neuronal function due to its 
ability to traffic neuronal proteins critical in synaptic plasticity such as AMPARs (Temkin et al. 
2011; Temkin et al. 2017). Furthermore, there is evidence that the retromer pathway may be 
perturbed in AD and PD (for a detailed analysis see ‘Diseases’ Section 1.5) (Munsie et al. 
2015; Mecozzi et al. 2014; Temkin et al. 2011). Therefore, due to the relevance of both 
PTEN and retromer in plasticity, and new evidence that PTEN can influence retromer 
(Jurado et al. 2010; Shinde and Maddika, 2017), examining how PTEN may influence 
retromer in cell models may give some insight into the development of synaptic pathology in 
neurodegeneration. As of yet, little is known about how PTEN influences retromer, and which 
cargoes are affected. PTMs of PTEN have also not been examined in the context of retromer 
trafficking. Retromer is involved in the sorting/trafficking of over 150 proteins including 
receptors, integral membrane proteins and ion channels (Cullen and Steinberg 2018; 
Steinberg et al. 2013; Steinberg et al. 2012; Fjorback et al. 2012). Such proteins include 
GluT1 and Alanine, Serine, Cysteine Transporter 2 (ASCT2) (Cai et al. 2011; Kvainickas et 
al. 2017). Retromer is also relevant in neurons and AD due to its ability to traffic Beta-
Secretase 1 (BACE1), Beta-2 Adrenergic Receptors (β2ARs) and AMPARs and has a 
significant role in plasticity (Wang et al. 2012; Temkin et al. 2011; Choy et al. 2014; Mecozzi 
et al. 2014). 
 
1.4.2 The Retromer Complex 
 
Generally speaking, when membrane proteins are trafficked away from the membrane, they 
go through one of two pathways: after absorption by clathrin-coated vesicles and subsequent 
retrieval by early endosomes, they are either recycled back to the membrane, or remain in 
early endosomes which then mature into late endosomes, leading to degradation via the 
lysosomal pathway (Kornfeld and Mellman 1989; Mellman 1996; Huotari and Helenius 2011; 
Burd and Cullen 2014; Elkin et al. 2016). Most proteins are recycled back to the plasma 
membrane via early endosomes, only a small proportion are degraded (Huotari and Helenius 
2011). An important part of this system is the retromer complex, which is mostly involved in 







recycling pathway) (Seaman et al. 1997; Vagnozzi and Pratico 2019). Deficits in retromer 
leads to mis-sorting of cargoes, and subsequent lysosomal degradation (Lucas et al. 
2016). Retromer has been described as a “master conductor of endosome sorting” (Burd 













































Figure 1.4.2.1. The Retromer Pathway. 
After endocytosis, cell surface proteins are engulfed by early endosomes; they then undergo 
degradation through the lysosomal pathway, or are recognised and retrieved by retromer, 
which recycles them back to the plasma membrane (Wang et al. 2018; Gallon and Cullen 
2015). For some proteins, SNX27 is also necessary for recycling back to the cell surface 
(Simonetti et al. 2019; Steinberg et al. 2013; Gallon et al. 2014; Yong et al. 2020; Rabouille 
2017). This schematic is adapted from Yong et al. (2020), Lee et al. (2016), Wang et al. 
(2018) and Gallon and Cullen (2015) and Rabouille, (2017) and created in biorender.com 
with pre- made shapes. 
 
1.4.3 Structure of the Retromer Complex 
 
Retromer was initially discovered in yeast in the late 1990’s, and includes proteins encoded 
vacuole protein sorting (VPS) genes (Seaman 2012; Seaman et al. 1997; Seaman et al. 
1998). Mammalian retromer is not stable, it is created by the transient association of its 
components, including SNX proteins, and the VPS26:VPS29:VPS35 trimer, which 







generally thought to be the main part responsible for cargo recognition, with VPS35 being 
the main component in this (Burd and Cullen 2014). Most cargoes contain the following 
hydrophobic motif necessary for sorting: “F/W-L-M/V,” (Seaman, 2007; Burd and Cullen 
2014). VPS26 can also recognise cargo and direct cargo localisation; KD of VPS26 lead to a 
more peripheral re-localization of Sortilin Related Receptor 1 (sorLA), it is thought that 
VPS26 facilitates retrieval of sorLA from endosomes to the Golgi (Fjorback et al. 2012). A 
highly conserved N-terminal motif in VPS35 (PRLYL), is responsible for interactions with 
VPS26, and VPS26 can regulate VPS35 membrane association (Gokool et al. 2007). VPS26 
can also regulate interactions between VPS35 and sorting nexins (Reddy and Seaman 
2001). 
 
1.4.4 Sorting Nexins 
 
Sorting nexins (SNX proteins), are associated with the retromer complex which are involved 
in trafficking away from degradative pathways (van Kerkhof et al. 2005). Of the 33 identified 
in mammals, only six are thought to interact with retromer: SNX1, SNX2, SNX3, SNX5, 
SNX6 and SNX27 (Lucas and Hierro 2017). SNX proteins contain a phox (PX) domain; this 
is a membrane interacting domain which can bind phosphoinositides (Chandra et al. 2019). 
The PX domain characterises SNX proteins and allows PIP₃ binding (Seet and Hong 2006), 
enabling them to localise at endosomes where PIP₃ is enriched (Carlton et al. 2004; Cheever 
et al. 2001; Worby and Dixon 2002; van Kerkhof et al. 2005; Fields et al. 2010; Lucas and 
Hierro 2017; Cai et al. 2011). SNX proteins then have different roles depending on the rest of 
their structure; broadly speaking, as explained by Lucas et al. (2016), SNX proteins fit into 
three groups: those which only possess a PX domain, those which also contain a BAR 
domain and SNX27, which is the only SNX to contain a FERM and PDZ domain, and can 
regulate potassium channel expression (Wassmer et al. 2007; Peter et al. 2004; Lunn et al. 
2007; Temkin et al. 2011; Steinberg et al. 2013; Burd and Cullen 2014; Balana et al. 2011; 
Clairfeuille et al. 2016; Ghai et al. 2013). SNX27 is known as an adaptor protein; adaptor 
proteins can recognise sorting motifs and mediate interactions between cargoes and 
retromer (Burd and Cullen 2014). SNX27 is enriched in early endosomes and localises there 
through interactions with PIP₃ (Cai et al. 2011). SNX27 knockout in mice leads to enhanced 
NMDAR expression and growth retardation, they also die within 3 weeks of birth (Cai et al. 
2011). It was concluded that SNX27 is important in development and may mediate 
endocytosis or endosomal sorting (Cai et al. 2011). SNX27 is able to regulate sorting of 







retromer via its PDZ ligand and is therefore known as an adaptor protein (Temkin et al. 2011; 
Gallon et al. 2014; Steinberg et al. 2013; Damseh et al. 2015; McMillan et al. 2020). 
However, SNX27 is not always necessary for retromer-mediated trafficking, in some cases, 
the VPS trimer is able to recycle proteins without SNX27 (Steinberg et al. 2013). An analysis 
of over 100 cell surface proteins has found that under VPS35 KD conditions, over 50 proteins 
were reduced at the cell surface which were not further reduced by SNX27 KD (Steinberg et 
al. 2013). GTPases Rab7a and Rab5 are necessary for VPS35/29/26 complex recruitment to 
membranes (Seaman et al. 2009; Rojas et al. 2008). 
While not retromer associated, SNX17 is important for maintaining the stability of membrane 
proteins and regulating their distribution; disruption of the SNX17 binding region of low- 
density lipoprotein receptor-related protein (LRP) results in reduced LRP degradation and 
expression at the membrane, suggesting SNX17 is important in recycling (van Kerkhof et al. 
2005). SNX17 is also able to regulate recycling of integrins and promote their stability 
through its FERM-like domain, without the recruitment of retromer (Steinberg et al. 2012). 
SNX3 has been shown to be involved in endosome to Golgi transport in a retromer 
Dependent pathway (Cui et al. 2019). 
 
1.4.5 The Retromer Component VPS35 in Neurons and Plasticity 
 
Retromer is involved in trafficking of many neuronal proteins including β2 adrenergic 
receptors (β2ARs), AMPARs, NMDARs and dopamine transporters (Munsie et al. 2014; 
Choy et al. 2014; Wu et al. 2017; Cai et al. 2011). Retromer protein VPS35 is important in 
AMPAR trafficking and function (Tian et al. 2015; Temkin et al. 2017). In PSD and 
synaptosomal samples from neurons from VPS35-depleted transgenic mouse brains, total 
GluA1 and GluA2 levels were also significantly decreased, and there were less mature 
spines (Tian et al. 2015). GluA2 overexpression could rescue this spine maturation deficit. 
Mini EPSCs were also lower compared to readings from neurons from WT mice, and 
AMPAR subunits were reduced at the surface (Tian et al. 2015). 
VPS35 is also reported to be critical in LTP; VPS35 KD blocked LTP in mouse hippocampal 
slices and neuronal cultures, while LTD was unaffected (Temkin et al. 2017). Spine density 
of dendrites in CA1 pyramidal cells were reduced in VPS35-KD cells. In imaging experiments 
in neurons, VPS35 KD induced AMPAR translocation from early endosomes, suggesting 
retromer is involved with sorting of AMPARs, possibly by ensuring they are sorted into 
vesicles and available to be inserted into the membrane during LTP (Temkin et al. 2017). It 
was concluded that VPS35 is important in trafficking of AMPARs in plasticity (Temkin et al. 







al. 2019). Basal AMPAR transmission was not affected by VPS35 KD (in contrast to Choy et 
al. (2014) who found an effect under basal conditions). 
Retromer also plays a developmental role in neurons; VPS35 is involved in dendritic growth; 
Reducing VPS35 in mouse embryonic hippocampal neurons leads to fewer spines, shorter 
dendrites and swollen axons (Wang et al. 2012). This suggests VPS35 KD causes deficits in 
protein trafficking in developing neurons in mice (Wang et al. 2012). 
 
1.4.6 Retromer Component SNX27 in Neurons and Plasticity 
 
SNX27 is also critical to neuronal function; SNX27 KO in mice leads to growth retardation in 
developing mice, and these mice die within three weeks (Cai et al. 2011). The PDZ binding 
motif of NMDAR receptor 2C (NR2C) is recognised by the SNX27 PDZ domain, and SNX27 
localises on early endosomes through its PX domain interaction with PIP₃ (Cai et al. 2011). 
SNX27 KO in neurons leads to enhanced NR2C levels and aberrant NR2C endocytosis; 
suggesting that SNX27 can regulate the endosomal sorting or endocytosis of NR2C (Cai et 
al. 2011). 
SNX27 is also involved in regulating AMPAR receptor trafficking (McMillan et al. 2020), and 
there is evidence that SNX27 can directly interact with AMPARs (Hussain et al. 2014). 
However, some reports suggest that rather than binding AMPARs directly, SNX27 binds 
leucine-rich repeat and fibronectin type-III domain containing protein 2 (LRFN2), which is 
involved in AMPAR trafficking (McMillan et al. 2020). 
This study involved injection of shRNA-expressing lentivirus into rat brains to knock down 
SNX27 or LRFN2; 6-8 weeks later hippocampal slices were made from these rats. SNX27 
KD profoundly reduced field EPSCs, and LFRN2 KD also caused a significant reduction 
(McMillan et al.2020). LFRN2 KD also blocked LTP induction. In rat cortical neurons, SNX27 
KD reduced GluA2 surface expression by 34%, while LRFN2 KD caused a 40% reduction. 
SNX27 KD also leads to a 50% reduction of total LRFN2. LRFN2 was suggested by 
McMillan et al. (2020) to act as link between SNX27 and AMPARs, which regulates their 
surface expression and transmission. The group also concluded that SNX27 is required for 
maintaining levels of LRFN2 expression, and subsequent LRFN2 reduction after SNX27 
depletion leads to reduction of surface GluA2 expression and defective transmission 
(McMillan et al. 2020). Other reports have shown that SNX27 overexpression can upregulate 
surface GluA1 and NMDAR subunit NR1, and SNX27 KD has the opposite effect (Wang et 
al. 2013). These studies together provide evidence that retromer proteins such as VPS35 





        
       including plasticity, neurotransmission and receptor trafficking (Temkin et al. 2017; McmiIllan et al. 
2020; Cai et al. 2011). 
 
1.4.7 PTEN Can Influence Retromer Through Direct Interactions 
 
Recent research has found a direct link between PTEN and retromer (Shinde and Maddika et 
al. 2017). PTEN can directly associate with SNX27, blocking its association with VPS26 and 
sequestering it away from retromer. This reduces the ability of retromer to traffic GluT1 from 
the endosome to the membrane of HepG2 and HeLa cells, and limits glucose transporter 
GluT1 expression at the surface (Shinde and Maddika, 2017). PTEN shRNA KD leads to 
increased surface GluT1 and glucose uptake levels compared to control shRNA cells. The 
authors discovered the T401I mutation in the PTEN PDZ binding motif is not able to obscure 
SNX27-VPS26 as the wildtype does, which also increases surface GluT1 compared to 
expression of PTEN-WT, suggesting PTEN has an important role in regulating surface GluT1 
levels and the PDZ binding motif of PTEN is critical in this. PTEN binds SNX27 next to its 
VPS26 binding site; Shinde and Maddika (2017) explain that this can obstruct SNX27-VPS26 
binding and is able to reroute GluT1 away from Rab11-positive recycling endosomes, 
towards lysosomes shown by co-localisation with LAMP1, leading to degradation. This may 
influence tumour progression due to a downstream effect on glucose uptake. Influence of 
PTEN phosphatase activity and through the Akt pathway in this context were ruled out, as a 
catalytically dead PTEN mutant did not associate with SNX27 differently to WT, and 
pharmacological Akt inhibition also did not alter SNX27-PTEN or SNX27-VPS26 interaction 







1.5 PTEN, PTMs and Retromer in Disease Pathology 
1.5.1 Overview 
 
Although PTEN is primarily known for its tumour suppression function, it also plays key roles 
in synaptic plasticity (Jurado et al. 2010; Liu et al. 2018). Intriguingly, this may be relevant to 
Alzheimer’s disease (AD), as PTEN inhibition is reported to relieve AD-related plasticity 
deficits, and PTEN is dysregulated in AD brains (Griffin et al. 2005; Knafo et al. 2016). AD, 
which accounts for 70% of dementia cases, is generally associated with synaptic dysfunction 
and enhancement of LTD (Kametani and Hasegawa 2018; Ondrejcak et al. 2010). PTEN has 
a preference for synaptic depression in neurons, and can enhance AD-related synaptic 
depression (Knafo et al. 2016; Arendt et al. 2014). PTEN is therefore a potential therapeutic 
target in AD, as suppression of PTEN activity can rescue AD-related synaptic dysfunction 
and learning and memory deficits in mouse models (Knafo et al. 2016). 
The retromer complex is also critical in plasticity through its ability to regulate trafficking of 
neuronal proteins such as AMPARs, and is therefore is also associated with 
neurodegeneration (Temkin et al. 2017; Munsie et al. 2014). PTEN may influence trafficking 
of AMPARs, and has recently been shown to influence retromer-mediated trafficking (Moult 
et al. 2010; Shinde and Madikka, 2017). Examining the influence of PTEN on retromer 
mediated trafficking in cell models may therefore provide a useful avenue to further 
understand the role of PTEN in plasticity and neurodegeneration. 
PTMs are also a point of interest in this context, as SUMOylation is implicated in plasticity 
and AD, as well as cancer (Xie et al. 2014; Hung et al. 2019; Jaafari et al. 2013; Lee et al. 
2014), and there is evidence that SUMOylation, ubiquitination and phosphorylation are 
important regulators of PTEN function (Huang et al. 2012; Rahdar et al. 2009; Trotman et al. 
2007). Ubiquitination may play a role in PTEN loss seen in AD brains (Kwak et al. 2010; 
Griffin et al. 2005), highlighting the relevance of PTMs and PTEN in neuronal function and 
neurodegeneration. The role of PTEN-SUMOylation in plasticity has not yet been examined. 
It is also not yet known whether PTMs of PTEN are relevant to its role in retromer mediated 
trafficking. This section will outline disorders associated with PTEN, retromer and PTMs, with 







1.5.2 Alzheimer’s Disease- Amyloid- Beta 
 
Alzheimer’s Disease is partially characterised by the accumulation of plaques of highly 
insoluble peptides such as Amyloid beta (Aβ) (Selkoe 1991; Murphy and LeVine 2010). 
Build-up of these peptides in neurons is suggested to begin the pathogenesis of Alzheimer's 
disease (Selkoe 1991; Glenner and Wong 1984; Chen et al. 2017), and is created via 
proteolytic processing of amyloid precursor protein (APP), by β- or γ-secretases, such as 
beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) or Presenilin-1 (PS1) (Cai et 
al. 2001; Bustos et al. 2017; Chow et al. 2010; Chen et al. 2017). Cleavage of APP by 
secretases is not very precise, which results in variation between Aβ species, but around 5-
10% is Aβ42, which is thought to be more fibrillogenic than other Aβ species and the cause of 
most deposits (Murphy and LeVine 2010). BACE1 is the main protease which generates Aβ42 
through APP cleavage (Cai et al. 2001). APP is cleaved by these proteases under normal 
conditions, but during AD, Aβ is accumulated to a greater extent due to a lack of degradation, 
leading to plaques and neurotoxicity (Hardy and Higgins 1992; Kametani and Hasegawa 
2018; Selkoe 1991; Murphy and LeVine 2010). 
Generally speaking, Aβ42 is associated with LTP inhibition and LTD enhancement (Ondrejcak 
et al. 2010). Application of Aβ42 oligomers to hippocampal slices at concentrations as low as 
200pM can influence neurotransmission; this was reported to increase mini EPSC frequency 
and reduce paired pulse facilitation (Gulisano et al. 2019). Changes were associated with a 
higher number of docked vesicles at the presynapse and longer postsynaptic density length, 
suggesting Aβ42 oligomers influence neurotransmitter release and postsynaptic structure 
(Gulisano et al. 2019). This study gives some insight into the mechanism by which Aβ42 
exerts its effects. 
There is evidence that Aβ can contribute to pathogenesis through effects on AMPARs 
(Chang et al. 2006). Chang et al. (2006) found AMPAR mediated synaptic scaling 
contributes to AD related pathology in double knock in (2KI) (APP/Presenilin-1) mutant mice. 
These mice have mutations in APP: K670N/M671L (mutated human Aβ sequence) and 
presenilin-1: P264L, causing them to have increased Aβ42 levels from 6 months of age as 
well as more plaques, without APP overexpression (Flood et al. 2002; Chang et al. 2006). 
These 2KI mice showed age-related downregulation of AMPAR-mediated basal and evoked 
currents and synaptic AMPAR decrease in CA1 cells. The mice had age-related deficits in 
both LTD and LTP, and impaired memory flexibility (Chang et al. 2006). This study shows 
through reducing AMPARs at the synapse and reducing AMPAR transmission, Aβ42 may 






Although it seemingly contrasts with Gulisano et al. (2019) who saw a Aβ42 -related increase 
in neurotransmission, these differences are consistent with the glutamate excitotoxic theory 
of AD, which explains that excessive or prolonged glutamate signalling may be neurotoxic 
(Doble 1999). AD could be due to Aβ‐mediated changes that could cause neurodegeneration 
as the diseases progresses, after memory impairment (Esposito et al. 2013). Considering 
this theory, it follows that the initial increase in transmission seen by Gulisano et al. (2019) 
after acute Aβ treatment could lead to neurodegeneration through excitotoxity, which could 
present as age-related AMPAR downregulation seen by Chang et al. (2006) in aging model 
mice. It is also of note that there was variation in methodology between these studies 
(transgenic mice vs Aβ42 application, and differences in current recording protocols). 
 
1.5.3 Alzheimer’s Disease – Tau 
 
AD is also characterised by the accumulation of abnormal fibres in neurons called 
neurofibrillary tangles (NFTs), which are made up of highly insoluble peptides such as Tau 
(Kametani and Hasegawa 2018; Braak et al. 1986; Pirscoveanu et al. 2017). Tau was 
discovered in 1975 as a Microtubule-Associated Protein (MAP), which helps to assemble 
microtubules, and could be immunoprecipitated with Tubulin (Weingarten et al. 1975). Tau 
pathology is thought to be one of the main causes of various neurodegenerative diseases 
including AD and Parkinson’s Disease (PD) (Braak et al. 1986; Pirscoveanu et al. 2017; 
Gendron and Petrucelli 2009). In healthy conditions, Tau is generally localised in axons 
(Binder, Frankfurter, and Rebhun 1985); in “tauopathies”, Tau forms neuritic plaques, 
neurofibrillary tangles (NFTs) and neuropil threads, often containing paired helical filaments 
(PHFs) (Braak et al. 1986; Pirscoveanu et al. 2017). There are varying phenotypes between 
the different diseases in terms of the localisation and characteristics of Tau pathologies, but 
one particular marker is usually present; NFTs formed of hyperphosphorylated, insoluble Tau 
in paired helical filament form or twisted filaments (Braak et al. 1986; Gendron and Petrucelli 
2009). Tau hyperphosphorylation depresses biological activity of healthy Tau, and seems to 
precede the assembly of tau filaments (Pirscoveanu et al. 2017). 
 
 
1.5.4 Alzheimer’s Disease and Excitotoxic Glutamate Signalling 
It is suggested that AD can be the result of glutamate toxicity, and dysregulation of glutamate 
signalling may be involved in learning and memory deficits in AD (Greenamyre and Young 
1998; Wang and Reddy 2017). Glutamate must be tightly controlled, as excess release can 
cause hyperexcitability of neurons; this prolonged activation can eventually be excitotoxic 





Wang and Reddy 2017). This excitotoxicity is thought to arise from the neuronal swelling that 
occurs after calcium influx, and lack of desensitisation of AMPARs after stimulation can also 
lead to cell death as this is protective against excessive stimulation by glutamate (Koh and 
Choi 1991; Koh et al. 1990; Jensen et al. 1998). Excessive AMPAR activation and calcium 
conductance through Calcium-Permeable (CP) AMPARs can lead to induced neuronal death 
(Mahajan and Ziff 2007). Mechanistically, uninhibited stimulation of AMPARs causes 
membrane depolarization and NMDAR activation (Hollmann and Heinemann 1994). This is 
because after glutamate or AMPA-induced stimulation, AMPARs rapidly undergo 
desensitisation after ligand binding, which involves a change in conformation of the dimer 
interface, which closes the channel and reduces conductance, inactivating the receptors 
(Sun et al. 2002). In AD, excessive NMDAR and AMPAR stimulation leads to calcium 
dysregulation and neurotoxicity (Armada-Moreira et al. 2020; Alberdi et al. 2010). Aβ 
oligomers significantly increase calcium currents through NMDARs and AMPARs, leading to 
oxidative stress and mitochondrial dysfunction in entorhinal–hippocampal slices and cortical 
neurons, and cell death in hippocampal slices (Alberdi et al. 2010). Furthermore, Aβ is also 
reported to potentiate potassium-evoked calcium currents in cortical and hippocampal slices 
at nanomolar concentrations (Kabogo et al. 2010). There are therefore several ways in which 
Aβ can cause synaptic dysregulation, including through increasing glutamate release and 
calcium influx through AMAPARs and NMDARs (Alberdi et al. 2010; Kabogo et al. 2010). 
 
1.5.5 PTEN and Alzheimer’s Disease Pathology 
 
PTEN is dysregulated in AD brains; total PTEN levels are reduced in the entorhinal cortex, 
while PTEN levels are increased in CA1 dendrites (Griffin et al. 2005). Furthermore, Akt 
levels are reduced, while phospho-Akt is increased in AD brains compared to controls. 
Importantly, neurodegeneration and plasticity-related Akt targets GSK and Tau were also 
more phosphorylated (Griffin et al. 2005; Jiang et al. 2005; Peineau et al. 2007; Gendron and 
Petrucelli 2009). PTEN loss, and Akt and GSK activation were correlated with Aβ plaque 
deposition (Griffin et al. 2005). This study suggests that PTEN and the Akt pathway may be 
dysregulated in AD (Griffin et al. 2005), and other work has supported the finding that PTEN 
is dysregulated in AD brains (Kwak et al. 2010). PTEN has also been implicated in AD 
related plasticity deficits in mouse models (Knafo et al. 2016). Knafo et al. (2016) found that 
Aβ induced synaptic depression, and PTEN overexpression also mimicked and occluded this 
in neuronal cultures and mouse models. Aβ induced PTEN translocation into the 
postsynaptic compartment, which is a PDZ-dependent event, and this mechanism is critical 
for Aβ-induced synaptic depression. Treatment with Aβ42 induced NMDAR-Dependent LTD in 
hippocampal slices from WT mice, but not from knock in mice with PTEN lacking the PDZ 






synaptic depression after Aβ treatment. This study suggests PTEN may be the link between 
Aβ and Alzheimer’s related synaptic depression, and highlights the importance of PDZ 
interactions of PTEN in Aβ-related neuropathology (Knafo et al. 2016). It is also congruent 
with Griffin et al. (2005), who showed that PTEN levels are enhanced in CA1 dendrites in AD 
brains, again suggesting the role of PTEN in neurodegeneration. NMDAR stimulation causes 
PTEN accumulation in the PSD, which is critical in LTD (Jurado et al. 2010). Knafo et al. 
(2016) therefore suggest the Aβ -driven accumulation of PTEN in the synaptic compartment 
may therefore enhance PTEN-mediated synaptic depression, which may occur though 
removal of AMPARs due to changes in PIP₃ levels (Arendt et al. 2010). According to Knafo 
et al. (2016), this link between Aβ, PTEN and AD suggests that Aβ can hijack and enhance 
PTEN-mediated mechanisms of synaptic depression, which plays a role in AD pathology. 
 
1.5.6 Ubiquitination of PTEN and Alzheimer’s Disease 
 
As mentioned, SUMOylation and ubiquitination have a role in plasticity (Lee et al. 2014; 
Colledge et al. 2003). PTEN is critical in LTD, plays a role in Aβ-induced pathology and is 
dysregulated in AD brains (Jurado et al. 2010; Griffin et al. 2005; Knafo et al. 2016). Due to 
the importance of PTMs in the regulation of PTEN (Huang et al. 2012), ubiquitination and S- 
nitrosylation of PTEN have been tested in the context of neurodegeneration (Kwak et al. 
2010). The brains of people with the early stages of Alzheimer’s disease showed 
reduced total PTEN levels and enhanced P-Akt compared to controls, as well as 
enhanced S- nitrosylation of PTEN (Kwak et al. 2010). It was shown that increased S-
nitrosylation of PTEN in cortical rat neurons, caused by treatment with Nitric Oxide 
(NO) donor S-nitroso cysteine (SNOC), leads to reduced PTEN levels through 
enhanced E3 ubiquitin-protein ligase NEDD4-1 mediated ubiquitination and 
subsequent degradation (Kwak et al. 2010). A triple PTEN mutant (C71/C83/C124A) 
was unable to be nitrosylated and this mutant also displayed less ubiquitination that 
WT, which Kwak et al. (2010) suggest may be ubiquitination of PTEN is in part 
Dependent on PTEN nitrosylation. SNOC treatment also inhibited PTEN’s lipid 
phosphatase activity, evidenced by increases in PIP₃ after SNOC treatment in a 
malachite green assay (an in vitro enzyme assay using bacterially expressed, purified 
PTEN). Interestingly, treatment of cultured neurons with glutamate or Aβ also 
increased PTEN S- nitrosylation and ubiquitination, as well as increased Akt 
phosphorylation (Kwak et al. 2010). Therefore, PTEN stability and phosphatase 
activity can be regulated by S-nitrosylation and ubiquitination, which may explain the 
PTEN loss seen in Alzheimer’s disease, and provides a link between PTEN PTMs 







1.5.7 Neuronal SUMOylation and Alzheimer’s Disease 
 
SUMOylation in neurons can influence plasticity (Jafaari et al. 2013), and is implicated in 
Alzheimer’s disease (Lee et al. 2014; Qin et al. 2019). SUMOylation dysregulation is found in 
Tg2576 AD mouse models, as well as post-mortem AD brains (Lee et al. 2014). Tg2576 
mice shown predominantly SUMO2/3 dysregulation, and minimal SUMO1 dysregulation. Lee 
et al. (2014) found slices from Tg2576 mice, and WT slices incubated with Aβ42 oligomers 
both showed LTP inhibition. Aβ42 oligomer application inhibits the natural increase in 
SUMOylation found after neuronal stimulation with KCI, which they suggested is the cause of 
LTP inhibition (Lee et al. 2014). Expression of dominant negative Ubc9 (DN-Ubc9) can also 
impair this stimulation-induced SUMOylation and reduces LTP (Lee et al. 2014). 
Furthermore, in CA1 pyramidal neurons, expression of SENP1, completely blocked single- 
cell LTP, again highlighting the role of SUMOylation. 
This plasticity inhibition from SUMOylation depletion was reflected in behavioural 
experiments; infusion of DN-Ubc9 20 minutes before or after foot shock training significantly 
impaired freezing behaviour the day in a contextual fear conditioning (FC) task and 
performance in the Morris water maze test; it was found DN-Ubc9 infusion after training 
sessions impaired performances in later sessions (Lee et al. 2014). Ubc9 perfusion was also 
able to rescue deficits in behavioural test scores after Aβ42 oligomer perfusion (Lee et al. 
2014). Expression of Ubc9 could also rescue LTP deficits both in slices from Tg2576 mice, 
and slices from WT mice after Aβ42 oligomer application, evidenced by increased fESPC 
slope in CA1 after theta burst stimulation. These experiments together show that 
enhancement of SUMOylation can significantly improve plasticity deficits and cognitive 
function in chronic Aβ-induced pathology; and hippocampal-dependent reference memory 
influenced by SUMOylation (Lee et al. 2014).  
More recently, SUMOylation of Protein phosphatase 2 (PP2) has been found to contribute to 
AD pathology (Qin et al. 2019). PP2 is a serine/threonine phosphatase with a wide range of 
targets in the cell, and represents a collection of enzymes with the same catalytic subunit 
rather than a single enzyme (Mumby 2007). PP2A inhibition induces tau 
hyperphosphorylation, a main contributor of NFTs (Liu et al. 2008; Qin et al. 2019). PP2 is 
regulated by an endogenous PP2 inhibitor called SET (Qin et al. 2019). Qin et al. (2019) 
report that SET can be SUMOylated by SUMO1 in vitro and in vivo at K68, and SET was 
more SUMOylated in mice with three AD-related mutations: PS1m146v, APPswe and 






Qin et al. (2019) also found that SUMOylation of SET causes its cytoplasmic retention and 
PP2A inhibition, with a downstream effect of tau hyperphosphorylation. Non-SUMOylated 
SET showed preferential localisation in the nucleus. SET SUMOylation also induced 
cognitive defects in mice including long term memory; expression of WT, but not non- 
SUMOylatable SET mutant K68R via injection into CA1 in mice, caused reduced freezing 
times in contextual fear tests. Expression of WT SET was associated with reduced levels of 
PSD-95, GluA1, synaptotagmin and NMDAR subunit NR2A compared to vector expressing 
group (Qin et al. 2019). Furthermore, expression of non-SUMOylatable SET mutant K68R 
rescued expression of these proteins to a level similar to the control group. These results 
suggest SET-SUMOylation limits expression of synaptic proteins involved in plasticity, which 
modulates its effect on memory defects (Qin et al. 2019). Furthermore, Aβ oligomer 
treatment increased SET SUMOylation in rat hippocampal neurons. It was concluded that 
SUMOylation of SET enhances its retention in the cytoplasm, which blocks PP2A activity 
leading to Tau hyperphosphorylation, and that through SET SUMOylation, Aβ can enhance 
neurodegeneration (Qin et al. 2019). 
SUMOylation therefore has a range of targets in neurons, and is able to influence plasticity 
and related processes including neuronal protein expression and neurotransmission (Lee et 
al. 2014; Qin et al. 2019). This has effects on long term memory and learning, and is 
influenced by Aβ (Lee et al. 2014; Qin et al. 2019). 
 
1.5.8 PTEN in Learning and Memory- PTSD 
 
In an innovative study by Lui et al. (2018), repetitive transcranial magnetic stimulation 
(rTMS), a kind of whole brain stimulation, was shown to relieve Post-Traumatic Stress 
Disorder (PTSD)- associated plasticity deficits through inhibition of the PTEN/Akt pathway. A 
mouse model of PTSD was induced using single prolonged stress (SPS) treatment on mice, 
which caused synaptic plasticity impairment, increased PTEN levels, reduced number and 
length of dendrites. It also lowered levels of the following NMDAR subunits: NR1, NR2A, 
NR2B and AMPAR subunits: GluA1, GluA2, GluA3 and GluA4 in the anterior cingulate cortex 
(ACC) (Lui et al. 2018). RTMS was able to significantly rescue the reduced glutamatergic 
receptor expression and decrease PTEN levels (Lui et al. 2018). The SPS-induced reduction 
of number and length of dendrites was also reversed by rTMS, and significantly enhanced by 
inhibition of PTEN using siRNA PTEN or PTEN inhibitor Bispovanadium (BpV). SPS also 
induced Akt dephosphorylation, which was blocked by BpV and PTEN siRNA. Blotting and 
confocal microscopy revealed HrTMS reversed the SPS-induced decrease of P-AKT, an 







partially block SPS-induced increase in PTEN expression (Liu et al. 2018). The effect of 
rTMS to block the reduction of NR2B and GluA1 induced by SPS, was also significantly 
increased by addition of siRNA PTEN or BpV. Effects through the Akt pathway were further 
confirmed by use of Akt inhibitor Wortmannin in conjunction with rTMS. Wortmannin inhibited 
the effects of rTMS on Akt phosphorylation, and simultaneously lowered GluA1 and NR2B 
expression, again suggesting the involvement of the PI3K/Akt pathway (Liu et al. 2018). This 
study provides useful evidence that at the whole animal level, PTEN is highly involved in the 
context of PTSD mouse models, and has its effects through the Akt pathway by influencing 
glutamate receptor expression and synaptic morphology.  
 
1.5.9 PTEN in Neurodegeneration- SMA and Axonal Regeneration 
 
In addition to AD and PTSD, there is evidence that PTEN attenuation can have a 
neuroprotective effect in other neuropathology including Spinal muscular atrophy (SMA) and 
may enhance cell survival through effects of AMPAR trafficking or transmission (Liu et al. 
2018; Ning et al. 2004; Park et al. 2008). 
 
Yang et al. (2014) wanted to further explore PTEN as a therapeutic target for 
neurodegenerative disorders. They developed induced pluripotent stem cell (iPS) -derived, 
motor neuron model, capable of expressing AMPARs. PTEN KD in both in these iPS-derived 
cells and cultured neurons reduced expression of GluA1 and GluA2, and AMPAR-mediated 
basal currents, which can lead to in AMPAR-induced cell death (Yang et al. 2014). Yang et 
al. suggest PTEN is therefore a potentially useful target for neuronal protection in 
neurodegeneration in motor neurons, via reducing excitatory transmission inhibition. These 
results are congruent with research in corticospinal tract (CST) regeneration; PTEN deletion 
promotes axonal regeneration in retinal nerve cells after injury (Park et al. 2008). It was 
suggested that this regeneration was due to an increase of signalling through the PI3K/ 
Mammalian Target of Rapamycin (mTOR) pathway (Park et al. 2008). 
SMA is caused by deletion/mutation of survival motor neuron (SMN) gene (Lefebvre et al. 
1995), so SMN-deficient motor neurons can be used as a SMA model (Ning et al. 2010). 
PTEN KD enhanced axonal elongation and growth cone size, which increased cell survival in 
these cells. These effects were associated with increases in p-Akt, as well as restoration of 
β-actin levels (Ning et al. 2010). Enhanced survival was not seen when cells were also treated with 
PI3K inhibitor LY294002,  suggesting the importance of the PI3K/Akt pathway. When adenovirus 
expressing PTEN KD siRNA was injected into p1 SMN-mutant mice, these mice showed improved 






and its potential use as a therapeutic target (Ning et al. 2010). Taken together, these studies 
show that modulation of PTEN can be neuroprotective in a range of neurodegenerative 
disorders, through mechanisms including AMPAR trafficking, cell death and synaptic 
transmission. 
 
1.5.10 The Autophagy–Lysosomal Pathway and Aβ Metabolism 
 
Deficits in the endosome-lysosome system are strongly implicated in neurodegeneration (Mayer et 
al. 1994; Kimura and Yanagisawa 2018; Vagnozzi and Pratico 2019; Martini-Stoica et al. 2016). 
Retromer is necessary to sort cargo proteins to be trafficked from endosomes to the Golgi and is 
therefore a vital part of this system (Cullen and Korswagen 2012; Seaman 2012). Due to their finding 
that AD post-mortem brains show up 32 times larger endosomes than controls, Cataldo et al. (1997) 
suggest that in AD there is increased endocytic activity and trafficking to endosomes, which can 
increase β-amyloidogenesis under certain conditions, due to rerouting of proteases able to cleave 
Aβ. Due to evidence that APP cleavage can result in Aβ creation through endocytic processes, 
Kimura and Yanagisawa et al. (2018) suggest the “traffic light” hypothesis, which suggests that AD 
pathology is in part caused by changes in the metabolization of Aβ and tau due to dysregulation of 
the endocytic pathway (Kimura and Yanagisawa 2018; Cataldo et al. 2001; Cataldo et al. 1997). 
Further evidence for this will be outlined below, along with evidence of other routes by which 
retromer making be involved in neurodegeneration. 
 
1.5.11 Retromer in Neurodegeneration 
 
Due to recent evidence implicating PTEN in retromer-mediated trafficking (Shinde and 
Madikka, 2017), this thesis will also aim to further examine how PTEN can regulate retromer. 
Retromer is also reported to be involved in plasticity, and may be relevant in 
neurodegeneration, via trafficking and metabolism of Aβ, and through effects on AMPARs 
and neurotransmission (Small et al. 2005; Muhammad et al. 2008; Temkin et al. 2017; Bhalla 
et al. 2012; Vilarino-Guell et al. 2011). 
VPS35 is found in the soma, axon and dendritic spines in neurons, and retromer is involved 
in trafficking of many neuronal proteins including β2 adrenergic receptors (β2ARs), AMPARs, 
NMDARs and dopamine transporters (Munsie et al. 2014; Choy et al. 2014; Cai et al. 2011; 
(Wu et al. 2017). There is direct evidence for the role of retromer in neurodegeneration 
pathology through separate mechanisms involving AMPAR trafficking and Aβ metabolism 







1.5.12 Retromer in Neurodegeneration- APP Processing 
 
Mecozzi et al. (2014) showed evidence for the role of retromer in APP processing. They 
found a compound called R55, which stabilised retromer, could reroute APP away from the 
endosome, reducing pathogenic APP cleavage in hippocampal neurons with double APP 
mutation (Mecozzi et al. 2014). Aβ40 and Aβ42 levels were significantly reduced, which 
Mecozzi et al. (2014) suggest is due to reduced APP processing by BACE1. This was 
confirmed by measuring β-CTF, a product of BACE1 cleavage of APP (Cai et al. 2001). 
These were significantly lowered by R55 treatment. Furthermore, R55 increased sAPPα 
levels in the medium, which Mecozzi et al. (2014) explain is consistent with APP 
processing through the α-secretase pathway when BACE1 processing is reduced 
(Mecozzi et al. 2014, (Luo et al. 2001). This study shows that retromer is critical in the 
fate of APP in the sense that it is highly implicated in which pathway it is processed by 
(Mecozzi et al. 2014). 
Furthermore, VPS35 haploinsufficiency can increase APP cleavage in AD mouse model 
Tg2576, which express a double-mutant form of APP (K670N/M671L), exhibit 14 times more 
Aβ1-42/43 and show age-related memory deficits (Hsiao et al. 1996; Wen et al. 2011). Deletion 
of one VPS35 allele in Tg2576 mice was associated with earlier-onset AD related pathology, 
including reduced LTP and impairment of spatial learning and memory. AMPAR and NMDAR 
mini EPSCs were both reduced in Tg2576 mice with VPS35 hemizygous deletion compared 
to WT or Tg2576 mice, and these mice also showed enhanced Aβ40 levels compared to 
Tg2576 or WT mice (Wen et al. 2011). VPS35 associates with BACE1 in mouse brain and 
during VPS35 depletion, BACE1 showed translocation away from the Golgi and increased 
colocalization with LAMP1 an endosome/lysosomal marker (Wen et al. 2011). It was 
suggested that VPS35 is therefore necessary for BACE1 localisation in the Golgi and 
retrieval from endosomes (Wen et al. 2011). There were higher levels of BACE1 activity, 
shown using a BACE1 assay kit and increase in products associated with BACE1 cleavage 
such as Soluble amyloid precursor protein alpha (sAPPβ) in the Tg2576/VPS35 deletion 
mice compared to Tg2576 (Wen et al. 2011). In conclusion, retromer is strongly implicated in 
APP processing through regulation of BACE1 localisation, and deficits in this mechanism 
have influence over neurotransmission and learning and memory in AD mouse models (Wen 
et al. 2011). 
Recently, Ansell-Schultz et al. (2018) found that Aβ oligomers accumulated when VPS35 
was diminished; Aβ oligomers also co-localise with VPS35 in early endosomes. Aβ oligomer 






and in cells which took up Aβ oligomers from neighbouring cells (Ansell-Schultz et al. 2018). 
This study suggests a bi-directional relationship between Aβ and retromer; retromer seems 
to be involved in Aβ distribution, and Aβ can disrupt retromer components (Ansell-Schultz et 
al. 2018). 
Furthermore, KD of VPS35, which is found in spines, endosomes and the TGN, reduces the 
frequency of APP transport and increases APP levels in early endosomes in processes of 
neurons (Bhalla et al. 2012). VPS35 KD also led to enhanced co-localisation of APP and 
BACE1, causing swelling of early endosomes, as well as increased Aβ levels (Bhalla et al. 
2012). After synthesis in the ER, BACE1 is trafficked through the Golgi, then a proportion of it 
moves to the plasma membrane (Tan and Evin 2012; Tan et al. 2020). It then is engulfed by 
early endosomes and is recycled through the to the Golgi, a process which is controlled by 
retromer (Tan and Evin 2012; He, Li, et al. 2005) Inhibiting VPS26 expression leads to 
BACE1 aggregation in early endosomes (He, Li, et al. 2005). 
SNX27 can also influence Aβ through regulation of PS1 activity (Wang et al. 2014). SNX27 
associates with PS1, reducing its activity. SNX27 suppression therefore leads to increased γ- 
secretase activity and subsequent Aβ production; while SNX27 over-expression reduces Aβ 
generation via γ-secretase inhibition in AD mouse model Tg2576 (Wang, Huang, et al. 2014). 
Furthermore, Sorting-related Receptor with A-type Repeats (SORLA) regulates APP 
processing; SORLA KO in mice leads to enhanced Aβ levels in the brain (Andersen et al. 
2005). SORLA interacts with the PDZ domain of SNX27, and SNX27 overexpression can 
increase surface expression of APP and SORLA in neurons, and can also increase sAPPα 
generation (Huang et al. 2016). 
 
1.5.13 Retromer in Neurodegeneration – AMPAR Trafficking 
 
There is strong evidence for the role of retromer in AMPAR trafficking (Munsie et al. 2014; 
Tian et al. 2015; Temkin et al. 2017). Retromer-mediated AMPAR trafficking may be relevant 
in neurodegeneration pathology; VPS35 mutations are associated with defective AMPAR 
trafficking and excitatory neurotransmission in PD models (Munsie et al. 2014). D620N is a 
loss-of-function mutation found in PD that blocks the ability of VPS35 to localise in spines 
(Munsie et al. 2014). D620N overexpression leads to altered surface AMPAR expression in 
cortical neurons compared to WT VPS35; neurons expressing this mutant show enhanced 
GluA1 synaptic clustering (Munsie et al. 2014). This is also seen in dopaminergic neurons 
derived from induced pluripotent stem (iPS) cell from fibroblasts from patients with this 
mutation. This increase clustering is attributed to two potential causes: reduction in GluA1 






Expression of this mutant also enhances excitatory synaptic transmission in cortical neurons 
(Munsie et al. 2014). Tsika et al. (2014) report that expression of this mutant, compared to 
WT, impairs neurite outgrows in cortical neurons and leads to axonal degeneration of 
dopaminergic neurons. 
These studies together provide evidence that retromer is involved in processes relevant to 
neuronal function and neurodegeneration including neurotransmission, receptor trafficking 
and Amyloid metabolism (Temkin et al. 2017; He et al. 2005; Vagnozzi and Praticò, 2019; 







The purpose of this work is to examine the role of PTEN in membrane protein trafficking, 
which is an important aspect of synaptic plasticity. The role of ubiquitination and 
SUMOylation on PTEN in this context will also be tested. 
The main aims are: 
 
• To create and test tools to study PTEN SUMOylation/ ubiquitination 
 
• To characterise these tools and examine how to changes to PTEN SUMOylation 
regulate its function 
• To test cross-regulation of SUMO and ubiquitin on PTEN 
 
• To test the role of PTEN and PTEN SUMOylation/ ubiquitination in AMPAR 
trafficking 
• To examine how PTEN affects retromer in terms of its trafficking ability and 
regulation of its components, and if SUMOylation/ ubiquitination are involved 











Materials and Methods 





3 Materials and Methods 
3.1 Culture of HEK and HeLa cells 
3.1.1 Passaging and Storage 
 
HEK293T and HeLa cells were grown in an incubator at 37 ⁰C 5% CO2 and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5796 Sigma) containing 5% Fetal Bovine 
Serum (Gibco). When confluent, cells were split into a new flask. Cells were washed twice in 
PBS, (10x stock from Gibco), trypsinised by addition of 0.1% trypsin-EDTA (Sigma) for five 
minutes, then fresh media was added and cells were centrifuged for 2 minutes at 1600 RPM. 
The media was then aspirated, and cells were suspended in fresh media. 10% of the total 
cells were added to a new T75 flask and kept as stock. For transfections, cells were stained 
with Trypan blue (Sigma) and counted, then split into dishes. HEK-293T cells were used until 
they had been passaged 25 times. 
 
3.1.2 Plating Cells 
 
6cm plastic dishes (Cellstar) were treated with 2mL 0.1mg/mL Poly-L-Lysine (PLL) (Gibco) 
for 2 hours at 37°C and washed three times with sterile water. PLL treatment was used to 
increase adherence of cells to the dish (Sun et al. 2012). HEK239T and HeLa cells were 




All immunoprecipitation experiments used one 6cm dish of confluent, transfected HEK cells 
per condition. 1.5 million HEK293T cells were split into each dish. The next day, cells were 
transfected with the relevant DNA and Lipofectamine 2000 (Invitrogen) (1.5x amount of μg 
DNA added). DNA and Lipofectamine mixtures were diluted in 500μl plain DMEM in 
Eppendorfs, vortexed and left for 30 minutes at RT. They were then added dropwise to cells 
and dishes were gently swirled, and then incubated. Cells were approximately 80% 
confluent when transfected. Experiments were carried out two days after transfections. For 
experiments involving MG132, this was added 6 hours before lysis at a concentration of 
20μM.





3.2 Culture of Neurons 
3.2.1 Dish Preparation 
 
Six well plates (Cellstar) were left overnight in 0.5 mg/ml Poly-L-Lysine, diluted in borate 
buffer (10mM sodium tetraborate and 50mM boric acid; Sigma). Plates were then washed 
three times in cell culture water and plating media added (Neurobasal (Gibco) with 2% B27 
(Gibco), 5% horse serum (Lab Tech/ Sigma), 1% Glutamax (ThermoFisher) and 1% 
Penicillin/Streptomycin (Gibco)). 
 
3.2.2 Dissection and Plating 
 
Pregnant Wistar rats were anesthetised according to Schedule 1 procedures and their E18 
embryos removed. Brains were removed from embryos and dissected in a 10cm dish 
containing Hanks Balanced Saline Solution (HBSS; Gibco) at RT. Hindbrain and meninges 
were discarded and cortices and hippocampus separated. Pieces of cortex and hippocampus 
were washed three times in 30ml HBSS in a 50ml falcon tube, and trypsinised in a water 
bath at 37 ⁰C (hippocampus for 9 minutes in 9ml HBSS with 1ml trypsin and cortex for 9 
minutes in 27ml HBSS with 3ml trypsin). Cortices and hippocampus were then washed again 
three times with 30ml HBSS, then once in 5ml plating media. Cells were then dissociated by 
pipetting (using a P100 for hippocampus and 5ml serological pipette for cortex). Dissociated 
cells were suspended in warm plating media to a total volume of 20 ml for cortical cells and 
5ml for hippocampal cells. A sterile 70μm nylon mesh filter (Sigma) was used to filter cortical 
cell suspension. A sample of the cell suspension was diluted 1:10 in Trypan Blue and 
counted on a haemocytometer. Hippocampal cells were plated into plating media in 15mm 
dishes on coverslips for imaging, and cortical cells were plated in 2ml plating media at a 
density of 600,000 in each well of a 6-well plate for biochemistry. The next day, media was 
replaced with 3ml feeding media (Neurobasal containing 2% B27, 1% Penicillin/Streptomycin 
(all Gibco) and 0.4% Glutamax (Thermofisher)). For imaging, hippocampal neurons were 
plated at 200,000 cells per coverslip in a 35mm dish in 2ml plating media. Cells were 
incubated at 37 ⁰C with 5% CO2. The next day, media was changed to feeding media. 
 
3.2.3 Neuronal Transfection 
 
1ml transfection media (Neurobasal with 0.4% Glutamax and 2% B27) was added to wells of 
a six well dish and incubated at 37°C. A tube of 1μg DNA in 100μl plain Neurobasal and a 
separate tube of 1.5μl Lipofectamine in 100μl were prepared, vortexed and left at RT for 5 
minutes. These were then mixed and vortexed again, then left at RT for 30 minutes. Each 






coverslip was washed in a dish containing plain neurobasal, then added to the transfection 
media dish. The DNA mixture was vortexed again then added to the well of the six well dish. 
This was incubated for 45 mins at 37°C. After incubation, coverslips were washed in plain 
media, then returned to their original dishes. 
 
3.2.4 Viral Transduction 
 
Lentivirus was defrosted at RT from -80⁰C, then warmed in a 37⁰C water bath. The relevant 
virus was added and cells returned to incubator. 
 
3.3 Western Blot 
3.3.1 SDS-Page 
 
(See tables below for complete supplier information) Immunoprecipitation experiment 
samples were centrifuged for 2 minutes before loading. All other samples were gently mixed 
before loading. 5μl PageRuler™ Prestained Protein Ladder (Thermo) was added to 1 or 
more wells of each gel. Samples were then loaded into remaining wells of 10% SDS-PAGE 
gels consisting of a stacking gel at the top (125 mM Tris-HCl pH 6.8, 4% acrylamide, 0.1%, 
SDS, 0.1% APS and 0.01% TEMED) and a resolving gel at the bottom (10% acrylamide, 375 
mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, and 0.01% TEMED). A 15-well comb was used  
to separate wells of the stacking gel. Gels were made in 1.5 mm glass plates and allowed to 
set for an hour before loading. Gels were inserted into electrode holders in Bio-Rad 
electrophoresis tanks with SDS-PAGE running buffer (25 mM Tris, 250 mM Glycine and 
0.1% SDS) and run at 100-150 volts for around 1-1.5 hours until all the dye front had passed 
through the bottom of the gel. Proteins on gels were then transferred to membranes in 
electrode cartridges with blotting paper and sponges either side. Tanks were filled with 
transfer buffer (25 mM Tris, 192 mM Glycine, 20% Methanol) and an ice block and stirring 
bean were added. Transfer was run for 66 minutes at 400mA. Membranes were washed 
once in Phosphate Buffered Saline and Tween (PBST; 137mM NaCl, 10mM Na2HPO4, 
2.7mM KCl, 2mM K2HPO4, 0.001% Tween) then blocked for one hour in 5% milk or BSA in 
PBST at RT, then incubated with the relevant primary antibody at 4⁰C (see Table 2 for 
antibodies and time of incubation.) After the required length of time, membranes were 
washed in PBST. Horseradish peroxidase-tagged secondary antibody was added in 5% milk 
or BSA in PBST at 1:10,000. Membranes were then washed five times in PBST, then 3 times 
for 5 minutes on a shaker. Membranes were then gently dried of excess PBST and 
enhanced chemiluminescence substrate (ECL) was added for 60-90 seconds. Membranes 
were then sealed in clear plastic to prevent drying. They were imaged in a Li-core Odyssey 




machine. All blots were developed in this way except Figure 4.3.2 which was developed on 
X-ray film in a Konica SRX-101A medical film developer in a dark room. 
 
3.3.2 Lysis of Cells for Western Blotting – Total Protein 
 
Confluent cells in 6-well dishes were lysed in 200μl 1x Laemmli buffer (see below), scraped 
into tubes and boiled on a heat block at 95°C for 10 minutes. In the case of neurons, cells 
were lysed at a specific number of days in vitro (DIV) as specified. Samples were stored up 
to a week at 4°C or for longer periods at -20°C. 
 
3.3.3 Laemmli Sample Buffer (4x) 
 
Buffer containing 4% SDS, 10% glycerol, 0.004% bromophenol blue, 125 mM Tris pH 6.4. 
For lysis for total protein experiments, this was diluted to 1x. For adding to beads after 
immunoprecipitation experiments, 2x was added. 10% 2-β-mercaptoethanol (βME) was 
added fresh each time before use. 
Table 2. Antibodies 
 
Antibody Cat. No./ Clone Supplier Diluent Conc. Secondary 
Antibody 
Time  
β-Actin A5441 Sigma-Aldrich Milk 1:10,000 Rabbit 1 hour 
Akt PAN40D4 (2920S) Cell-Signalling 
Technologies 
BSA 1:1000 Mouse Overnight 
ASCT2  8057 (D7C12) Cell-Signalling 
Technologies 
Milk 1:1000 Rabbit Overnight 
Phos Akt 
S473 
D9E (4060S) Cell-Signalling 
Technologies 
BSA 1:1000 Rabbit Overnight 
GAPDH ab8245 Sigma Milk/BSA 1:10,000 Mouse 1 hour 
GFP Pabg1-100 ChromoTek Milk/BSA 1:4000 Rat 1 hour 
GluA1 13185 (D4N9V) Cell Signalling 
Technologies 
Milk 1:1000 Rabbit Overnight 
GluA2 182103 Synaptic 
Systems 
Milk 1:1000 Rabbit Overnight 
GLUT1 ab115730 Abcam Milk 1:1000 Rabbit Overnight 
HA HA-7 H3663 Sigma Milk/BSA 1:1000 Mouse 1 hour 
VPS26 ab23892 Abcam BSA 1:1000 Rabbit 1 hour 
VPS35 ab95745 Abcam BSA 1:1000 Mouse Overnight 
GST 27457701V GE Healthcare Milk 1:500 Goat 1 hour 
Myc 9B11 Cell-Signalling 
Technologies 
Milk 1:4000 Mouse 1 hour 
PTEN 95525 Cell Signalling 
Technology 
Milk/BSA 1:1000 Rabbit 1 hour 
SBP 10764 Millipore Milk 1:4000 Mouse 1 hour 
SENP3 5591S Cell Signalling 
Technology 
BSA 1:1000 Rabbit 1 hour 
SUMO1 4930S Cell-Signalling BSA 1:1000 Rabbit Overnight 





SUMO2/3 4971S Cell-Signalling 
Technologies 
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Santa-Cruz Milk 1:1000 Mouse Overnight 
N-Cadherin 13A9 Cell-Signalling 
Technologies 
BSA 1:1000 Mouse Overnight 
Phospho-
ERK 




Sigma BSA 1:1000 Rabbit Overnight 
 
Horseradish peroxidase (HRP)-conjugated secondary antibodies for Western blotting (anti-rat  
raised in rabbit, anti-mouse and anti-rabbit raised in goat) were sourced from Sigma and used at 
1:10,000 concentration in the same diluent in which the primary had been used (5% milk or BSA in 
PBST). Cy3 secondary antibody for confocal imaging (chicken, raised in donkey) was sourced  

































Table 3. Reagents- SDS-PAGE and Western Blot
Reagent Description Supplier 
Milk powder For blocking and blotting membranes The Co-Operative 
Pageruler™ Prestained Protein Ladder for SDS-PAGE Thermo-Fisher 
30% Acrylamide For SDS-PAGE gels Geneflow Limited 
TEMED Tetramethyl-ethylenediamine Sigma-Aldrich 
APS Ammonium Persulfate Sigma-Aldrich 
BSA Bovine Serum Albumin Sigma-Aldrich 
0.45 μm Immobilon-PVDF Polyvinyl difluoride membrane Millipore 
NEM N-Ethylmaleimide Sigma-Aldrich 
BME 2-Mercaptoethanol Sigma-Aldrich 
Triton-X 100-X Detergent Sigma-Aldrich 
SDS Sodium dodecyl sulphate Sigma-Aldrich 
Tris-HCL TRIZMA base T1503 + dh20 + HCL Sigma-Aldrich 
SuperSignal™ Enhanced chemiluminescent substrate: 
Pico and Femto 
Thermo-Fisher 
Immobilon Enhanced chemiluminescent substrate: 
Classico and Forte 
Millipore 





3.4 Immunoprecipitation Experiments 
3.4.1 PSD-95 and SNX27 Immunoprecipitation – GFP Trap 
 
See tables below for supplier information- cells were lysed in 0.7 ml ice cold buffer containing 
50mM Tris-HCL pH 7.4, 150mM NaCl, 0.5% Triton-X 100, 20μM NEM (Sigma), and protease 
inhibitors (Roche). Samples were vortexed, left on ice for 25 minutes, then centrifuged in a 
benchtop centrifuge for 20 minutes at 4⁰C at 13.2 rpm. The supernatant was removed and a 
20μl input sample taken from each sample and kept on ice. The remaining supernatant was 
added to 6μl GFP-Trap beads (Chromotek) and samples were left at 4⁰C on a rotating wheel 
at for one hour. Samples were then washed three times in 1ml wash buffer containing 50mM 
Tris-HCL pH7.4, 150 mM NaCl and 0.5% Triton-X 100. Samples were centrifuged at 
4000rpm for 2 minutes at 4⁰C between each wash to pellet beads. 2X Laemmli buffer was 
then added to inputs and samples and all were heated on a shaking heat block at 95 ⁰C for 
10 minutes. 
 
3.4.2 SUMO and Ubiquitin Immunoprecipitation – GFP Trap 
 
Two days after transfection, cells were lysed in 0.7ml ice cold buffer containing 20mM Tris- 
HCL pH 7.4, 137mM NaCl, 2mM EDTA, 1%Triton-X 100-X, 10% Glycerol, 0.1% SDS, 20μM 
NEM and protease inhibitors and scraped. Samples were sonicated to enhance 
likelihood of SUMOylation detection, as sonication can improve immunoprecipitation of 
proteins which can be hindered by viscous components in lysate (Meng et al, 2017). 
Each Eppendorf was subject to 5x 5 second pulses using a Microson Ultrasonic Cell 
Disrupter on the highest setting (5), they were then left on ice for 25 minutes and 
centrifuged in a benchtop centrifuge for 20 minutes at 4⁰C at 13.2 rpm. The supernatant 
was removed and a 20μl input sample taken from each sample and kept on ice. The 
remaining supernatant was added to 6μl GFP-Trap beads and samples were left at 4⁰C 
on a rotating wheel at for one hour. Beads were then washed three times in the same 
buffer as the lysis buffer, without protease inhibitors and NEM. 2x Laemmli buffer was 
added and samples were boiled at 95⁰C for 10minutes. For the ubiquitin 
immunoprecipitation, 10μM MG132 was added for 6 hours prior to lysis. 
 
3.4.3 SUMO2/3 Immunoprecipitation in 2% SDS – GFP Trap 
 
The same protocol as above was followed, with same lysis buffer but with 2% SDS during 
lysis. Before being added to beads, lysate was diluted with lysis buffer without SDS so that 
final concentration of lysate on beads contained 0.5% SDS. 





3.4.4 SUMO2/3 and Ubiquitin Immunoprecipitation with SENP1 – GFP Trap 
 
Cells were lysed in 0.7ml ice cold buffer containing 20mM Tris-HCL pH 7.4, 137mM NaCl, 
2mM EDTA, 1%Triton-X 100-X, 10% Glycerol, 0.5% SDS, 20μM NEM and protease 
inhibitors. Samples were sonicated, left on ice for 25 minutes, then centrifuged in a benchtop 
centrifuge for 20 minutes at 4⁰C at 13.2 RPM. The supernatant was removed and a 20μl 
input sample taken from each sample and kept on ice. The remaining supernatant was 
added to 6μl GFP-Trap beads and samples were left at 4⁰C on a rotating wheel at for one 
hour. Samples were washed three times in wash buffer containing 50mM Tris-HCI pH 7.4, 
150mM NaCl and 5mM MgCL2, pH 7.5. Recombinant SENP1 enzyme was added at a final 
concentration of 100nM diluted in wash buffer, the same amount of buffer was left on the 
other samples not treated with SENP1. All samples were incubated at 37⁰C for an hour. 2x 
Laemmli buffer was then added to all samples and inputs and they were boiled at 90⁰C for 10 
minutes. 
 
3.4.5 PTEN Dimer Immunoprecipitation 
 
Cells were lysed in 0.7mL ice cold buffer containing 50mM Tris-HCL pH 7.4, 150 mM NaCl, 
0.5% Triton-X 100, 20μM NEM, and protease inhibitors. Samples were vortexed, left on ice 
for 25 minutes, then centrifuged in a benchtop centrifuge for 20 minutes at 4⁰C at 13.2 rpm. 
The supernatant was removed and a 20μl input sample taken from each sample and kept on 
ice. The remaining supernatant was added to 6μl GFP-Trap beads and samples were left at 
4⁰C on a rotating wheel at for one hour. Samples were then washed three times in 1ml wash 
buffer containing 50mM Tris-HCI pH7.4, 150 mM NaCl and 0.5% Triton-X 100. Samples 
were centrifuged at 4000rpm for 2 minutes at 4⁰C between each wash to pellet beads. 2X 
Laemmli buffer containing 10% BME was then added to inputs and samples and all were 
heated on a shaking heat block at 95 ⁰C for 10 minutes. 
3.4.6 Cycloheximide Timepoint Experiments 
 
The day after splitting, wells of a 12 well dish of HEK293T cells were transfected with 1µg 
GFP-tagged WT-PTEN or 3KR-PTEN DNA. The next day, cycloheximide was added to 
media at a concentration of 100µg/ml. 24 hours later, cells were lysed in 1x Laemmli buffer. 





3.4.7 Surface Biotinylation - Neurons 
 
Wells of 6 well plates of neurons were biotinylated, with 600,000 cells in each well for each 
condition. Plates were cooled on ice for 2 minutes, then kept on ice for the rest of the 
protocol. After cooling, cells were washed three times in PBS, then 0.3mg/ml Sulpho-NHS- 
SS-biotin (Thermo-Fisher) in PBS was added for 10 minutes. Cells were then washed five 
times in PBS and lysed in buffer containing 50mM Tris pH 7.4, 150mM NaCI, 1% Triton-X 
100, 0.1% SDS, and protease inhibitors. All steps were carried out on ice and all buffers 
were kept on ice. After cells were lysed, samples were vortexed and left on ice for 25 
minutes, then centrifuged for 20 minutes at 4⁰C at 13.2 RPM. A 20μl input sample taken from 
each sample and kept on ice. Equal amounts of the remaining supernatant were then added 
to 30μl Streptavidin beads (Sigma) and tubes were left at 4⁰C on a rotating wheel at for one 
hour. Samples were then washed three times in 1ml wash buffer (lysis buffer without 
protease inhibitors). Samples were centrifuged at 4000rpm for 2 minutes at 4⁰C between 
each wash to pellet beads. 2X Laemmli buffer containing 10% BME was then added to inputs 
and samples and all were heated on a shaking heat block at 95 ⁰C for 10 minutes. 
 
3.4.8 Surface Biotinylation - HeLa cells 
 
250,000 stable HeLa cells expressing Scr, PTEN KD, PTEN-WT, PTEN-3KR and PTEN CM 
were plated into each well of a 6-well plate. The next day, cells were washed three times in 
PBS, then 0.3mg/ml Sulpho-NHS-SS-biotin in PBS was added for 10 minutes. Cells were 
then washed five times in PBS and lysed in buffer containing 50mM Tris pH 7.4, 150mM 
NaCl, 1% Triton-X 100, 0.1% SDS and protease inhibitors. All biotinylation steps were 
carried out on ice and all buffers were kept on ice. After cells were lysed, samples were 
vortexed and left on ice for 25 minutes, then centrifuged for 20 minutes at 4⁰C at 13.2 rpm. A 
20μl input sample taken from each sample and kept on ice. The remaining supernatant was 
added to 30μl Streptavidin beads and samples were left at 4⁰C on a rotating wheel at for one 
hour. 
Samples were then washed three times in 1ml wash buffer (lysis buffer without protease 
inhibitors). Samples were centrifuged at 4000rpm for 2 minutes at 4⁰C between each wash to 
pellet beads. 2X Laemmli buffer was then added to inputs and samples and all were heated 
on a shaking heat block at 95 ⁰C for 10 minutes. 






Table 4. Biochemistry Reagents 
 
Reagent Description Supplier Cat No. 
EZ-Link™ Sulfo-NHS- 
SS-Biotin 
Biotin for surface 
Biotinylation 
Thermo-Fisher 21331 
ChromoTek GFP-Trap® GFP beads ChromoTek N/A 
SENP Enzyme SENP1 catalytic domain Made in the lab by 
Dr A. Nishimune 
N/A 
MG132-R Degradation blocker Tocris 6033 
Complete™ Protease 
Inhibitor tablets 
Protease inhibitors Roche 
Diagnostics 
11697498001 
Streptavidin beads From Streptomyces avidinii Sigma-Aldrich GE90100484 
NEM N-Ethylmaleimide Sigma-Aldrich E3876 
PBS Phosphate Buffered Saline Gibco  
 
3.5 Confocal Imaging 
3.5.1 Coverslip Preparation 
 
Coverslips were treated in nitric acid overnight, then washed 3 times in H20 and left on a 
rotating plate for 30 minutes during each wash. They were then left in ethanol for 4 hours, 
then washed three times in cell culture water on a rotating plate. Coverslips were then left 
overnight in 1mg/ml Poly-L-Lysine, diluted in borate buffer (10mM sodium tetraborate and 
50mM boric acid, both Sigma). Coverslips were then washed three times in cell culture water 
and plating media added. 
 
3.5.2 Coverslip Fixing, Antibody Staining and Confocal Imaging 
 
25mm coverslips were placed in a six well dish with 1ml 4% paraformaldehyde (PFA) 
(Sigma) in 1x PBS facing upwards and incubated for 15 minutes at 37°C. Coverslips were 
then washed three times in 1x PBS at RT. PFA was then quenched with 100mM glycine in 
1x PBS and coverslips washed three times in PBS. 1.5ml TBP (0.1% Triton-X 100, 2% 
BSA in 1x PBS) was added for 20 minutes at RT. 90μl primary antibody (GFP) was then 
added in 3% BSA in PBS for 45 minutes, while coverslips face down on parafilm at RT. 
Coverslips were put back into six well dishes and washed three times in PBS, then put 




face down again onto parafilm with 90μl secondary antibody in 3% BSA for 45 mins in the 
dark. Coverslips were then put back into six well dish, washed four times in PBS and once 
in ddh20 and fixed onto glass slides with Fluoromount-G mounting medium containing 
DAPI (4′,6-diamidino-2-phenylindole) nuclear fluorescent stain (eBioscience). Coverslips 
were imaged with a 63x Harmonic Compound X PL APO CS oil immersion objective on a 
Leica SP5-II confocal laser scanning microscope. 1024x1024 pixel resolution was used. 
Zoom parameters were not kept constant due to the preliminary nature of this experiment.  
 
3.5.3 Analysis and Statistics 
 
For, immunoprecipitation experiment samples, 2μl of each sample was run and blotted for 
the tag of the immunoprecipitated protein. The signal from the immunoprecipitated protein 
was normalised to this, to account for differences in expression of the recombinant protein 
between conditions. The blot of the 2μl immunoprecipitated sample is labelled re-probe. 
ImageStudio software was used to analyse bands for LI-CORE images, ImageJ was used to 
analyse bands developed on film. Statistical analysis and presentation were carried out in 
Prism. All error bars represent SEM unless otherwise stated.





3.6 Cloning of DNA Constructs 
 
Table 5. Reagents- Cloning 
 
Reagent Description Supplier Cat No. 
Hyperladder (1kb) DNA marker DNA gel marker Bioline BIO-33053 
GeneJET Plasmid Miniprep Kit Miniprep kit Thermo-Fisher K0503 
GeneJET Plasmid Midiprep Kit Midiprep kit Thermo-Fisher K0481 
DNA gel Loading dye (6x) DNA gel dye New England Biolabs B7025 
XL1-Blue E-coli Competent cells Agilent 200236 
DMSO Dimethyl Sulfoxide Sigma-Aldrich D8418 
KOD Hot Start DNA Polymerase 
kit (MgSO4, dNTPS, 10x hot 
start buffer, polymerase) 
PCR Reagents Merk-Millipore 71086 
Restriction enzymes  New England Biolabs  
T4 DNA ligase solution1  Takara 2011B 
Custom DNA Oligonucleotide 
primers 
 Sigma N/A 
Luria broth Bacterial medium Fisher Scientific BP14262 
Ampicillin Ampicillin sodium salt 
100mg/ml stock in 50% 
ethanol 
Sigma-Aldrich A-9518 
Kanamycin Kanamycin monosulfate 
10mg/ml stock in Dh20 
Sigma-Aldrich K-4000 
Agarose DNA Gel A-6013 Agarose Type I, 
Low EEO 
Sigma-Aldrich A6013 
GeneJET™ Gel Extraction Kit DNA extraction Thermo-Fisher K0691 






Table 6. Plasmids 
 
Construct Tag Creator/ 
Source 
Vector Cloning Sites and 
Promotor 
Notes 
Empty Vectors      
pSUPER-neo- 
GFP 




GFP Dr K 
Wilkinson 
- - Lentiviral vector 
ShRNA 
Constructs 
     







into the PacI 
and XhoI sites 
shRNA target sequence: 
CGACTTAGACTT 
GACCTATAT 







into the PacI 
and XhoI sites 
Control shRNA- 
expressing plasmid 
used as a control for 
the PTEN shRNA. 
Contains a mock target 
sequence:AATTCT 
CCGAACGTGTCA C 








into the KpnI 
site 
Control shRNA for the 
SENP3 shRNA. 



































sites. Driven by 
a CMV 
promoter 
Source of the rat PTEN 
cDNA 
sequence used 





































































































     
pMD2.G  Prof. 
Pete 
Cullen 
  Addgene plasmid 
12259 
p8.91  Prof. 
Pete 
Cullen 




3.6.1 General Cloning Methods 
 
All plasmids were sequenced by Eurofins Genomics. All PCR reactions were carried out in a 












KOD Polymerase Reaction 
 
Reagent Amount 
10x Buffer* 5μl 
dNTPs* (0.2mM each final concentration) 5μl 
MgSO4* (1.5mM final concentration)  3μl 
Polymerase* (0.02U/µl final concentration)  1μl 
10uM forward primer (0.3 µM final concentration) 1.5μl 
10uM forward primer (0.3 µM final concentration) 1.5μl 
Template DNA (1ng/μl; 10ng total template DNA in reaction) 10μl 
dH20 23μl 
 
(* from KOD Hot Start DNA Polymerase Kit; Millipore Novagen) 
PCR Cycling  
Step Temperature Duration 
1. Polymerase Activation 95⁰C 2 minutes 
2. Denature 95⁰C 20 seconds 
3. Annealing 55⁰C 10 seconds 
4. Extension 70⁰C 10 seconds for shRNA fragment 
5. Repeat steps 2-4 24 cycles  
Designed according to Novagen User Protocol TB34 
Digest of Vectors and PCR products 
5μl vector DNA was mixed with 0.25μl enzymes, 2μl 10x Cutsmart buffer, 2μl CIP (all NEB) 
and 12.5μl H20. For PCR products, 45μl was mixed with 10μl Cutsmart buffer, 2μl enzymes 
and H20 up to 100μl. Digest mixtures were incubated for 1.5 hours at 37°C. 
Ligation 
Digested PCR products and vectors were run on an agarose gel and imaged on a UV 
transilluminator to determine approximate relative concentrations. PCR products and vectors 
were then ligated at an insert: vector ratio of 5:1. PCR products and vector were first diluted 
in water. 1μl vector was mixed with 1μl PCR product and 2μl Takara 1 solution (Takara). The 
tube was flicked and incubated for 30 minutes. 
 
3.6.2 PTEN KD Plasmid 
 
PTEN KD shRNA primers were designed with the help of Dr Kevin Wilkinson. These 
oligonucleotide primers diluted in Tris EDTA buffer, left to mix for an hour then were heated 
at 95⁰C for 4 minutes to anneal them: 
GATCCCCCGACTTAGACTTGACCTATATTTCAAGAGAATATAGGTCAAGTCTAAGTCGTT 
TTTC-3’ (see target sequences in table above) and 5’- 
TCGAGAAAAACGACTTAGACTTGACCTATATTCTCTTGAAATATAGGTCAAGTCTAAGTC 




GGGG-3’. The double stranded product was then cloned next to a H1 promotor in the 
plasmid pSUPER-neo-GFP, between BamHI and XhoI sites. To create a PTEN KD construct 
in a viral vector, the H1-shRNA section was amplified by PCR using generic primers H1 PacI 
F (5’-CACTTAATTAACGAACGCTGACGTCATCAACC-3’) and M13_30nt R (5’- 
AGCGGATAACAATTTCACACAGGA-3’). The product was then cloned into lentiviral vector 
pXLG3-PX-GFP-WPRE between PacI and XhoI sites, creating pXLG3-shPTEN-GFP-WPRE. 
As a control, a pXLG3-PX-GFP-WPRE vector expressing a non-targeting, scrambled shRNA 
(mock target sequence 5’- AATTCTCCGAACGTGTCAC-3’) under the control of a H1 
promoter was used.   
3.6.3 GFP PTEN-WT and GFP PTEN-3KR 
 
Dr Michaela Heimann and Dr Kevin Wilkinson originally created this mutant in the plasmid 
pNTAP-B (Agilent Technologies). The PTEN-3KR mutant has mutations at lysine residues 
shown to be SUMOylated on PTEN: K266, K254 and K289 (Huang et al. 2012, Gonzalez- 
Santamaria et al. 2012, Bassi et al. 2013). These were mutated to arginine. 
Dr Kevin Wilkinson created a GFP-tagged PTEN-3KR mutant via the following methods. He 
also made a GFP-tagged PTEN-WT clone using the PTEN-WT rat sequence (NCBI entry: 
AF455569.1). The following methods were conducted by Dr K Wilkinson: First, shRNA- 
resistant GFP-PTEN-WT and PTEN-3KR rescue constructs were made by using site- 
directed mutagenesis to make 6 silent mutations in the shRNA sequence of pNTAP-B. This 
was done with primers: shPTEN-res F (5’- 
CAAGAGGATGGATTCGACCTGGATCTAACATATATTTATCCAAATATT-3’) and shPTEN- 
res R (5’- AATATTTGGATAAATATATGTTAGATCCAGGTCGAATCCATCCTCTTG-3’). 
These constructs were then amplified by PCR using the primers PTEN F (5’- 
GTGGGATCCACAGCCATCATCAAAGAGATC-3’) and PTEN R (5’- 
CACTGGCCATCAGACTTTTGTAATTTGTGA-3’), creating GFP-PTEN-WT and PTEN-3KR 
rescue constructs. A digestion was then carried out on the PCR product and pXLG3- 
shPTEN-GFP-WPRE vector using BamHI and MscI and the PCR product was cloned into 
the vector. 
 
3.6.4 Bacterial Transformation and DNA Preparation 
 
To amplify DNA plasmids for midiprep, 1μl of DNA was mixed with 30μl of XL-1 Blue E. coli 
and kept on ice for 20 min before 45 second heat shocked at 37⁰C. The mixture was kept on 
ice for 2 minutes and added to 100ml Luria Bertani (LB) broth for 24 hours at 37⁰C with 
antibiotics (Ampicillin or Kanamycin). Kanamycin resistant plasmids were first mixed with 
100μl plain broth then incubated at 37 ⁰C for an hour to allow antibiotic resistance before 




being added to broth with Kanamycin. 24 hours later, cultures were midiprepped using 
GeneJET™ Midiprep Kit to isolate the relevant DNA according to manufacturer’s protocol. 
 
3.6.5 Bacterial Strains 
 
For cloning and DNA amplification, Competent DH5α were used. These were made in house. 
DH5α (supE44 Δlac Φ80 lacZΔ M15 hsdR17 recA1 endA1 gyrA96 thi-1 relA1 u169) 
For cloning and DNA amplification of Lentiviral plasmids, XL1-Blue Competent Cells were 
used. (XL1-Blue (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F proAB 
lacIqZΔM15 Tn10 (Tetr)]) 
 
3.6.6 Agar Plates and Broth for Bacterial Growth 
 
Agar plates were made using 1.5% agar and LB broth and stored at 4°C. Bacteria were 
grown in LB broth. Both were used with antibiotics kanamycin (25µg/ml) or ampicillin 
(100µg/ml) and made in house by University of Bristol Technician Team. 
 
3.6.7 Lentivirus Production 
 
To make the SENP3, Scr, PTEN KD, PTEN-WT, PTEN-3KR and PTEN CM Lentivirus, 7 
million HEK293T cells were split into 10cm dishes with DMEM and 5% FBS (1 dish per 
virus). The next day, media was removed and cells were transfected. The following DNA was 
added to 2.5ml plain DMEM: 
 
- 10μg XLG viral vector 
- 2.5μg pMD2.G (expresses VSV-G envelope) 
- 7.5μg p8.91 (helper vector) 
 
2.5ml plain DMEM was mixed with 120 μl 1mg/ml PEI (Sigma) and this was added to the 
DMEM/ DNA mixture. Transfections were left for 30 minutes at RT then added to the cells 
after media had been removed. Four hours later, transfection mix was replaced with 
complete DMEM. 36-48 hours later, virus-containing media was centrifuged to remove dead 
cells, virus was then aliquoted and stored at -80⁰C. 
 
3.6.8 HeLa Cell Line Production 
 
40,000 HeLa cells were split into a 12 well dish. The next day, 250μl of each of Scr, PTEN- 
KD, PTEN-WT, PTEN-3KR or PTEN-C124S Lentivirus were added. Two days later, cells 
were split into T75 flasks and allowed to grow until confluent, and kept for four passages. 
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4 Detecting PTEN SUMOylation and Ubiquitination 
4.1 Introduction 
4.1.1 PTEN SUMOylation Sites and Recombinant SUMO in Previous Research 
 
PTEN is reported to be SUMOylated, which has effects on its localisation, phosphatase 
activity and stability (Huang et al. 2012; Bawa-Khalfe et al. 2016), but PTEN SUMOylation in 
the context of neurons or neurodegeneration has not yet been tested. This is of interest due 
to evidence PTEN attenuation can relieve AD-related synaptic deficits (Knafo et al. 2016). 
Furthermore, other PTMs such as ubiquitination can influence PTEN stability, which is 
thought to underlie PTEN loss seen in AD (Kwak et al. 2010). (For a more detailed analysis 
of the current literature on PTEN SUMOylation, see General Introduction, section 1.3.). 
PTEN has been shown to be SUMOylated at three sites: K254, K266 and K289 (Huang et al. 
2012; Gonzalez-Santamaria et al. 2012), and SIM sites on PTEN have also been identified 
(Bawa-Khalfe et al. 2016). It was reported that PTEN-SUMOylation enables membrane 
localisation and nuclear retention of PTEN, which has effects on its ability to regulate p-Akt 
and limit tumorigenesis (Huang et al. 2012). It should be noted that most studies that 
previously tested the level of SUMOylation of PTEN mutants lacking one or more 
SUMOylatable lysine did so with recombinant, tagged SUMO1 or 2 in immunoprecipitations, 
or recombinant SUMO in in vitro SUMOylation assays (where SUMO proteins are produced 
in bacteria then purified and mixed with PTEN in a tube, along with the essential enzymes of 
the SUMOylation cascade), rather than with endogenous SUMO. Overexpression of 
recombinant SUMO has been suggested to lead to artefacts if it is not controlled (Eifler and 
Vertegaal, 2015). Furthermore, tagged proteins can behave differently to their endogenous 
counterparts (Skube et al. 2010). Therefore, although the biochemical evidence for the 
expected reduction in SUMOylation of these non or reduced-SUMOylation mutants in cell 
lines is compelling, it has so far perhaps not been widely validated in the most physiologically 
relevant way. Testing endogenous SUMOylation of PTEN is therefore critical in 
understanding the physiological relevance of SUMOylation. 
 
4.1.2 Evidence for PTEN SUMOylation by Endogenous SUMO 
 
Most of the previous studies have not evaluated the level of endogenous SUMO on PTEN 
mutants, so from these studies, it cannot be unequivocally concluded how these mutants are 
affected by endogenous SUMO. The only study to test endogenous SUMO in this way to 
date was carried out by Bawa-Khalfe et al. (2016), who tested SUMOylation in the context of 
prostate cancer models. A PTEN K254A/K266A double mutant was reported to be less 
modified by endogenous SUMO1 and ubiquitin than PTEN-WT, in IPs from transfected PC-3 





cells (Bawa-Khalfe et al. 2016). The group failed to detect endogenous SUMOylation of 
PTEN with SUMO2/3. 
 
4.1.3 SUMO and Ubiquitin Crosstalk on PTEN 
 
PTEN has also been shown to be ubiquitinated at K13, K66, K266 and K289 (Trotman et al. 
2007; Gonzales-Santamaria et al. 2012, Wu et al. 2016). PTEN ubiquitination is important in 
various aspects of PTEN regulation including stability, catalytic activity and nuclear 
localisation; some of these effects may be relevant in cancer (Bassi et al. 2013; Trotman et 
al. 2007, Leslie and Gupta, 2016; Maccario et al. 2010, Duerr et al. 1998) and 
neurodegeneration (Kwak et al. 2010). Ubiquitination of PTEN is thought to be involved in the 
reduced levels of PTEN reported in AD brains (Kwak et al. 2010; Griffin et al. 2005). 
Generally speaking, when target proteins are SUMOylated, the conjugated SUMO can recruit 
a SUMO targeted ubiquitin ligase (STUbL), which is a ubiquitin E3 ligase that can facilitate 
ubiquitination (Ohkuni et al. 2018). This mechanism allows for cross-talk between SUMO and 
ubiquitin on target proteins (Geoffroy and Hay 2009; Ohkuni et al. 2018). An example is 
reported by Bawa-Khalfe et al. (2016) who showed that in cells lacking SENP1, PTEN 
associates with WWP2, a ubiquitin E3 ligase. This increased ubiquitination and subsequent 
degradation of PTEN, so it was concluded that SENP1, through de-SUMOylating PTEN, 
inhibits SUMO1-Dependent PTEN ubiquitination and degradation (Bawa-Khalfe et al. 2016). 
This mechanism plays a role in prostate cancer development (Bawa-Khalfe et al. 2016). 
However, SUMO-ubiquitin cross-regulation on PTEN is complex, as SUMOylation has also 
been found to limit ubiquitination and subsequent degradation of PTEN (Wang et al. 2014). It 
is not clear exactly why this is seen; one explanation suggested by Gonzales-Santamaria et 
al. (2012), is that SUMO and ubiquitin compete for the same sites on PTEN. This is possible 
given that K266 and K289 are known to be modified by both proteins (Huang et al. 2016, 
Gonzales-Santamaria et al. 2012; Trotman et al. 2007). Another possibility is that 
SUMOylation at one site blocks ubiquitination at another site; this is supported by evidence 
that simultaneous SUMOylation at both sites is not possible, shown by a lack of band shift 
between single and double mutations at known PTEN SUMOylation sites (Wang et al. 2014). 
Huang et al. (2012) explain that more space is needed on PTEN for SUMO modification 
compared to other PTMs such as phosphorylation, making it difficult for concomitant 
SUMOylation of K254 and K266 to occur. As ubiquitin is a similar size, it is in theory possible 
that it is also blocked by SUMOylation at another site. 





4.1.4 SUMO-Ubiquitin Hybrid Chains 
 
SUMO and ubiquitin can also form mixed chains on target proteins (Tatham et al. 2008). 
Receptor-associated protein 80 (RAP80), a subunit of a complex containing breast cancer 
susceptibility gene 1 (BRCA1), mediates recruitment of BRCA1 to sites of DNA damage 
(Kim, Chen, and Yu 2007; Guzzo et al. 2012). The ubiquitin E3 ligase RNF4 can facilitate 
SUMO-ubiquitin hybrid chains at DNA damage sites, which are necessary for BRCA1 
recruitment to these sites (Guzzo et al. 2012). SUMO-ubiquitin hybrid chains at DNA damage 
sites are recognised by RAP80 due the close proximity of a SIM and UIM (Ubiquitin 
Interacting Motif) on RAP80 (Guzzo et al. 2012). The presence of these mixed chains at DNA 
damage sites increased recognition by RAP80 80-fold, compared to chains formed of SUMO 
or ubiquitin alone, suggesting the importance of combined SUMO/ubiquitin signals (Guzzo et 
al. 2012). Hybrid chains can also act as a signal for degradation (Tatham et al. 2008). 
A point of interest in this field is that two sites on PTEN are known to be both SUMOylated 
and ubiquitinated (K266 and K289) (Trotman et al. 2007; Huang et al. 2012; Gonzales- 
Santamaria et al. 2012), so it is hard to distinguish which effects are caused by either SUMO 
or ubiquitin. The Bawa-Khalfe (2016) paper is perhaps most useful for this reason, as they 
used SENP knockdown and overexpression, and SENPs are specific to SUMO 




The goal of the work in this chapter was to create tools to examine SUMOylation and 
ubiquitination of PTEN, with a view to later examining how SUMO and ubiquitin modification 
of PTEN may affect plasticity and protein trafficking in neurons and cells lines. It was 
important to optimise SUMOylation and ubiquitination detection with endogenous SUMO, as 
this has not been widely tested, and previous studies on SUMO-regulation of PTEN lack 
homogeneity. I also wanted to characterise SUMO/ubiquitin crosstalk. Specifically, my aims 
were to 
 
• Optimise the detection of SUMOylation and Ubiquitination of PTEN 
 
• Create and characterise PTEN-SUMO/Ubiquitin mutants as tools to study the 
effects of PTEN SUMOylation and ubiquitination 
• Characterise SUMO/ubiquitin crosstalk on PTEN and examine hybrid chains 






4.3.1 Creation of PTEN KD Lentivirus 
 
To make a PTEN knockdown (KD) Lentivirus, I first cloned a PTEN KD short hairpin RNA 
(shRNA) into pSuper (an shRNA expression vector). shRNA along with its promoter were 
then cloned into a GFP expressing viral plasmid (pXLG) (see Methods for all cloning 
protocols). This was then transfected in HEK cells along with Lentiviral helper plasmids to 
create Lentivirus (see Methods for virus making protocols). A control virus was also made 
using a pXLG plasmid containing a scrambled shRNA sequence (Scr), cloned by Dr K 
Wilkinson. To validate the PTEN KD virus and PTEN antibody, different amounts of PTEN 
KD or control Scr Lentivirus were added to rat cortical neurons on DIV 7 and left for 7 days. 
Cells were lysed, subjected to Western blot for PTEN (Figure 4.3.1.1). The blot suggests that 
PTEN is greatly reduced by the PTEN KD virus in a dose Dependent fashion (this was later 
repeated and analysed statistically, see Figure 5.3.7.1), suggesting the detected band is 
indeed PTEN and the lentivirus is successfully knocking it down. This Lentivirus is therefore 
a useful tool to study PTEN. 
 
 
Figure 4.3.1.1. PTEN KD Lentivirus Knocks Down Total PTEN. 
Western Blot showing PTEN expression after Lentiviral transduction in neurons. PTEN KD 
shRNA or Scr viruses were added to wells of a 6 well dish containing rat cortical neurons 
and 1.5mL media. 7 days later, cells were lysed and subject to Western Blot, then blotted 
for PTEN and B-Actin (N=1). 





4.3.2 Detection of Modified PTEN 
 
In cultured cortical neurons, blotting for PTEN at high exposure reveals a band at around 
70kDa, above the usual band detected at 55kDa (Figure 4.3.2.1). A similar band has been 
detected by Bassi et al. (2013), who suggest it is SUMOylated PTEN as it is increased by N- 
ethylmaleimide (NEM), an inhibitor of cysteine protease enzymes including SENPs, and is 
decreased by recombinant SENP treatment. The figure shows PTEN signal after two 
different exposure times; the 55kDa PTEN band is visible, and the higher exposure also 
shows an additional higher band of PTEN at ~65-70kDa. The absence of this upper band in 
the PTEN KD Lentiviral condition suggests it is specific to PTEN. However, through further 
examination of the literature I found that this higher band could also be “PTEN-L”, a longer 
isoform of PTEN (Hopkins et al. 2013). Therefore, I stopped using this method as I could not 





Figure 4.3.2.1 PTEN KD Reduces Modified PTEN. 
Cortical rat neurons were transduced with either PTEN KD or Scr Lentivirus. 7 days later, 
cells were lysed in buffer containing NEM and subject to Western blot. Membranes were 
blotted for PTEN, at two different exposure times. Blot shows two sets of samples from one 
dissection. 





4.3.3 Creation of PTEN-3KR Mutant and Testing with Recombinant, Tagged SUMO 
 
As a tool to study the absence of SUMOylation on PTEN, Dr K Wilkinson constructed GFP- 
tagged PTEN-WT and PTEN-3KR. This mutant (PTEN-3KR), has the three sites identified as 
the main/only lysine SUMO acceptor sites on PTEN mutated to arginine, making it non- 
SUMOylatable (4.3.3.1A.) (Huang et al. 2012; Gonzales-Santamaria et al. 2012). 
The GFP-tagged constructs allowed me to use GFP-trap, which is extremely efficient at 
immunoprecipitating GFP-tagged proteins under both native and denaturing conditions. It 
was hoped this would make a useful tool to study PTEN in the context of the absence of 
SUMOylation, when compared to the WT. This is a novel approach because most previous 
attempts at assessing the SUMOylation status of PTEN involved use of single or double 
mutants K289/K266 or K266/K254 (Huang et al. 2012; Gonzales-Santamaria et al. 2012). 
I carried out an IP using GFP trap, after transfection with GFP, GFP-tagged PTEN-WT or 
PTEN-3KR along with HA-SUMO2 in HEK293T cells (4.3.3.1B and C) and observed that 
PTEN-WT is significantly more SUMOylated than PTEN-3KR by HA-SUMO2. Although 
PTEN-3KR is a novel mutant, the results are in line with similar experiments in the literature 
showing single/double mutation of the same sites reduces PTEN SUMOylation by tagged, 
recombinant SUMO (Huang et al. 2012; Gonzales-Santamaria et al. 2012). 











Figure 4.3.3.1. GFP PTEN-3KR is less SUMOylated Compared to WT by HA-SUMO2. 
A) Schematic of points of mutation in PTEN-3KR. Schematic showing all identified SUMO 
sites on PTEN, and which of these are ubiquitinated. Schematic adapted from Xu et al. 
(2014) and CytoskeletonNews; created in Biorender.com. B) Representative blot showing 
anti-GFP immunoprecipitation of cells transfected with HA-SUMO2, along with either GFP, 
GFP-WT- PTEN or GFP-3KR-PTEN. 2 days after transfection, cells were lysed in NEM- 
containing lysis buffer and immunoprecipitated with GFP-Trap. Samples were blotted with 
HA and GFP antibodies. C) Quantification of B). Immunoprecipitated HA-SUMO2 signal was 
normalised to both total HA and GFP signal. PTEN-3KR was expressed as a percentage of 
WT, which was set to a hypothetical value of 100. A one sampled t-test was used to calculate 
statistical differences (p=0.0266; N=3). 





4.3.4 PTEN-3KR is More SUMOylated than WT by Endogenous SUMO2/3 
 
Most previous attempts at assessing the SUMOylation status of PTEN have involved its 
expression in cell lines alongside recombinant, tagged SUMO 1 or 2, followed by 
immunoprecipitation and blotting for tags, or in vitro SUMOylation assays (Huang et al. 2012; 
Gonzales-Santamaria et al. 2012). In addition to tagged SUMO, I aimed to detect 
endogenous SUMO, as this would enable me to avoid overexpressing recombinant SUMO in 
my cells, which can lead to artefacts (Eifler and Vertegaal, 2015). GFP, GFP-tagged PTEN- 
WT or PTEN-3KR were transfected into HEK239T cells. Cells were immunoprecipitated two 
days later, and blotted for GFP and endogenous SUMO 2/3. This method revealed a smear 
above ~65kDa (Figure 4.3.4.1) which we attributed to multiple levels of SUMOylation. 
Unexpectedly, however, PTEN-3KR was significantly more SUMOylated by endogenous 
SUMO compared to PTEN-WT (N=6; p=0.0393). This contrasts with Figure 4.3.3.1. and the 
literature, which suggest mutation of these SUMO sites reduces PTEN-SUMOylation when 
tagged, recombinant SUMO is used. It is noted that there is a smear on the IP blot at  
~30kDa on the GFP lane; it could be that the SUMO antibody is cross reacting with GFP, 
possibly due to the large amount of GFP immunoprecipitated. This is however not seen 
when the experiment was later repeated in 2% SDS conditions (Figure 4.3.5.1). 
 
Figure 4.3.4.1. PTEN-3KR is more SUMOylated by Endogenous SUMO2/3 compared to 
PTEN-WT. 
HEK293T cells were transfected with GFP, GFP-tagged PTEN-WT or PTEN-3KR. Two days 
later, samples were lysed in buffer containing NEM and immunoprecipitated with GFP-Trap 
before being subject to Western blot and blotted for GFP and SUMO2/3. Representative blot 
shows endogenous SUMO2/3 modification of PTEN. Graph shows SUMO2/3 signal after being 
normalised to GFP. PTEN-3KR was expressed as a percentage of WT, which was set to a 
hypothetical value of 100. A one sampled t-test was used to calculate statistical differences. 
(N=6; p=0.0393). 





4.3.5 Validation of PTEN SUMOylation by Endogenous SUMO in 2% SDS 
 
To further validate the finding that PTEN-3KR is more SUMOylated than WT, and establish if 
this modification is specific and covalent, immunoprecipitation under harsh denaturing 
conditions was carried out (Figure 4.3.5.1). Cells were transfected with empty GFP- 
containing plasmid, or GFP-tagged PTEN-WT or PTEN-3KR, then two days later lysed under 
denaturing conditions in buffer containing 2% SDS (Rocca, Wilkinson, and Henley 2017). 
Lysates were then diluted in buffer without SDS before being added to GFP trap beads, so 
that the final concentration of SDS on in the solution of the beads was <0.5% and IP 
protocols were completed. The high molecular weight smear was preserved under these 
conditions, suggesting that the smear is due to specific, direct and covalent modification of 
PTEN by SUMO, which persists under strong denaturing conditions. It is noted that this is a 





Figure 4.3.5.1. Detection of PTEN modification by SUMO2/3 after cell lysis in 2% SDS 
HEK239T Cells were transfected with GFP, GFP-tagged PTEN-WT or PTEN-3KR. The next 
day cells were lysed in lysis buffer containing NEM and 2% SDS. Lysate was kept at RT for 
20 minutes, then centrifuged at RT for 20 minutes. The supernatant was then diluted to 
0.5% SDS with lysis buffer without NEM or protease inhibitors before being added to GFP- 
trap beads, and IP protocol was completed according to Methods 3.4.2). 
SUMO 2/3 





4.3.6 Detection of Endogenous PTEN SUMOylation- SUMO1 
 
To test if the PTEN-3KR would be more SUMOylated by endogenous SUMO1 as it was for 
SUMO2/3, GFP immunoprecipitation was carried out as previous, followed by blotting for 
SUMO1 (Figure 4.3.6.1) Cells were transfected with empty GFP-containing plasmid, or GFP- 
tagged WT or PTEN-3KR and subject to immunoprecipitation 2 days later. The result shows 
that PTEN-3KR seems to be modified by SUMO1 more than WT, as was seen with 
SUMO2/3. This experiment was not repeated as I decided to make SUMO2/3 the focus of 
my thesis, since AD brains show greater SUMO2/3 dysregulation and minimal SUMO1 
dysregulation (Lee et al. 2014). Furthermore, SUMO2/3 is shown to colocalise with synaptic 
marker and AMPAR scaffolding protein PSD-95 to a greater extent than SUMO1, suggesting 
it is possibly more relevant to regulation of AMPARs (Schnell et al. 2002; Colnaghi et al. 
2019). While interpreted with caution, this preliminary result suggests PTEN-3KR is more 
SUMOylated than WT by SUMO1, which is consistent with Figure 4.3.4.1. showing PTEN- 
3KR is more SUMOylated by SUMO2/3. 
 
 
Figure 4.3.6.1. PTEN-3KR is more modified by SUMO1 than PTEN-WT. 
HEK293T cells were transfected with GFP, GFP-tagged PTEN-WT or PTEN-3KR. 2 days later, 
cells were lysed in buffer containing NEM and immunoprecipitation with GFP-Trap was carried 
out followed by Western blotting for SUMO1 and GFP (N=1). 





4.3.7 PTEN-3KR is More Ubiquitinated than WT 
 
Because of the completely unexpected observation that PTEN-3KR is more SUMOylated 
than WT, I next investigated the ubiquitination status of this mutant (Figure 4.3.7.1). HEK 
cells were transfected with empty GFP-containing plasmid, or GFP-tagged PTEN-WT or 
PTEN-3KR and treated with the proteasome inhibitor MG132 24h later (10μM). MG132 was 
used due to the finding in previous studies that it can aid detection of ubiquitination of PTEN 
(Gupta and Leslie, 2016). MG123 was added and cells were left for 6 hours, then were 
immunoprecipitated with GFP- Trap. Subsequent Western blotting for GFP and 
endogenous ubiquitin showed that PTEN- 3KR is significantly more ubiquitinated than 
PTEN-WT (N=5; **=p=0.0090). The blot shows a smear which is common for poly-
ubiquitinated proteins (Haglund et al. 2003). Wu et al. (2016) also report double mutation 
K254R/K266R, or these mutations alone increased the level of PTEN ubiquitination 
compared to WT. It is not clear exactly why this is seen, although Wang et al. (2014) 
suggest it is due to SUMOylation at K254 and K266 limiting ubiquitination. 
 
Figure 4.3.7.1. PTEN-3KR is more Ubiquitinated Compared to PTEN-WT. 
(A) HEK293T cells were transfected with GFP, PTEN-WT and PTEN-3KR and treated with 
10μM MG132 after 24h. 6h later samples were lysed in buffer containing NEM and 
immunoprecipitated with GFP-Trap. Representative blot shows endogenous ubiquitin 
modification of PTEN. (B) Quantification of (A). PTEN-3KR was expressed as a percentage 
of WT, which was set to a hypothetical value of 100. A one sampled t-test was used to 
calculate statistical differences. (N=5; **=p=0.0090). 
Ubiquitin 





4.3.8 SENP treatment cleaves SUMO2/3 Chains Without Effecting Ubiquitin 
 
As explained in Section 4.1.3, previous work has suggested SUMO and ubiquitin can form 
hybrid chains on target proteins (Tatham et al. 2008). To explore whether hybrid chains can 
form on PTEN, immunoprecipitation was carried out, followed by treatment of the 
immunoprecipitated proteins with the recombinant catalytic domain of human SENP1 
enzyme. This enzyme will remove SUMO, but not ubiquitin, from the immunoprecipitated 
proteins and has been used previously in our lab by Dr Richard Seager, who reported 
SUMO1 and 2 on Mitochondrial fission factor (MFF) were entirely removed by SENP1. This 
enzyme has also been used successfully by Bekes et al. (2011) to remove SUMO chains. It 
was hoped that using this enzyme could reveal whether hybrid SUMO-ubiquitin chains are 
forming (since removal of SUMO would be expected to lead to reduction of ubiquitination). It 
would also help clarify whether one modification is recruiting or obstructing the other. 
The SENP enzyme entirely cleaved SUMO from PTEN, while having no effect on ubiquitin 
(Figure 4.3.8.1). This preliminary result was not repeated due to time constraints and 
therefore should be interpreted with caution, however it suggests that it is possible that 
SUMO forms chains on ubiquitin on PTEN, but ubiquitin does not form chains on SUMO. 
Although the PTEN-3KR was more SUMOylated and ubiquitinated than PTEN-WT as seen 
previously, the interaction between these modifiers in this context after SENP treatment does 
not seen to vary between PTEN-WT and PTEN-3KR. The result suggests that under these 
conditions, SUMO on PTEN is not recruiting a STUBL. Furthermore, this experiment helps to 
validate that SUMO2/3 antibody is specifically detecting SUMO2/3 modification of PTEN. 







Figure 4.3.8.1. SENP1 treatment removes SUMO2/3, but not ubiquitin from PTEN. 
HEK293T cells were transfected with GFP, GFP-WT-PTEN or GFP-3KR-PTEN. 3 days 
later, cells were lysed in buffer containing NEM and immunoprecipitated on GFP-Trap 
beads. Beads were then washed and 100nM recombinant SENP1 was then added to one 
set of tubes of beads. All samples were then incubated for 1 hour at 37°C, 4x sample buffer 
was added and samples were boiled at 95°C for 10 minutes. Samples were then Western 
blotted for SUMO 2/3, then stripped and reblotted for Ubiquitin (N=1). 





4.3.9 Testing SUMO/Ubiquitin Interplay with SUMO and Ubiquitin Overexpression 
 
To further investigate SUMO/ubiquitin crosstalk, experiments were carried out to establish 
whether over-expression of each protein could alter PTEN modification by the other. To this 
end, PTEN-WT was immunoprecipitated in HEK cells, with or without expression of HA- 
SUMO2 (Figure 4.3.9.1.A) or HA-ubiquitin (Figure 4.3.9.1.B), and ubiquitin and SUMO2/3 
were blotted for in each case. Over-expression of HA-SUMO2 seemed to reduce PTEN 
ubiquitination but this did not reach significance (Figure 4.3.9.1.A; N=3, p=0.0541), and over- 
expression of HA-ubiquitin did not alter PTEN SUMOylation (Figure 4.3.9.1.B) (N=3). 
Ubiquitination was reduced by SUMO2 expression in all three repeats in Figure 4.3.9.1.A, but 
the extent to which it was reduced varied substantially (85%, 35% and 69%), so this is likely 
why this result did not reach significance. Nonetheless, with this in mind, it is therefore likely 
that HA-SUMO2 expression reduces ubiquitination of PTEN; however, clearly more repeats 
would improve confidence in this result. 
These data indicate that SUMO and ubiquitin may be competing for the same sites on PTEN 
as suggested by Gonzales-Santamaria et al. (2012). This also supports observations made 
by Wang et al. (2014), who report that SUMOylation at K266 thought to limit ubiquitination, 
however, it is not clear whether SUMOylation may also sterically block ubiquitination at other 
sites. Nonetheless, according to this result, if SUMO is overexpressed and there is more 
SUMO modification of PTEN, ubiquitination is reduced. 







Figure 4.3.9.1. Effect of Overexpression of SUMO2 on PTEN ubiquitination and 
overexpression of ubiquitin on PTEN SUMOylation. 
(A) HEK293T cells were transfected with GFP+ HA-SUMO2, GFP-WT-PTEN or GFP-WT-PTEN 
+ HA-SUMO2 (S2). Two days later, cells were lysed in buffer containing NEM and subject to 
immunoprecipitation (IP). Samples were blotted for ubiquitin, HA and GFP. (B) HEK cells were 
transfected with GFP+ HA-ubiquitin (HA-Ub), GFP-WT-PTEN or GFP-WT-PTEN + HA-Ub. 2 
days later, cells were lysed and subject to IP. Samples were blotted for SUMO2/3, HA and 
GFP. C) Quantification of ubiquitin signal in A) after being normalised to GFP. PTEN-3KR was 
expressed as a percentage of WT, which was set to a hypothetical value of 100, and analysed 
in a one-sample t-test (N=3; p=0.0541). D) SUMO2/3 signal was analysed as in C) (N=3). 






4.4.1 Detection of SUMO and Ubiquitin on PTEN 
 
Here I show that I can detect both recombinant and endogenous SUMOylation of PTEN in 
GFP-Trap immunoprecipitation experiments by using GFP-tagged PTEN (Figures 4.3.3.1- 
4.3.4.1.). Initial blotting of PTEN suggested the higher band of PTEN shown in Figure 
4.3.2.1. could be SUMOylated PTEN, consistent with data from Bassi et al. (2013), 
however, subsequent literature investigation showed that this band was also seen by 
Hopkins et al. (2013), who suggest it is a different, longer isoform of PTEN which they 
named “PTEN-L”, and therefore not post-translationally modified PTEN. Thus, blotting for 
this upper band to detect PTEN PTMs may not be valid, and optimising the 
immunoprecipitation method was essential. The creation of GFP-tagged PTEN also made 
detection of endogenous ubiquitin possible. 
 
4.4.2 Differences Between Recombinant and Endogenous SUMO on PTEN 
 
In Figure 4.3.3.1 I show that in my hands, PTEN-3KR is less SUMOylated by HA-tagged 
SUMO2, compared to WT, which fits with the literature regarding single/ double PTEN 
mutants. However, the evidence in this thesis suggests that endogenous SUMO may behave 
differently, and PTEN-3KR exhibits enhanced SUMOylation compared to WT. My preliminary 
result indicating that the endogenous SUMO-PTEN modification persists under 2% SDS 
conditions (Figure 4.3.5.1.), goes towards validating that interaction detected is specific and 
covalent (Rocca et al. 2017). 
It is not clear exactly why PTEN-3KR is less SUMOylated by tagged, recombinant SUMO 
and more SUMOylated by endogenous SUMO compared to WT. This change in modification 
site can occur with ubiquitination; some studies have shown ubiquitination is increased when 
certain ubiquitination sites are mutated (Wang et al. 2014; Wu et al. 2016). The additional 
endogenous SUMOylation of PTEN-3KR could occur because SUMO preferentially 
conjugates at different sites when known SUMO sites are mutated, for example K102 is also 
suggested as a possible SUMO site according to SUMOplot software (Gonzales-Santamaria 
et al. 2012). Evidence for this comes from Wang et al. (2014), who suggest SUMOylation at 
one site may block SUMOylation at another site given the large size of SUMO (>90 
residues), the lack of band shift between single and double mutants, and the proximity 
between the K254 and K266 sites. Furthermore, mutations in PTEN-3KR may increase 
binding at a SIM site, possibly because SUMO cannot bind at sites in close proximity due to 
its size (Huang et al. 2012). Additional SUMO binding at SIMs can move SUMO into closer 
proximity with additional SUMO sites (Wang and Dasso 2009); this may enhance 




A) PTEN-WT is SUMOylated at K254, K266 and K289 (Huang et al. 2012; 
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Figure 4.4.2.1. Schematic Depicting Potential Reasons for Enhanced SUMOylation 
of 3KR. 
PTEN-WT is SUMOylated at K254, K266 and K289 (Huang et al. 2012; Santamaria et al., 
2012). B) Enhanced SUMO on PTEN-3KR could be attaching to an additional SUMO site; 
K102 is a suggested possible SUMO site on PTEN (Gonzales- Santamaria et al., 2012). 
Furthermore, SUMOylation at one site may block SUMOylation at another (Wang et al., 
2014; Huang et al., 2012), so mutations in PTEN-3KR may free up more lysines to be 
SUMOylated. C) SIM sites on PTEN have been identified by Bawa- Khalfe et al. (2016), 
mutations in PTEN-3KR may enhance SUMO binding at SIM sites. SUMO binding at SIMs 
can bring SUMO closer to additional SUMO sites which it could SUMOylate (Wang and 
Dasso, 2009). D) PTEN-3KR could be in a different structure to WT; it could be that 
SUMO-site mutations induce this change, leaving more potential SUMO site lysines 
exposed for SUMO to modify. Huang et al. (2016) tested K266A, K266R and K266Q 
PTEN mutants in molecular dynamic simulations and found little effect on PTEN 
conformation, but PTEN-3KR has not been tested in this way. Schematic based on work 
by Bawa-Khalfe et al. (2016); Huang et al. (2012); Gonzalez-Santamaria et al. (2012). 
Made in Biorender.com with premade shapes. 
 
There is also a possibility that the mutations could cause PTEN to be in a different 
conformation which could potentially leave more SUMOylatable lysines exposed for SUMO 
to bind to (Huang et al. 2016). However, Huang et al. (2016) examined this and found the 
single mutants K266R, K266A and K266Q had little effect on PTEN structure in molecular 





dynamics simulations, although double mutants and PTEN-3KR have not been tested in 
these experiments. It is also noted that SUMO modification of PTEN could change its 
conformation; Gonzales-Santamaria et al. (2012) suggest that SUMO binding to PTEN can 
block intramolecular interactions that enable it to form the closed conformation, thus forcing it 
into the open conformation. Although it was not expected to have enhanced SUMOylation, I 
nonetheless reasoned that PTEN-3KR can still be used as a tool to study the effects of 
enhanced SUMOylation/ ubiquitination of PTEN. 
 
4.4.3 Overexpression of SUMO may Confound Results 
 
Consistent with the literature, when I examined tagged, recombinant SUMO conjugation to 
my WT and PTEN-3KR constructs, I saw a significant reduction in HA-SUMO2 on PTEN- 
3KR compared to WT (Figure 4.3.3.1.). These data are in agreement with studies using 
similar SUMO overexpression techniques, showing single and double mutations of these 
sites reduced SUMOylation (Huang et al. 2012; Gonzales-Santamaria et al. 2012). Crucially, 
however, these results with tagged SUMO differ to my results with endogenous SUMO 
(Figure 4.3.4.1.). 
Previous studies have mostly looked at tagged and/or recombinant SUMO in cells, or in in 
vitro SUMOylation assays, rather than endogenous SUMO; Eifler and Vertegaal (2015) note 
that compared to endogenous, exogenous SUMO expression can increase levels of 
SUMOylation of target proteins and can lead to over-expression artefacts if it is not 
controlled. Therefore, I argue that my experiments with endogenous SUMO are more 
physiologically relevant due to less confounding factors from SUMO overexpression. 
Interestingly, in Figure 4.3.9.1., HA-SUMO2 overexpression seemingly led to a reduction of 
PTEN ubiquitination (although this did not quite reach significance). This suggests again that 
recombinant SUMO may have different effects. This may be because SUMO overexpression 
can enhance target SUMOylation (Eifler and Vertegaal, 2015) so there could be more SUMO 
to displace ubiquitin on PTEN. 
 
4.4.4 Discrepancies Regarding “Non-SUMOylatable” Mutants 
 
The only study to date which tested endogenous SUMOylation of PTEN by Bawa-Khalfe et 
al. (2016), showed that the double mutant K266A/K254A was less modified than WT by 
SUMO1. Although it is noted the PTEN-3KR mutant contains an additional site of mutation to 
this mutant, and lysines in PTEN-3KR were mutated to arginine rather than alanine, this is in 
contrast to my preliminary data on SUMO1 (Figure 4.3.6) showing that PTEN-3KR is more 
SUMOylated by SUMO1. Furthermore, Bawa-Khalfe et al. (2016) failed to detect 
endogenous SUMO2 or 3 on PTEN-WT, while I have repeatedly shown this in this chapter.  





This suggests that my system may be more sensitive to detecting SUMOylation, given that 
other groups have provided evidence that PTEN is SUMOylated by recombinant SUMO2 
(Gonzales- Santamaria et al. 2012). Furthermore, Bawa-Khalfe et al. (2016) also showed 
the K266A/K254A mutant was less ubiquitinated, which also goes against my own 
observations with PTEN-3KR (Figure 4.3.7.). Similarly, Wu et al. (2016) and Wang et al. 
(2014) both showed that PTEN K266R/K254R mutant is actually more ubiquitinated than 
WT. 
It is noted that Huang’s work focuses on SUMO1 and this thesis focuses on SUMO2/3. It 
could be argued that these proteins conjugate differently, however, I have preliminary data 
showing PTEN-3KR is also more SUMOylated by SUMO1 than WT (Figure 4.3.6.1), as it is 
by SUMO 2/3 (Figure 4.3.4.1). I have also shown that in my samples, endogenous SUMO2/3 
acts differently to recombinant SUMO2, which conjugates more to WT than PTEN-3KR; the 
literature also shows mutation of residues K254, K266 or K289 sites reduces modification by 
recombinant SUMO2 as well as SUMO1 (Gonzales-Santamaria et al. 2012). Therefore, it 
seems more likely that the differences in conjugation are due to whether SUMO is 
endogenous or expressed, rather than due to paralogue specific effects. 
 
4.4.5 PTEN Ubiquitination 
 
Regarding ubiquitination, as explained, it initially seems surprising that the PTEN-3KR is also 
more ubiquitinated (Figure 4.3.7.1), given that K266 and K289 are ubiquitinated and these 
are mutated in PTEN-3KR (Gupta and Leslie, 2016, Trotman et al. 2007). However, there are 
additional known ubiquitin sites not mutated in the PTEN-3KR, such as K13 (Trotman et al. 
2007). Furthermore, Wang et al. (2014) showed single mutations of K254R and K266R did 
not alter PTEN ubiquitination level, but mutations of both sites simultaneously increased 
PTEN ubiquitination. This was suggested to be because SUMOylation at these sites blocks 
ubiquitination (Wang et al. 2014). Similarly, Wu et al. (2016) also showed K266R mutation 
had a small effect in increasing ubiquitination, but K254R or double mutant hugely increased 
ubiquitination. There is some controversy in this area as Bawa-Khalfe et al. (2016) found 
K266A/K254A double mutant to be less ubiquitinated, although PC-3 cells were used, which 
have homozygous deletion of PTEN (Vlietstra et al. 1998). Therefore, although in some ways 
unexpected, my results are generally in line with the literature. It is possible that blocking 
SUMOylation at sites mutated in PTEN-3KR (K254 and K266) causes the increased 
ubiquitination as suggested by Wang et al. (2014). 
 
 





4.4.6 SUMO/Ubiquitin Crosstalk- SENP/Ubiquitin Overexpression 
My data suggests that SUMO and ubiquitin modification are increased on PTEN-3KR 
compared to WT (Figures 4.3.4.1 and 4.3.7.1), and increasing PTEN SUMOylation reduces 
ubiquitination on PTEN-WT (although it is noted it did not quite reach significance) (Figure 
4.3.9.1 Some possible explanations for both of these effects involve crosstalk. 
 
Although it has been shown that PTEN SUMOylation can promote ubiquitination of PTEN 
through increasing association with ubiquitin ligase WWP2 (Bawa-Khalfe et al. 2016), overall, 
SUMO seems to negatively regulate ubiquitin modification of PTEN (Gonzales-Santamaria et 
al. 2012; Wang et al. 2014, Wu et al. 2016). My results show that increasing HA-ubiquitin 
conjugation to PTEN does not affect modification by SUMO2/3, but increasing HA-SUMO2 
conjugation reduces ubiquitin modification (Figure 4.3.9.1). This is in line with Gonzales- 
Santamaria et al. (2012), who found that SUMO1 conjugation reduces mono-ubiquitination, 
but mono-ubiquitination does not reduce SUMO1 conjugation. They also support Wang et al. 
(2014), who found SUMOylation at K254 and K266 can limit ubiquitination, as well as Wu et 
al. (2016). While not well characterised, the protein RWD-containing Sumoylation Enhancer 
(RSUME), can increase SUMOylation of targets including PTEN (Wu et al. 2016; Carbia- 
Nagashima et al. 2007). This increased SUMOylation through RSUME has an effect of 
reducing PTEN ubiquitination (Wu et al. 2016). Mutation of both K254R and K266R SUMO 
sites blocked the effect of RSUME on inhibiting PTEN ubiquitination, while individual 
mutation of each site had no effect, suggest both sites are critical in RSUME-mediated PTEN 
ubiquitination inhibition (Wu et al. 2016). PTEN-WT stability was increased by RSUME 
overexpression, but stability of K254R/K266R double mutant was not affected. (Wu et al. 
2016). It was concluded that by increasing SUMOylation, RSUME reduces ubiquitination on 
PTEN, which increases its stability (Wu et al. 2016). Therefore, my results are in line with the 
literature, as increasing PTEN modification by SUMO2/3 decreased ubiquitination. My data 
argues against the findings that SUMO on PTEN recruits a STUbL. 
SUMO and ubiquitin may compete for the same sites (Gonzales-Santamaria et al. 2012), as 
K266 and K289 are both SUMOylated and ubiquitinated (Huang et al. 2012; Gonzales- 
Santamaria et al. 2012; Bassi et al. 2013; Trotman et al. 2007; Gupta and Leslie, 2016), and 
SUMOylation at some sites may block ubiquitination at other sites. Evidence for this comes 
from Wang et al. (2014), who found SUMOylation at K254 and K266 sites limits ubiquitination 
(Wang et al. 2014). They suggest that SUMOylation at one site may block SUMOylation at 
another site given the lack of band shift between single and double mutants, and the 
proximity between K254 and K266 sites. Therefore, considering ubiquitin is a similar size 
(>70 residues), it is possible SUMO could also block ubiquitination at another site; indeed, 
Wang et al. (2014) suggest that SUMOylation of PTEN at K254 and K266 is necessary to 
limit ubiquitination level and stability, as mutation of these sites increases ubiquitination. 





Moreover, concurrent mutation of K254R and K266R, or K254R alone increases 
ubiquitination, and reduces SUMOylation (Wu et al. 2016). This suggests SUMOylation at 
K254 may block ubiquitination at other sites, especially given that this paper also shows 
K254 to be the dominant SUMOylation site, and its proximity to the K266 site. However, this 
does not explain why/ how the PTEN-3KR mutant is also more SUMOylated. It is also noted 
that these results are not necessarily physiologically relevant, as they involved 
overexpression of tagged SUMO and ubiquitin constructs; it may be that endogenous SUMO 
in cells is not enough to displace ubiquitin from PTEN. 
 
4.4.7 SUMO/Ubiquitin Crosstalk- SENP Enzyme Treatment 
 
Figure 4.3.8 involved removal of SUMO from PTEN using SENP enzyme treatment (an effect 
seen previously on other proteins by Dr R Seager in the lab). While interpreted with caution 
due to the lack of repeats, the SENP treatment removed SUMO on PTEN, without effecting 
PTEN ubiquitination (Figure 4.3.8.1), suggesting that ubiquitin is not attaching to PTEN via 
SUMO. This contrasts with Bawa-Khalfe et al. (2016) who found SENP1 expression removed 
both SUMO and ubiquitin from PTEN, however there are methodological differences in terms 
of modulation of protein expression vs enzyme application, and cell types used. It also 
contrasts with Tatham et al. (2008) who suggest SUMO2/3 and ubiquitin can form mixed 
chains, although it is noted that they were not examining PTEN. This result has also gone 





In conclusion, in this chapter I have gone some way towards addressing gaps of knowledge 
in PTEN-SUMOylation by optimising endogenous PTEN SUMOylation and ubiquitination 
detection, creating a tool which can be used to study the enhanced SUMOylation of PTEN, 
and providing evidence that mutants previously thought to be non/reduced SUMOylated may 
actually be more SUMOylated than WT when endogenous SUMO is concerned. I also have 
initial data which helps to validate the endogenous detection of SUMOylation of PTEN in 2% 
SDS. I provided evidence that PTEN-3KR is more SUMOylated by endogenous SUMO2/3, 
and have preliminary evidence that the same is true for SUMO1. 
The question of whether PTEN SUMO-site mutants are more or less SUMOylated than WT is 
important given the conclusions drawn from previous work on these mutants in the literature. 
SUMOylation is suggested to control PTEN localisation and ability to regulate Akt pathway 
(Huang et al. 2012), characteristics both likely to be relevant to PTEN function in neurons 





and plasticity (Jurado et al. 2010; Liu et al. 2018). It has been suggested that SUMOylation at 
specific sites on PTEN can block SUMOylation at another site; Huang et al. (2012) suggest 
concomitant SUMOylation of K254 and K266 cannot occur due to the relatively large space 
needed for SUMO modification. Therefore, it may be that blocking SUMOylation through 
mutation of K254, K266 and/or K289 enables more SUMO to bind at other sites on PTEN- 
3KR, leading to enhanced SUMOylation. This could also possibly occur through a SIM site 
on PTEN (Bawa-Khalfe et al. 2016). 
Additionally, I demonstrated that PTEN-3KR is more ubiquitinated than WT, which is largely 
fitting with the literature on double mutants (Wang et al. 2014; Wu et al. 2016). I have 
provided further evidence of the order of SUMOylation and ubiquitination by demonstrating 
that SUMOylation is likely to be able to limit ubiquitination of PTEN, similar to effects seen by 
Wang et al. (2014) who showed that SUMOylation is needed to limit ubiquitination. Using the 
SENP1, enzyme, I have preliminary data suggesting that ubiquitin is not forming chains on 
SUMO on PTEN, but more work is needed to establish whether SUMO is forming chains on 
ubiquitin, which could be carried out using a de-ubiquitinating enzyme in similar in vitro 
ubiquitination assays. 
Clearly more research is needed to establish the exact role of SUMO and ubiquitin in terms 
of how they may regulate each other, and how they may influence localisation, as there is 
controversy about this (Bassi et al. 2013; Huang et al. 2012; Bawa-Khalfe et al. 2016). A 
major issue in making conclusions about the current literature is that there is little 
homogeneity between studies in terms of cell types and methods used. 
 
4.6 Future Directions 
 
To further these results, the following experiments should be conducted 
 
• Mutate the SIM site in PTEN-3KR and repeat immunoprecipitation to detect 
SUMOylation, to establish whether SUMO on PTEN-3KR is enhanced by SIM-sites 
• To clarify whether SUMO is forming chains on ubiquitin, experiment in Figure 4.3.8 
could be repeated with a DUB such as Ubiquitin-Specific Protease-2a (USP2a) which 
would remove ubiquitin from PTEN (Graner et al. 2004). 
• Immunoprecipitation of PTEN-3KR to establish whether it is in a different 
conformation to WT, using a methodology developed by Odriozola et al. (2007) and 
also used by (Rahdar et al. 2009). This involves immunoprecipitating tagged mutants 
of the PTEN C-tail and the rest of WT or PTEN-3KR, and immunoprecipitating the C- 
tail with the other fragment. If PTEN-3KR was able to immunoprecipitate more C-tail 





fragment than WT, this would imply it occurs more in the “closed” conformation, due 
to reduced ability to form intramolecular interactions between the C-tail and PTEN- 
3KR. This experiment would in part test the theory by Gonzales-Santamaria (2012) 
that SUMOylation can force PTEN into the “open” conformation through blocking C- 
tail/C2 domain interactions. 
• Repeat immunoprecipitation for SUMO and ubiquitin on PTEN in neurons to establish 
if PTEN is SUMOylated in neurons, and if PTEN-3KR is more SUMOylated as it is in 
HEK293T cells. 
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5 Characterising PTEN-3KR in Cell Lines and Neurons 
5.1 Introduction 
5.1.1 PTEN Functions and Post-Translational Modifications 
 
In this chapter, I aimed to characterize PTEN-3KR in terms of its stability, localization, and 
function, as previous work has shown SUMOylation of PTEN can regulate these properties 
(Wang et al. 2014; Huang et al. 2012). This PTEN regulation via SUMOylation may have 
implications in neurons, as the phosphatase activity of PTEN is critical in NMDAR-dependent 
LTD, and can drive depression of AMPAR-mediated neurotransmission (Jurado et al. 2010). 
SUMOylation can regulate memory consolidation and plasticity, and SUMOylation dysregulation 
is present in the Tg2576 AD mouse models and post-mortem AD brains (Lee et al. 2014). 
Furthermore, ubiquitin-mediated PTEN degradation has been suggested to underlie the PTEN 
loss seen in AD (Kwak et al. 2010), highlighting the importance of post-translational regulation of 
PTEN stability in neurons. Therefore, a point of interest is PTEN SUMOylation in neurons, which 
has not yet been assessed. 
Previous work has tested single/ double PTEN mutants including K266A/K289A, K254A/K266A 
and K254R/K266R, with reduced SUMOylation capacity (Huang et al. 2012; Gonzalez- 
Santamaria et al. 2012; Wang et al. 2014; Bawa-Khalfe et al. 2016). Here I test the novel PTEN- 
3KR mutant PTEN, which contrary to our expectations, displays enhanced ubiquitination and 
SUMOylation by endogenous SUMO/ubiquitin compared to WT. Analysis of this mutant will 
avoid potential confounding variables in previous studies such as SUMO overexpression 
artefacts (Eifler and Vertegaal; 2015), and modulation of global SUMOylation which can 
confound results due to the large range of SUMO targets related to PTEN including Akt (de la 
Cruz-Herrera et al. 2015). The aim of this chapter is therefore to test how enhanced 
SUMOylation and ubiquitination of PTEN can affect PTEN regulation, and if this has a role in the 
context of AMPAR trafficking. 
 
5.1.2 Role of PTEN SUMOylation in Membrane Localization 
 
There is debate regarding the role of SUMOylation on the localization of PTEN, and studies 
have separately examined effects of SUMOylation at different sites. PTEN localization is an 
important issue as its membrane localisation is critical in Akt pathway regulation and 
tumorigenesis (Rahdar et al. 2009; Vazquez et al. 2006; Huang et al. 2012). Huang et al. 
(2012) initially reported that in subcellular fractionation experiments in HEK293T cells, PTEN 
K266R was almost totally absent from the membrane fraction compared to WT, and the K254R  






mutant was also slightly reduced in the membrane fraction. They concluded that addition of 
positively charged SUMO at K266 on PTEN facilitates membrane localization, through 
increasing electrostatic interactions between PTEN and the electronegative membrane (Huang 
et al. 2012). 
Gonzales-Santamaria et al. (2012) also reported reduced-SUMOylation mutants K289A, K266A 
and double mutant K289A/K266A exhibit increased cytoplasmic localisation in PC-3 and MCF-7 
cells compared to WT (although this confocal microscopy experiment compared nuclear to 
cytoplasmic localisation; membrane localisation was not quantified). Further experiments 
involved Vesicular Stomatitis Virus (VSV) infection to test PTEN’s role in antiviral response in 
MEFs, which showed that VSV causes PTEN to move to the membrane, where it co-localises 
with SUMO1 or 2. Gonzales-Santamaria et al. (2012) hypothesise that membrane localisation 
and SUMOylation may be associated and suggest SUMO may block PTEN C-terminus 
interactions with the C2 domain, forcing the protein into an “open” conformation, which 
facilitates membrane localisation. This differs from the view of Huang et al. (2012), who suggest 
PTEN SUMOylation aids membrane localisation independently of a conformational change. 
In neurons, the localisation of PTEN may also be important in plasticity; PSD-95 interactions with 
PTEN are critical in LTD, possibly by allowing PTEN to position near the membrane and 
improving its catalytic activity (Jurado et al. 2010) (See 5.1.7 for more information on PTEN and 
AMPAR trafficking). 
 
5.1.3 Other Effects of PTEN SUMOylation on Localization 
 
Bassi et al. (2013) reported SUMOylation at K254 facilitates nuclear localisation of PTEN, since 
a reduced-SUMOylatable K254R mutant failed to be retained in the nucleus in HEK293T cells in 
imaging experiments. This was contrasted by Bawa-Khalfe et al. (2016) who showed by 
subcellular fractionation that a PTEN K254A/K266A double mutant was localised more in the 
nucleus rather than cytosolic fraction in human prostate adenocarcinoma (LNCap) cells (Bawa- 
Khalfe et al. 2016). LNCap cells contain a frame-shift PTEN mutation and do not express PTEN 
(Vlietstra et al. 1998), and were presumably used in this experiment so that a tagged PTEN 
could be observed without confounding effects of endogenous PTEN. These contrasting results 
could be due to differences in cell types used, also, Bawa-Khalfe did not specifically test the 
location of K254A/K266A mutant in HEK293T cells as Bassi et al. (2013) did. The mutants in 
these studies also varied in terms of amino acid substitution and single versus double mutants. 
Different methods were used to analyse PTEN mutant localisation; Bassi et al. used confocal 
imagining while Bawa-Khalfe et al. used subcellular fractionation. 
In summary, it seems there is little consistency between results on effects of PTEN - 




SUMOylation on localisation, which may be due to differences, in methods, mutants and cell 






types used. Many studies to date have relied on methods such as overexpressing recombinant 
SUMO, or manipulating global SUMOylation to asses PTEN SUMOylation; testing endogenous 
PTEN SUMOylation may be more valid (Eifler and Vertegaal; 2015). In neurons, PTEN is 
redistributed to the post synaptic density after NMDAR stimulation, where it co-localises with 
PSD-95; a process critical in LTD (Jurado et al. 2010). Therefore, if SUMOylation of PTEN in 
neurons can regulate localisation, this may have the potential to influence plasticity. 
 
5.1.4 Effects of PTEN SUMOylation on the Akt Pathway 
 
PIP₃ and its regulation through PTEN phosphatase activity are important in plasticity; PTEN can 
counter the PIP₃ increase in spines after NMDAR-LTD, and PIP₃ levels control AMPAR surface 
expression (Jurado et al. 2017; Arendt et al. 2010; Arendt et al. 2014). Furthermore, PTEN’s 
phosphatase activity is critical in NMDAR-LTD and can influence AMPAR transmission (Jurado 
et al. 2010). Furthermore, through effects on the Akt pathway, PTEN attenuation can relieve 
plasticity deficits and restore AMPAR and NMDAR levels in PTSD mouse models (Liu et al. 
2018). 
 
PTEN SUMOylation has not yet been tested in neurons, but Huang et al. (2012) report that 
SUMO plays a role in PTEN’s ability to limit PIP₃ levels and Akt signalling in cell lines. They 
examined the signalling capability of PTEN-WT and reduced-SUMOylation mutants using PC-3 
cells, which contain a homozygous PTEN exon deletion (Vlietstra et al. 1998). Injection of 
immunodeficient mice with PC-3 cells resulted in tumour formation, and expression of PTEN-WT 
in these cells was able to suppress tumour growth shown by bioluminescent imaging of tumours. 
However, K266R and K254R PTEN mutants were unable to supress tumour growth. Since the 
tumour suppressor capacity of PTEN depends on its ability to inhibit the Akt pathway 
(Georgescu 2010; Cantley and Neel 1999; Furnari, Huang, and Cavenee 1998; Phadngam et al. 
2016; Carnero and Paramio 2014) these results suggest that these mutants show reduced ability 
to inhibit Akt. Consistent with this, PTEN-WT expression in PC-3 cells resulted in ~67-69% 
suppression of Akt phosphorylation; however, cells infected with the K266R mutant did not have 
significantly different Akt phosphorylation levels compared to control cells lacking PTEN. 
Furthermore, the K254R mutant was able to supress Akt phosphorylation by only ~38-39% 
compared to control (Huang et al. 2012). Huang et al. (2012) also reported that compared to 
WT, PTEN K266R mutant showed dramatically less phosphate release in Malachite green 
phosphatase assays. Staining for PIP₃ in confocal imagining experiments in PC-3 stable cell 
lines expressing PTEN-WT or K266R revealed an increase of PIP₃ at the membrane in K266R- 
expressing cells. Therefore, the SUMOylation of PTEN plays an important or even critical role in 






PTEN phosphatase activity with downstream effects against Akt and tumour suppressive 
activity, depending on the site of conjugation (Huang et al. 2012). 
I therefore wanted to compare activity of WT and PTEN-3KR against the P-Akt pathway, to see 
how enhanced SUMOylation of PTEN would regulate P-Akt. Taking into account work by Huang 
et al. the K254R and K266R mutations in PTEN-3KR should block the ability of PTEN to inhibit 
the Akt pathway. 
 
5.1.5 PTEN Dimerization and Effects of SUMOylation 
 
PTEN can form homodimers in vitro; the dimer interface is formed by the two phosphatase 
domains (Heinrich et al. 2015). Dimerized PTEN is also more catalytically active than monomeric 
PTEN, and has a higher affinity for the membrane (Heinrich et al. 2015; Papa et al. 2014). As 
PTEN catalytic activity is critical to LTD, and PIP₃ can regulate AMPAR localisation, (Arendt et 
al. 2010; Jurado et al. 2010), a point of interest is how SUMOylation might influence 
dimerization. 
Catalytically inactive PTEN mutants can hetero-dimerize with WT and have a dominant-negative 
effect in limiting phosphatase activity (Papa et al. 2014). It was reported that one mutated PTEN 
allele can have a stronger effect on tumour phenotypes and p-Akt regulation than deletion of one 
allele, so PTEN mutations can be “worse than nothing”, in the sense that having a mutated form 
of PTEN can be worse than having one missing PTEN allele (Papa et al. 2014; Leslie and den 
Hertog 2014). Papa et al. (2014) examined PTEN mutant G129E which retains protein 
phosphatase activity but lacks phosphoinositide phosphatase activity, and PTEN C124S mutant 
which lacks all phosphatase activity (Myers et al. 1998; Myers et al. 1997; Myers and Tonks 
1997). Compared to PTEN-WT and PTEN+/- cells, PTEN G129E/+ or PTEN C124S/+ cells showed 
lower ability to regulate PI3K/Akt pathway. Mice with these mutations also showed higher tumour 
progression (Papa et al. 2014). It concluded that mutants can dimerize with WT shown in 
immunoprecipitation experiments, and suppress WT activity against PIP₃ shown in phosphatase 
assays where PIP₃ was used as a substrate (Papa et al. 2014). Considering this, I wanted to test 
the ability to PTEN-3KR to dimerize with PTEN-WT. It was reported that C-terminal tail 
phosphorylation negatively regulates PTEN dimerization but effects of SUMOylation on 
dimerization has not been tested. It is also suggested that C-terminal tail phosphorylation 
negatively regulates dimerization and causes dimer destabilization (Heinrich et al. 2015; Papa et 
al. 2014). Furthermore, polyubiquitination of PTEN at K342 and K344 has been shown to reduce 
dimerization as well as membrane localisation and ability to limit the Akt pathway (Lee et al. 
2019). 






These studies together show that phosphorylation and ubiquitination can regulate PTEN 
dimerization, and dimerization can regulate PTEN’s localisation and catalytic activity against 
PIP₃ (Papa et al. 2014; Heinrich et al. 2015; Lee et al. 2019). 
 
5.1.6 Effects of SUMOylation on PTEN Stability 
 
Due to the finding that PTEN-3KR is more ubiquitinated and SUMOylated, I also wanted to 
examine the rate of its degradation. I expected it to be less stable than WT, as ubiquitination of 
PTEN is reported to reduce its stability (Leslie and Gupta, 2016). Wang et al. (2014) reported 
that SUMOylation at K254 and K266 enhances stability, by blocking ubiquitination and 
subsequent degradation, but the effects of PTEN SUMOylation on stability have not been widely 
tested. 
Furthermore, as explained in Section 1.5.6, ubiquitination of PTEN may be involved in PTEN 
loss seen in AD brains (Kwak et al. 2010). 
 
5.1.7 PTEN in Synaptic Plasticity- AMPAR Trafficking in Neurons 
 
AMPAR trafficking is a process essential in plasticity, and that has been reported to be defective 
in AD (Chang et al. 2006; Shi et al. 2001; Passafaro, Piech, and Sheng 2001). As reviewed in 
the Introduction, the lipid phosphatase activity of PTEN is critical in NMDAR-dependent, 
hippocampal LTD; LTD is blocked by pharmacological PTEN inhibition or expression of a PTEN- 
G129E mutant that lacks lipid phosphatase activity, but retains has protein phosphatase activity 
(Myers et al. 1998; Jurado et al. 2010). PTEN localizes at the PSD after NMDAR activation, 
where it associates with PSD-95 (Jurado et al. 2010). Jurado et al. (2010) suggest this enables 
PTEN to be positioned near the membrane at activated synapses, which would improve its 
catalytic activity by allowing access to PIP₃, which is critical in AMPAR clustering at the 
membrane (Arendt et al. 2010). Furthermore, PTEN has been shown to directly downregulate 
the increase in PIP₃ levels after plasticity events (Arendt et al. 2014). 
Conversely, overexpression of PTEN-WT can reduce AMPAR EPSCs under basal conditions, 
without affecting subsequent LTD induction (Jurado et al. 2010). Jurado et al. (2010) suggest 
this could because overexpressed PTEN is either acting on a different pool of AMPARs to those 
involved in LTD, or that the suppression of AMPARs by PTEN overexpression is not able to 
saturate LTD expression. 
Liu et al. (2013) provide more evidence of PTEN’s role in AMPAR trafficking in hippocampal 
neurons in a model of stretch injury, where neurons are grown on silicone which is then 
stretched, used to simulate conditions under traumatic brain injury (Geddes et al. 1995). PTEN 
protein and mRNA levels were increased after stretch injury, which was associated with reduced 




GluA2 surface expression. Furthermore, PTEN inhibition with bisperoxovanadium was able to 






enhance neuron survival by inhibiting the reduction of surface GluA2 (Liu et al. 2013), 
suggesting that enhanced PTEN levels are directly damaging in this model of traumatic brain 
injury. 
PTEN’s mechanism of action in neurotransmission and NMDAR- Dependent LTD is reliant on its 
phosphatase activity against PIP₃, and PIP₃ levels also regulate AMPAR trafficking by enabling 
AMPAR clustering at the membrane (Jurado et al. 2010; Arendt et al. 2010; Arendt et al. 2014). 
PTEN’s phosphatase activity against PIP₃ is reported to be regulated by SUMOylation (Huang et 
al. 2012), so it’s possible that SUMOylation of PTEN could have influence on NMDAR- 
Dependent LTD and AMPAR trafficking. Given the lack of phosphatase action against PIP₃ from 
PTEN-reduced SUMOylatable mutants (Huang et al. 2012), it will be interesting to test the 
effects of PTEN-3KR with enhanced SUMOylation in the context of AMPAR trafficking, which 
has not yet been assessed. 







My data indicate that that mutation of 3 lysines in PTEN (K254R/K266R/K289R; PTEN-3KR) 
results in enhanced SUMOylation and ubiquitination of PTEN. I therefore reasoned that further 
examination of this mutant would be informative of the effects of SUMOylation on PTEN 
localization, stability, dimerization and catalytic activity. I aimed to characterize these parameters 
in cell lines, and compare WT and PTEN-3KR localization in neurons. I also wanted to test 
surface GluA2 expression under PTEN knockdown, and WT or PTEN-3KR rescue conditions, to 
further understand how PTEN might influence plasticity through AMPAR trafficking, and to 
determine whether PTEN SUMOylation and ubiquitination are involved. I also aimed to test 
whether changes to global SUMOylation in neurons could alter AMPAR expression. 
Specifically, my aims were to 
• Characterise the PTEN-3KR mutant as a tool to study PTEN SUMOylation and 
ubiquitination in terms of its stability, localisation and ability to dimerize in cell lines 
and/or neurons 
• Create a stable cell line to characterize the phosphatase activity of PTEN-3KR 
 
• Examine whether enhancement of global SUMOylation in neurons through SENP3 
KD can influence AMPAR levels 
• Examine the role of PTEN on AMPAR trafficking in neurons, and determine whether 
PTEN-3KR has different functional effects to WT 






5.3.1 PTEN-3KR and WT are Degraded at a Similar Rate in HEK293T Cells 
 
Due to previous work showing the role of SUMO and ubiquitin in PTEN stability (Wang et al. 
2014; Gupta and Leslie, 2016), and given that PTEN-3KR is both more SUMOylated and 
ubiquitinated than WT, a cycloheximide timepoint experiment was carried out to compare 
stability of these constructs. Cycloheximide is an inhibitor of protein synthesis; it binds the 
ribosome, preventing translocation (Obrig et al. 1971; Schneider-Poetsch et al. 2010). It can 
therefore be used to determine the half-life of a protein, and examine how quickly a protein is 
turned over after protein synthesis is inhibited (Kao et al. 2015). 
HEK293T cells were transfected with GFP-tagged PTEN-WT or PTEN-3KR, and the next day 
treated with cycloheximide. 24 hours later they were lysed, subject to Western blot and blotted 
for GFP. There was no significant difference in the total amount of PTEN-WT or PTEN-3KR 
remaining after 24h, suggesting they are both being degraded to a similar extent. This is in 
contrast to findings that ubiquitinated PTEN is less stable (Gupta and Leslie, 2016). However, 
Gupta and Leslie (2016) suggest K66 (which is not mutated in PTEN-3KR) is the most significant 
site in terms of stability, and it is not clear which sites are more ubiquitinated in PTEN-3KR. 
 
 
Figure 5.3.1.1. WT and PTEN-3KR show similar levels of turnover in 24 hours. 
A) HEK 293T cells were split into a 12 well dish. The next day, cells were transfected with 
1µg of either GFP-tagged PTEN-WT or PTEN-3KR DNA. 24 hours later 100µg/mL 
cycloheximide was added. Cells were incubated for another 24 hours then lysed in 1x SDS 
loading buffer and subject to Western blot. B) Quantification of A: cycloheximide-treated 
samples were normalised to untreated samples as a control, graph shows percentage of 
remaining signal compared to untreated samples. Samples were normalised to GAPDH as a 
loading control. PTEN-WT and PTEN-3KR were compared using an unpaired t-test with 
Mann Witney correction. There was no significant difference between total levels of PTEN- 
WT and PTEN-3KR expressing cells after 24h cycloheximide treatment (p=0.208, N=4). 
WT 3KR WT 3KR 





5.3.2 PTEN-3KR and WT do not Dimerize Differently with PTEN-WT in HEK293T Cells 
 
Due to evidence that PTEN mutants can hetero-dimerize with PTEN-WT and obscure its ability 
to regulate the Akt pathway (Papa et al. 2014), I wanted to test whether PTEN-3KR would 
dimerize differently with WT. To do this, Tandem Affinity Purification (TAP) tagged WT-PTEN 
was expressed with either GFP, GFP-tagged WT-PTEN or 3KR-PTEN, and a GFP trap was then 
carried out and the samples blotted for the SBP-tag in TAP-PTEN. The TAP tag contains 
Streptavidin-Binding Peptide (SBP) and Calmodulin-Binding Peptide (CBP) tags. GFP-tagged 
WT-PTEN and 3KR-PTEN immunoprecipitated similar amounts of WT-TAP-PTEN. This 
suggests PTEN-3KR can also dimerise with WT, and there was no significant difference in 




Figure 5.3.2.1. WT and PTEN-3KR Dimerize with PTEN-WT to a Similar Extent. 
6cm dishes of HEK cells were transfected with TAP-WT-PTEN along with GFP, GFP- 
tagged WT-PTEN or 3KR-PTEN (TAP PTEN is both SBP and CBP tagged). Two days 
later, cells were lysed and subject to immunoprecipitation via GFP-trap and blotted for SBP 
and GFP. SBP was normalised to GFP, then PTEN-3KR binding with WT was expressed 
as a percentage of WT binding with WT. A One-sampled t-test showed there was no 
significance difference between conditions (P=0.963, N=3). 





5.3.3 PTEN-3KR has Reduced Ability to Limit the Akt Pathway in HeLa Cells 
 
PTEN mutants with reduced SUMOylation capacity have been reported to have limited ability to 
supress Akt activation (Huang et al. 2012). To compare p-Akt suppression between WT and 
PTEN-3KR conditions, I created HeLa cell lines Lentivirally expressing GFP-tagged plasmids 
with either Scrambled shRNA (Scr), PTEN knockdown shRNA (KD), or knockdown-rescue GFP- 
tagged PTEN-WT or PTEN-3KR (Figure 5.3.3.1.A). To create this cell lines, 40,000 HeLa cells 
were plated into wells of a 12 well plate. Four hours later 250μl Scr, PTEN KD, GFP-tagged 
PTEN-WT, or PTEN-3KR Lentivirus was added to separate wells. Three days later, cells were 
split into T75 flasks and allowed to grow until confluent. Blotting of these cells for PTEN showed 
clear expression of GFP-tagged WT and PTEN-3KR and confirmed knockdown of endogenous 
PTEN, and overexpression of the GFP-PTEN replacements (Figure 5.3.3.1.A). 
 
Akt and Phosphorylated (active) Akt were then blotted for in these cell lines (Figure 5.3.3.1.C.). 
Consistent with previous reports (Cantley and Neel 1999; Manning and Cantley 2007), PTEN KD 
cells show enhanced Akt activation, evidenced by the large increase in p-Akt (Ser473) compared 
to Scr control. Furthermore, cells expressing PTEN-3KR also showed enhanced p-Akt levels 
normalised to total Akt, compared to cells expressing WT-PTEN. This suggests in PTEN-3KR 
conditions there is a higher p-Akt/ total Akt ratio, which is commonly used to measure Akt 
activation (Griffin et al. 2005). PTEN-3KR is therefore less able to supress Akt activation. 
However, p-Akt levels were reduced by PTEN-3KR expression compared to cells lacking PTEN, 
suggesting this mutant is not completely inactive. This is in line with Huang et al. (2012) who 
also showed single mutations at SUMO sites K254R and K266R (two of the three mutations also 
in PTEN-3KR) reduces its activity against Akt. However, I note that the group state that this 
deficiency is due to reduced SUMOylation of PTEN, while my results show PTEN-3KR exhibits 
enhanced SUMOylation (Figure 4.3.4.1). 
Interestingly, total Akt was significantly increased in WT-PTEN expressing cells compared to 
control (Scr) cells, but reduced in PTEN-3KR-expressing cells. Potentially, these results suggest 
the cell could be trying to compensate for the enhanced inhibition of p-Akt resulting from WT- 
PTEN overexpression by producing more Akt. This could be tested by expressing a catalytically 
dead form of PTEN and examining whether the same effect is seen. Conversely, cells 
expressing the PTEN-3KR mutant exhibit enhanced Akt activity, and may thus respond by 
reducing total Akt levels. 







Figure 5.3.3.1. HeLa cell lines expressing PTEN-3KR have Significantly Increased P-Akt/ 
Akt Ratio Compared to PTEN-WT Cells. 
A) Representative blot of HeLa stable cell lines. 300,000 cells were plated into each well of a 6 
well dish. When confluent, cells were then lysed in sample buffer, subject to Western blot and 
blotted for PTEN. B) Quantification of A. PTEN was normalised to GAPDH. Each experiment 
was normalised to the mean of each experiment, then one-way ANOVA with Tukey correction 
was used to assess significance (N=3). C) Representative blot showing Akt, phosphorylated 
Akt (site S473) in samples of the cell lines shown in A. D/E) Quantification of Akt, P-Akt and P- 
Akt/Akt. Samples were run on gels separately, one membrane of each was blotted for P-Akt 
and the other was blotted for Akt and GAPDH. P-Akt was normalised to Akt for quantification 
of P-Akt. Akt was normalised to GAPDH for quantification of Akt. Each experiment was 
normalised to the mean of each experiment, then One-way ANOVA with Tukey correction was 
then carried out to assess significance (N=3, *=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001). 
Scr KD WT 3KR Scr KD WT 3KR 





5.3.4 Phospho-Erk is not Significantly Altered in PTEN-3KR Versus PTEN-WT 
Expressing HeLa Cells 
 
Extracellular Signal-Regulated Kinase (Erk) is part of a signal transduction pathway which 
mediates various cellular processes including cell cycle progression and cell proliferation (Yoon 
and Seger 2006). Erk is also involved in plasticity through regulating GluA2 delivery to synapses 
(Qin et al. 2005). There is evidence that PTEN can negatively regulate Erk phosphorylation 
(Weng et al. 2002), so I wanted to see if phospho-Erk (p-Erk) level would change between 
conditions in my cell lines. Samples of Scr, PTEN KD, PTEN-WT and PTEN-3KR were blotted 
for p-Erk and Erk. Although both an Erk and p-Erk antibody were used, only the phospho-Erk 
was successful in detecting bands at the right molecular weight. This is a double band at 44kDa 
and 42kDa, which are p-Erk1 (T202/T204) and p-ERK2 (T185/T187) respectively (Sigma 
datasheet Product Number E7028). For this reason, p-Erk has been normalised to GAPDH. 
There is no significant difference between any of the conditions, suggesting PTEN levels are not 
influencing p-Erk levels in these cell lines (Figure 5.3.4.). 
 
 
Figure 5.3.4.1. Phospho-Erk activity is unaffected by manipulation of PTEN. 
Samples from Scr, PTEN KD, PTEN-WT and PTEN-3KR HeLa cell lines shown in Figure 
5.3.3. were blotted for phospho- Erk (p-ERK1 (T202/T204) and p-ERK2 (T185/T187) and 
GAPDH. P-Erk was normalised to GAPDH. All experiments were individually normalised to 
the mean of each experiment, then a one-way ANOVA with Tukey correction was used to 
analyse significance (N=3). 





5.3.5 Imaging of PTEN-WT and PTEN-3KR in Neurons 
 
There is evidence that PTEN with K254R and K266R mutations at SUMOylation sites localise to 
different parts of the cell in cell lines compared to WT (Huang et al. 2012). I therefore compared 
the localisation of GFP-tagged WT and PTEN-3KR constructs in neurons, which has not 
previously been examined. Transfection of constructs into hippocampal neurons and subsequent 
fixing and imaging showed that both proteins show an extremely diffuse expression pattern, 
making it difficult to establish any differences in localisation. Nonetheless there were no obvious 
differences in localisation between conditions, however it is noted that to improve validity, 
neurons with a lower expression of the constructs should be imaged. However, I decided to 





Figure 5.3.5.1. Imaging of WT and PTEN-3KR in Hippocampal Neurons. 
Hippocampal neurons were transfected on DIV 8/9 with GFP-WT-PTEN or GFP-3KR- 
PTEN. 4/5 days later, neurons were fixed and stained with GFP antibody before confocal 
imaging. Image shows representative neurons from 2 independent cultures. 
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**=p ≤ 0.01, ***=p ≤ 0.001, ****=p ≤ 0.0001). 116 
 
 
Figure 5.3.6.1. SENP3 Knockdown does not Significantly Alter GluA1 or 2 Levels in Neurons. 
 
5.3.6 SENP3 Knockdown does not Influence Total AMPAR Levels in Neurons 
 
PTEN has previously been shown to play a role in AMPAR trafficking (Liu et al., 2013); as a 
starting point to begin examining the role of PTEN SUMOylation in this, I tested whether SENP3 
KD could alter AMPAR levels. KD of SENP can be used to model enhanced SUMOylation 
conditions (Bawa-Khalfe et al. 2010). SENP3 can deconjugate SUMO2/3, and to a lesser extent, 
SUMO1, so it was expected that SENP3 KD would enhance global SUMOylation by blocking de- 
SUMOylation (Gong and Yeh 2006; Yeh 2009). SENP3 KD Lentivirus, made by Dr K Wilkinson, 
was added to neurons and left for 7 days before lysis and blotting. SENP3 levels had no 
significant effect on GluA1 or GluA2 total levels. This suggests that level of global SUMOylation 





























(A) Representative blot of SENP3 expression after SENP3 Lentiviral KD by two shRNA KD viruses: 
SENP3 KD-1 (KD-1) or SENP3 KD-2 (KD-2) in neurons. Neurons were infected on DIV8-12, 7 days 
later were lysed and subject to Western blot. B) Quantification of A: samples were individually 
normalised to the mean of each experiment, then analysed in a one-way ANOVA with Dunnett’s 
correction (both KDs were compared to Scr as a control). C/D) Samples show in A) were blotted for 
GluA1 and GluA2. E/F) Quantification of C) and D). GluA2 was normalised to β-Actin or GAPDH, 
then each experiment was normalised to the mean of that experiment, then analysed using one- 
way ANOVA with Dunnett’s correction comparing KD samples to Scr (Cl= 95%) (N=5; *=p ≤ 0.05, 





5.3.7 Lentiviral PTEN KD Significantly Reduces Surface GluA2 Levels in DIV 20-22 
Neurons 
 
To further investigate role for PTEN in AMPAR trafficking, surface biotinylation was conducted to 
establish whether PTEN KD could influence surface or total AMPAR levels. PTEN has 
previously been reported to regulate AMPAR surface levels (Liu et al. 2013), Furthermore, PIP₃ 
levels are critical in AMPAR localisation at the membrane (Arendt et al. 2010), so as PTEN-3KR 
had reduced phosphatase activity against p-Akt, I reasoned this could regulate AMPAR levels at 
the membrane differently to WT. 
After 7-day lentiviral PTEN knockdown, or treatment with Scr control, DIV 20-22 cortical rat 
neurons were surface biotinylated, and labelled surface proteins isolated using streptavidin- 
beads before Western blotting of surface and total samples (Figure 5.3.7.1.). Lentiviral KD of 
PTEN significantly reduced the proportion of GluA2 expressed on the surface, without 
significantly affecting total GluA2 levels. 
This is in contrast to Lui et al. (2013) who reported that increases in PTEN are associated with 
a loss of GluA2 at the surface. PTEN inhibition was able to limit the reduction of GluA2 lost from 
the surface after stretch injury, so overall in this context, PTEN negatively regulated surface 
GluA2 (Liu et al. 2013). However, PTEN KD was not tested in that study, instead BpV was used 
to transiently block PTEN activity. Moreover, there were other methodological differences, my 
experiments involved surface biotinylation of cortical neurons to measure surface GluA2, while 
Liu et al. (2013) conducted imaging on hippocampal neurons. 









Figure 5.3.7.1. Lentiviral PTEN KD Significantly Reduces Surface GluA2 Levels in DIV 
20-22 Neurons. 
(A) Representative blot showing PTEN KD after 6-7 day lentiviral infection. Cortical neurons 
were infected on DIV 14-16 with Scr or KD lentivirus. (B) Quantification of blot on the left, 
showing PTEN total signal after PTEN KD compared with Scr (p<0.0001, N=7). (C) 
Representative blot of surface biotinylation after PTEN KD. Scr and PTEN KD lentiviruses 
were added to DIV 14-16 cortical neurons for 6-7 days, then surface biotinylation was 
carried out. (D) Quantification of GluA2 total signal after PTEN KD (p=0.484, N=7). (E) 
Quantification of GluA2 surface blot above. Surface samples were normalised to total 
samples and Scr was compared to KD (p=0.0397, N=7). In all analyses, Scr and KD were 
compared using a One sampled t-test where Scr was set to a hypothetical value of 100. 
Surface was normalised to total and GluA2 totals were normalised to GAPDH as a loading 
control. 





5.3.8 PTEN-WT and PTEN-3KR do not Bind Myc-PSD-95 Significantly Differently 
in HEK293T Cells 
 
PSD-95 is important for clustering of AMPARs at synapses (Chen et al. 2000; Bats, Groc, and 
Choquet 2007). Furthermore, PTEN binding to PSD-95 is reported to be critical in NMDAR- 
Dependent mediated LTD (Jurado et al. 2010). I therefore wanted to see if PTEN-3KR would 
bind PSD-95 differently to WT, to see if enhanced SUMOylation could influence this interaction. I 
expressed GFP-WT and PTEN-3KR with Myc-PSD-95 in HEK293T cells, then carried out 
immunoprecipitation and blotted for Myc and GFP. There was no statistical difference between 
WT and PTEN-3KR binding to Myc-PSD-95, suggesting enhanced SUMOylation on PTEN-3KR 
is not influencing binding to PSD-95. 
 
 
Figure 5.3.8.1. WT and PTEN-3KR do not bind Myc-PSD-95 significantly differently. 
Representative blot showing immunoprecipitated Myc-PSD-95 in HEK cells. Cells were 
transfected with Myc-tagged PSD-95 along with GFP, PTEN-WT or PTEN-3KR and subject 
to immunoprecipitation and Western blot protocols (see Methods 3.4.1). Samples were 
blotted for Myc and GFP. Immunoprecipitated Myc signal was normalised to total Myc signal 
for each condition, then normalised to GFP to allow for differences in total expression levels 
of both proteins to be controlled for. PTEN-3KR was then compared with WT which was set 
to a hypothetical value of 100. A one sampled T-test was then used to establish significance 
(p=0.690, N=3). 





5.3.9 Surface GluA2 is Unaffected by PTEN Knock Down in DIV 15-16 Neurons 
 
To further explore effects of PTEN in AMPAR trafficking, the experiment was repeated with two 
more conditions: PTEN-WT-KD rescue and PTEN-3KR-KD rescue (both cloned by Dr K 
Wilkinson) (Figure 5.3.9.1). The purpose of the experiment was to see if expressing recombinant 
PTEN-WT after the KD could rescue effects of KD, which would validate the previous finding that 
PTEN KD influences GluA2 surface levels. The addition of the PTEN-3KR mutant-KD rescue 
also allowed me to examine whether enhanced SUMO or ubiquitin modification of PTEN could 
be involved in its effects on GluA2 expression. Given that PTEN-3KR could not regulate the P- 
Akt pathway (Figure 5.3.3.1), and given the involvement of PIP₃ levels in AMPAR anchoring at 
the synapse (Arendt et al. 2010), I postulated that PTEN-3KR may affect GluA2 differently than 
WT. The result was that the KD effect of reducing surface GluA2 did not replicate; there was no 
significant effect of any of the conditions when compared against each other. However, it is 
noted that the neurons were younger in this experiment than the previous experiment (infected 
on DIV 8-10 rather than DIV 14-16). As gene transfer of viral constructs is more effective in 
younger neurons (Levin, Diekmann, and Fischer 2016), I used these younger neurons in this 
experiment to improve the level of rescue expression. However, this may have confounded the 
results, given that past DIV 14, neurons are considered to be at the “late mature” stage, where 
the neuronal network is stable and synaptic transmission is in its prime (Moutaux et al. 2018). 
Considering this with the importance of PTEN in synaptic development (Fraser et al. 2008; Kwon 
et al. 2006), reviewed in 1.2.13), this may explain the variation between this experiment (Figure 
5.3.8.1.) and the previous (5.3.7.1.). 







Figure 5.3.9.1. PTEN KD, or expression of WT or PTEN-3KR, does not alter surface or 
total GluA2 levels in DIV 15/16 Neurons. 
(A) Representative blot of PTEN level after surface biotinylation of DIV 15/16 cortical neurons 
after 6/7 day viral infection with GFP-tagged Scr, PTEN KD, PTEN-WT and PTEN-3KR 
Lentiviruses. B) Quantification of PTEN level in each condition, normalised to GAPDH. All 
experiments were individually normalised to the mean of each experiment, then all conditions 
were compared against each other using a One-way ANOVA with Tukey correction. PTEN 
levels differed significantly between Scr and WT or PTEN-3KR (****=p ≤ 0.0001, N=4). There 
was no significant difference in PTEN level between WT and PTEN-3KR or Scr and KD. C 
and D) Representative blot of surface and total GluA2 levels after surface biotinylation. E and 
F) Quantification of GluA2 total (N=4) and surface (N=5) signal after surface biotinylation. 
Surface GluA2 samples were normalised to total GluA2 samples, total GluA2 was normalised 
to GAPDH. All experiments were individually normalised, then all conditions were compared 
against each other using a One-way ANOVA with Tukey correction. No significant differences 
were found in GluA2 surface or total expression between conditions. 
 






     5.3.10 WT and PTEN-3KR Expression Increases Surface GluA2 in DIV20-22 Neurons 
 
As the effect of the knockdown did not replicate in younger neurons, I decided to repeat these 
experiments in older neurons, to match the experiments shown in Figure 5.3.7.1. This meant 
that at the time the virus was added (DIV 14/15), neurons should already be mature (Moutaux et 
al. 2018). Unexpectedly, once again the decrease in surface GluA2 in PTEN KD seen in Figure 
5.3.7.1 was not observed. However, both WT and PTEN-3KR overexpression significantly 
increased surface GluA2 levels. Taken together, these experiments suggest that PTEN level is 
having an effect on GluA2 surface expression, but the effect is not robust. The variation in 
results could be due to differences arising from different cell culture reagents such as horse 
serum or B27 in neuronal cultures having an effect on growth/health of neurons, or differences in 
density or activity of neurons. There is evidence that different dissections of cortical cultures can 
vary considerably in neuronal activity patterns, due to either differences in the rat which the 
cultures came from, or from later in development (Wagenaar, Pine, and Potter 2006). 
There was no significant difference in surface GluA2 levels between WT and PTEN-3KR, 
suggesting enhanced SUMOylation/ubiquitination is not relevant to PTEN’s ability to influence 
surface AMPAR expression. This is surprising given the defects in PTEN-3KR activity (Figure 
5.3.3.1), and evidence that PIP₃ reduction limits postsynaptic AMPAR expression (Arendt et al. 
2010). However, PTEN-3KR is not totally defective in its ability to supress p-Akt, so this lower 
level of activity could be enough to regulate AMPAR surface levels. It is also possible that the 
vast overexpression of PTEN-3KR and PTEN-WT from the KD-rescue constructs negates this 
difference; this overexpression would likely increase phosphatase activity and could cancel out 
potential differences between WT and PTEN-3KR at endogenous levels. Future experiments 
could include repeating this experiment with a lower level of expression to test this. 







Figure 5.3.10.1. Lentiviral PTEN-WT and PTEN-3KR Overexpression Significantly 
Increase Surface GluA2 Levels in DIV 20-22 Neurons. 
Cortical neurons were infected on DIV 14/15 and surface biotinylation protocol was carried 
out 6/7 days later. Samples were subject to Western blot protocols and blotted for GluA2 
and GAPDH. A) Representative blot of PTEN expression after surface biotinylation of 
cortical neurons after 6/7-day viral infection with GFP-tagged Scr, PTEN KD, PTEN-WT 
and PTEN-3KR Lentiviruses. B) PTEN signal was normalised to GAPDH. Experiments 
were individually normalised to the mean of each experiment and analysed using One-way 
ANOVA with Tukey correction. C) and D) Representative blot showing surface and total 
GluA2 respectively. E) and F) Analysis of surface and total GluA2. Surface GluA2 was 
normalised to total GluA2 and total GluA2 was normalised to GAPDH. All experiments 
were individually normalised to the mean of each experiment. One-way ANOVA analysis 
was used with Tukey correction to analyse significance across all conditions (N=5, *=p ≤ 
0.05, **=p ≤ 0.01, ***=p ≤ 0.001, ****=p ≤ 0.0001). 






5.4.1 PTEN Dimerization and Stability 
 
In an attempt to reveal the effects of enhanced SUMOylation and/or ubiquitination on PTEN 
function, in this chapter I sought to characterise the functions and behaviour of PTEN-3KR, in 
terms of its regulation and effects on AMPAR trafficking. 
I first compared PTEN-WT and PTEN-3KR in terms of stability and dimerization. Given that 
dimeric PTEN is more active than monomeric PTEN (Papa et al. 2014), and reduced-SUMO 
mutants are less catalytically active (Huang et al. 2012), I tested whether PTEN-3KR could 
dimerize with WT. No obvious difference was seen between conditions, suggesting WT and 
PTEN-3KR dimerize with WT to a similar extent. 
Overexpression of SUMO ligase PIASxα reduces P-Akt in a PTEN-Dependent manner; this is 
suggested to be because PIASxα- driven SUMOylation increases PTEN stability (Wang et al. 
2014). SUMOylation at K254 and K266 is thought to block ubiquitination and subsequent 
degradation (Wang et al. 2014). Other work has confirmed the role of ubiquitination in reducing 
stability and reported K266 to be the dominant site for stability (Wang et al. 2016; Leslie and 
Gupta, 2016). Therefore, PTEN-3KR could have been predicted to be more or less stable given 
that it is both more SUMOylation and ubiquitinated than PTEN-WT, and it is not known which 
sites SUMO and ubiquitin are conjugating to. No significant difference was found between 
degradation rate of WT and PTEN-3KR after cycloheximide treatment (Figure 5.3.1.1.), 
suggesting enhanced SUMO or ubiquitin modification in PTEN-3KR is not relevant to stability. 
This could be because the increased ubiquitin on PTEN-3KR is a Lys63 linked chain, rather than 
degradation-associated Lys48 (Kawadler and Yang, 2006; Haglund et al. 2003; Komander, 
2009; Hicke et al. 1996). This could be tested by blotting with chain-specific ubiquitin antibodies. 
 
5.4.2 PTEN-3KR, Localisation and the P-Akt Pathway 
 
Ability to supress P-Akt is a well-documented ability of PTEN (Cantley and Neel, 1999; Manning 
and Cantley, 2007). Previous work has shown that PTEN mutants with reported reduced 
SUMOylation capacity show deficits compared to PTEN-WT in supressing P-Akt (Huang et al. 
2012). It is therefore in line with previous work that PTEN-3KR could not regulate P-Akt as WT 
can (Figure 5.3.3.). However, previous work argues separate/ double mutations of PTEN at 
K266/K254/K289 reduce SUMOylation, whereas my results in chapter 3 show SUMOylation is 
increased. 
Gonzales- Santamaria (2012) argue that SUMO forces PTEN into the “open” conformation by 
obscuring interactions between the C2 domain and C-tail, facilitating membrane localisation, 






which is suggested to enable P-Akt regulation (Huang et al. 2012). This is based on the 
observation that viral infection causes translocation of PTEN to the membrane where it is 
SUMOylated by SUMO1 and 2. As mentioned, this paper tested PTEN-mutant SUMOylation 
level with tagged, recombinant SUMO, and results contrast with my own with endogenous 
SUMO. Therefore, my results suggest that this model may not be correct, and SUMOylation may 
inhibit membrane localisation, evidenced by lack of P-Akt regulation in PTEN-3KR. It was hoped 
that the imaging experiment (Figure 5.3.5.) could elucidate any differences between WT and 
PTEN-3KR localisation, but the expression levels were too high for any potential differences to 
be observed. Nonetheless, it seems mutation of the three known SUMO sites reduce PTEN’s 
ability to regulate P-Akt. However, I argue that this is due to an excess of endogenous SUMO (or 
ubiquitin) on these mutants, rather than a lack of SUMO. This is in line with Shenoy et al. (2012), 
who argue SUMO would be more likely to hinder membrane localisation (This will be discussed 
further in the general discussion). Alternatively, it could be that PTEN SUMOylation must be 
tightly regulated, and extremes at either end of the scale can obstruct its activity. In addition to 
SUMO, it could be that effects seen are due to the increased polyubiquitination on PTEN-3KR, 
although my results do not support a difference in turnover rate of the PTEN-3KR mutant (Figure 
5.3.1.). 
Importantly, however, differences between PTEN-WT and PTEN-3KR cannot be unequivocally 
attributed to an increase of SUMO or ubiquitin on PTEN-3KR. It could be that mutations in 
PTEN-3KR have effects through another mechanism, such as a change in conformation 
(although molecular dynamic simulations by Huang et al. (2012) has shown K266R mutation 
does not induce conformational change). Repeating experiments in this chapter with the addition 
of SENP or a DUB would elucidate whether effects seen are due to enhanced SUMO/ubiquitin 
or another aspect of regulation. 







Figure 5.4.2.1. Schematic Representing the Possible Role of SUMO in Regulating 
PTEN Activity. 
PTEN-WT at the membrane with phosphatase activity is capable of dephosphorylating PIP₃, 
reducing Akt activity (Maehama and Dixon 1998; Stambolic et al. 1998; Myers et al. 1998; Leslie 
et al. 2008). PTEN-3KR exhibits enhanced SUMOylation, and thus may be less able to be 
recruited to the membrane, and therefore unable to supress Akt activation, as membrane 
localisation is important in PIP₃ regulation (Leslie et al. 2008). Lack of suppression of P-Akt can 
lead to enhanced cell proliferation, growth and tumorigenesis (Stambolic et al. 1998; Cantley 
and Neel 1999; Shi et al. 2019). This model is congruent with Shenoy et al. (2012) who suggest 
SUMOylation is more likely to inhibit, rather than facilitate membrane localisation, and contrasts 
with Gonzales-Santamaria et al. (2012) who postulate SUMO binding facilitates membrane 
localisation through blocking its “closed” formation. This schematic is adapted from Carnero et 
al. (Carnero and Paramio 2014) Huang et al. (2012) and Lang et al. (2015) and made in 
Biorender.com with premade shapes. 
 
 
5.4.3 PTEN, PTEN-3KR and AMPAR Expression 
 
Figure 5.3.7.1. indicates that KD of PTEN significantly reduces surface GluA2. However, in a 
separate series of experiments investigating KD-rescue, the KD alone condition did not 
decrease surface GluA2 (Figure 5.3.9.1.). In these experiments, WT KD-rescue and PTEN-3KR 
conditions significantly increased GluA2 on the surface, supportive of the role of PTEN in GluA2 
trafficking. The lack of replication of the PTEN KD decreasing GluA2 surface expression 
suggests this effect is not robust, and potentially sensitive to the culture conditions, plating 
density or network activity of the individual cell preparation. Nonetheless, taken with the 
observations that WT and PTEN-3KR overexpression increase surface GluA2, overall, my data 
support a role for PTEN role in positively regulating surface GluA2 expression. 
Increased levels of PIP₃ is have been associated with synaptic plasticity (Arendt et al. 2010; 
Arendt et al. 2014; Jurado et al. 2010; Knafo et al. 2016). Indeed, Arendt et al. (2014) report 
that during LTP and LTD levels of PIP₃ are increased. Moreover, PTEN phosphatase activity is 






necessary for LTD, and overexpression of WT, but not catalytically dead PTEN, can hamper 
AMPAR-mediated synaptic transmission under both basal and stimulation conditions (Jurado et 
al. 2010). It has been proposed that PTEN acts as a “switch” that dictates the outcome of this 
PIP₃ increase; there is an increase of PIP₃ in LTP and LTD which is counteracted by PTEN 
during LTD, blocking the net change in PIP₃ (Arendt et al. 2014). The effect is that the PTEN 
phosphatase activity favours LTD; although AMPAR surface expression was not examined 
directly, it is a well characterised outcome of LTD (Carroll et al. 1999; Fleming and England 
2010; Jurado et al. 2010; Arendt et al. 2014). 
Furthermore, PIP₃ can have a variety of effects on AMPARs, including limiting AMPAR surface 
expression (Arendt et al. 2010). PIP₃ is necessary to maintain AMPARs at synapses and 
inhibition of PIP₃ causes synaptic depression due to distribution from away from synapses to 
extra/ peri synaptic areas (Arendt et al. 2010). PIP₃ depletion has also been reported to increase 
AMPAR accumulation in spines and membrane (Arendt et al. 2010). Thus, an explanation of my 
data is that PTEN overexpression increases surface GluA2 through a mechanism that involves 
decreasing PIP₃ levels. 
However, the relationship between PTEN, PIP₃, AMPAR trafficking and plasticity is complex, 
and previous research is contradictory. Imaging experiments would be useful to validate my 
finding that PTEN positively regulates surface GluA2. Considering Arendt et al. (2010) report 
that PIP₃ can regulate local AMPAR movement between synapses and extra/peri-synaptic 
regions, I would like to examine whether PTEN can influence this AMPAR movement through 
regulation of PIP₃. Arendt et al. (2010) propose that during basal conditions, PTEN maintains 
low PIP₃ levels in neurons. 
It is noted that there was no significant difference in surface GluA2 expression between cells 
expressing PTEN KD-rescue WT and PTEN KD-rescue PTEN-3KR; both exhibited significantly 
increased surface GluA2 levels compared to control (scrambled PTEN shRNA).This was 
unexpected because PTEN-3KR has likely reduced phosphatase activity, evidenced by 
increased P-Akt (Figure 5.3.3.1.), so its lack of effect on surface GluA2 compared to WT argues 
against the involvement of PIP₃ levels in surface AMPAR expression. Nonetheless, PTEN-3KR 
does retain some phosphatase activity since it partially rescues the effect of PTEN KD. I propose 
that this remaining phosphatase activity is sufficient to limit potential PIP₃-depletion-Dependent 
increases to AMPAR levels. Furthermore, the residual phosphatase activity coupled with marked 
overexpression of PTEN constructs may account for the lack of difference between PTEN-WT 
and PTEN-3KR in these experiments. The experiment therefore should be repeated with lower 
expression levels of the rescue constructs. 







In summary, the data I present suggest 
• There is no significant difference in PTEN-3KR stability compared to PTEN-WT 
 
• There is no significant difference in the ability of PTEN-3KR to dimerize with PTEN-WT 
 
• PTEN-3KR is defective in its ability to inhibit the Akt pathway compared to PTEN-WT in 
HeLa cell lines 
• P-Erk levels are not significantly altered by PTEN loss or expression of WT or PTEN-3KR 
 
• PTEN may play a modest role in GluA2 surface expression in neurons 
 





In this chapter I have characterised aspects of the phosphatase activity, stability and 
dimerization ability of PTEN-3KR. This has revealed that PTEN-3KR has reduced ability to 
regulate phospho-Akt. Given that PTEN-3KR is more SUMOylated than WT, this suggests 
enhanced SUMOylation may negatively regulate PTEN phosphatase activity, but more research 
is needed to clarify this. 
The lack of reproducibility means that interpretation of the GluA2 surface biotinylation 
experiments must be treated with caution. However, in conjunction with evidence that increasing 
PTEN expression increases surface GluA2, my tentative conclusion is that PTEN positively 
regulates surface GluA2. This is in contrast to reports showing that upregulation of PTEN is 
associated with reduced surface GluA2 (Liu et al. 2018; Liu et al. 2013). A potential explanation 
for these apparent discrepancies is that PIP₃ is necessary for AMPAR clustering and surface 
expression (Arendt et al. 2010). Since PTEN negatively regulates PIP₃ (Maehama and Dixon et 
al. 1998), it is possible that PTEN exerts its effect on GluA2 through its activity against PIP₃. 
Arendt et al. (2010) postulate that under basal conditions, PTEN may limit PIP₃ levels in 
unstimulated neurons. Furthermore, it has been reported that PTEN counteracts PIP₃ increases 
after NMDA stimulation, blocking net change in PIP₃, skewing plasticity events towards LTD 
which is associated with reduction of AMPARs at the synaptic membrane (Arendt et al. 2014; 
Carroll et al. 1999; Fleming and England 2010). 






With this in mind, it was unexpected that PTEN-3KR did not have a differential effect to WT, 
given that it had reduced activity against Akt activation, a known outcome of PIP₃ signalling 
(Rosivatz and Woscholski 2009). It would be useful to repeat this experiment with a lower level 
of expression, in case overexpression is confounding the result. Taken together, my current data 
suggest that enhanced SUMOylation and/or ubiquitination of PTEN do not influence its effect on 
surface GluA2. 
 
5.7 Future Experiments 
 
To extend these findings, the following experiments could be carried out 
• Repeat surface biotinylation measuring surface GluA2 with expression of KD-rescue WT 
and PTEN-3KR at endogenous levels 
• Repeat surface biotinylation measuring surface GluA2 with expression of KD-rescue 
catalytically inactive PTEN mutant, to confirm role of PTEN phosphatase activity in 
regulating surface GluA2. This could be validated by observing changes after PI3K 
inhibitor treatment. 
• Assess plasticity capacity of WT, PTEN-3KR and catalytically inactive PTEN using in 
vitro LTD experiments. 
• Examine P-Akt levels between PTEN KD, WT, PTEN-3KR and control conditions in 
neurons 
• The model in Figure 5.4.1 could be directly tested by expressing WT versus catalytically 
inactive SENP1 in the PTEN HeLa cells lines and examining P-Akt levels, to establish 
whether it is enhanced SUMO on PTEN-3KR that reduces its ability to regulate Akt 
phosphorylation. 
• Imaging experiments should be repeated with lower levels of PTEN-WT and PTEN-3KR 
expression, and compartment specific markers, to compare their localisation 





6 PTEN, SUMO and Retromer 
6.1 Introduction 
6.1.1 PTEN and Retromer 
 
Recent evidence suggests that PTEN may regulate protein trafficking via regulation of the 
retromer complex (Shinde and Maddika, 2017). Retromer sorts cargo proteins to be 
trafficked from endosomes to the Golgi and plasma membrane (Cullen and Korswagen, 
2012; Seaman, 2012, Burd and Cullen, 2014). KD of retromer component SNX27 induces a 
loss of over 100 proteins from the cell surface, highlighting the importance of retromer in 
membrane protein trafficking (Steinberg et al. 2013). Through trafficking of neuronal 
proteins, retromer can regulate plasticity, and this process is thought to be perturbed in AD 
and PD (Munsie et al. 2015; Temkin et al. 2017; Choy et al. 2014; Wang et al. 2012). 
PTEN may have a role in neuronal surface expression of GluA2 (Figures 5.3.7 and 5.3.10), 
which has also been reported previously (Moult et al. 2010; Liu et al. 2013). To extend my 
findings, I decided to test the role of PTEN in retromer mediated trafficking, partly due to 
evidence that GluA2 is reported to be a retromer cargo (Temkin et al. 2017). I reasoned that 
PTEN could therefore influence AMPAR trafficking through retromer. PTEN has been 
reported to interrupt formation of the retromer complex via direct interactions with SNX27, 
but this has not been widely tested (Shinde and Madikka, 2017). I was interested to see if 
PTEN can regulate retromer components and trafficking of other retromer cargoes. This will 
help to elucidate the role of PTEN in membrane protein trafficking, a process that is relevant 
to fundamental aspects of cellular regulation, as well as plasticity, neurodegeneration and 
cancer (Temkin et al. 2017; Munsie et al. 2015; Zhang et al. 2018). 
Additionally, the role of SUMOylation of PTEN on retromer has not been examined. So far, I 
have shown PTEN-3KR is more SUMOylated and ubiquitinated than WT and has limited 
activity against the Akt pathway. I was interested to see if SUMOylation of PTEN has a role 
in its influence over retromer. 
 
6.1.2 Importance of the Retromer Complex in Neurons and Synaptic Plasticity 
 
Retromer is reported to be directly involved in plasticity and can regulate trafficking of 
neuronal receptors such as β2 adrenergic receptors (β2ARs), AMPARs and dopamine 
transporters (Munsie et al. 2014; Choy et al. 2014; Wu et al. 2017, Cai et al. 2011). Deficits 
in retromer are reported to perturb an array of neuronal processes including neuronal 
maturation, LTP, AMPAR trafficking, AMPAR-mediated transmission, NMDAR endocytosis 
and Aβ deposition and metabolism (Cai et al. 2011; McMillan et al. 2020; Wang et al. 2012; 




Bhalla et al. 2012; Choy et al. 2014; Temkin et al. 2011; Temkin et al. 2017; Tian et al. 2015; 
Li, Chiu, and Pratico 2020) (See Introduction 1.4.6-1.4.7 for more detail on this). Notably, KD 
of retromer component VPS35 KD blocks LTP, through inhibition of AMPAR sorting and 
insertion at the membrane necessary for LTP (Temkin et al. 2017). 
Table 7. Key Retromer Proteins (For More Information see General Introduction 1.4). 
 
Protein Key Mechanism of Action Roles in Neuronal Regulation 
SNX27 Adaptor protein, mediates interactions 
between cargoes and retromer (Burd and 
Cullen, 2014). 
Regulates AMPAR trafficking, LTP, 
neurotransmission (McMillan et al. 
2020). Regulates NR2C endocytosis, 
crucial for mouse survival past 3 weeks 
(Cai et al. 2011) 
VPS26 Regulates cargo recognition and 
localisation, VPS35 membrane 
localisation, and VPS35-SNX protein 
interactions (Reddy and Seaman, 2001; 
Gokool et al. 2007; Fjorback et al. 2012). 
Regulates VPS35 levels in neurons 
(Bhalla et al. 2012) 
VPS29 Binds VPS35, stabilises VPS26 and 
VPS35 (Kovtun et al. 2018; Jimenez- 
Orgaz et al. 2018; Baños-Mateos, Rojas, 
and Hierro 2019; Fuse et al. 2015) 
Regulates endo-lysosomal function and 
synaptic transmission (Ye et al. 2020) 
VPS35 Cargo recognition (Burd and Cullen, 
2014), major regulator of cell surface 
protein recycling (Steinberg et al. 2013). 
Regulates Aβ deposition/ levels (Li et 
al. 2019; Small et al. 2005), AMPAR 
surface levels and spine maturation 
(Tian et al. 2015). Critical in LTP 
(Temkin et al. 2017). 
Retromer dysfunction is implicated in a range of neurodegenerative diseases including AD 
and PD (Small et al. 2005; Muhammad et al. 2008; Bhalla et al. 2012; Munsie et al. 2014). 
Mutations of retromer genes are also found in AD and PD, and are thought to lead to deficits 
in both receptor trafficking and Amyloid metabolism (Small et al. 2005; Muhammad et al. 
2008; Bhalla et al. 2012; Temkin et al. 2017; Munsie et al. 2014; see General Introduction 
1.5.11-1.5.13). Haploinsufficiency of VPS35, a key retromer protein, is associated with AD 
(Wen et al. 2011), and levels of VPS26 and VPS35 are downregulated in AD brains (Small 
et al. 2005). Furthermore, VPS35 upregulation in Tau/APP mutant mice reduces Aβ 




deposition and levels and improves behavioural deficits and neuroinflammation (Li et al. 
2019). 
 
6.1.3 Retromer, Phosphoinositides and PTEN 
 
There is a potential role for PTEN phosphatase activity in retromer regulation, as PIP₃ levels 
are known to influence retromer function (Verges, Sebastian, and Mostov 2007; Laporte et 
al. 2002). PIP₃ levels are reported to influence SNX27 targeting to endosomes (Cai et al. 
2011), and SNX1/2 localisation with VPS26 and membrane targeting is dependent on PIP₃ 
(Vergés et al. 2006). Therefore, it is plausible that the phosphatase action of PTEN could 
influence retromer mediated trafficking. This is worth exploring as AMPARs are also 
influenced by PIP₃ levels, and PTEN phosphatase activity plays a role in plasticity and has a 
preference for synaptic depression (Jurado et al. 2010; Arendt et al. 2010, Arendt et al. 
2014; Knafo et al. 2016). Furthermore, PI3K signalling favours synaptic potentiation (Arendt 
et al. 2010). Therefore, PTEN’s lipid phosphatase influence on retromer needs to be further 
explored, as this may elucidate its role in plasticity. Given than PTEN-3KR seems to have 
reduced ability to limit P-Akt (Figure 5.5.3), suggestive of reduced lipid phosphatase activity 
(Stambolic et al. 1998; Myers et al. 1998; Maehama and Dixon 1998), this makes a useful 
tool to examine the role of lipid phosphatase activity alongside KD and WT conditions, and 
can also enable testing of PTEN SUMOylation and ubiquitination in this system. 
 
6.1.4 PTEN Direct Interactions and Retromer-Trafficking 
 
Aside from the potential for PTEN phosphatase action to influence retromer, Shinde and 
Maddika (2017) showed that through interaction with SNX27, PTEN can influence retromer 
in the context of GluT1 trafficking (GluT1 can be used as a model cargo to study retromer, 
see 5.1.5.). PTEN can bind SNX27 independently of its catalytic activity, which blocks the 
ability of SNX27 to associate with VPS26, reducing retromer formation and forward- 
trafficking of GluT1 (Shinde and Maddika, 2017). Diminishment of PTEN levels increased 
GluT1 surface expression and glucose uptake. Expression of WT PTEN, but not a PTEN 
mutant unable to bind SNX27 (PTEN ΔTKV, which has a PDZ binding motif deletion) was 
able to rescue these effects. It was concluded that through binding to SNX27 and 
sequestering it, PTEN could interrupt retromer formation and influence trafficking of GluT1 
away from Rab11-positive recycling endosomes, and move it towards lysosomes to be 
degraded, which was evidenced by GluT1 co-localisation with LAMP1 (Shinde and Maddika, 
2017). This shows a direct, phosphatase-independent role for PTEN in retromer-mediated 
trafficking of GluT1 (Shinde and Maddika et al. 2017). 




6.1.5 PTEN and Possible Regulation of Retromer Via TFEB 
 
Transcription Factor EB (TFEB) is described as “a master regulator of lysosomal pathways”, 
and is strongly implicated in lysosomal degradation in settings relevant to neurodegeneration 
(Palmieri et al. 2017; Palmieri, Pal, and Sardiello 2017; Sardiello et al. 2009; Settembre et al. 
2012; Martini-Stoica et al. 2016). PTEN has been implicated in this through the proposed 
feedback loop of TFEB–PTEN–Akt–mTOR–TFEB, whereby through upregulation of PTEN 
by TFEB, Akt and mTOR are then inactivated, which further activates TFEB (Polito et al. 
2014; Settembre et al. 2012). mTOR may not be crucial in this pathway as Palmieri et al. 
(2017) reported that Akt phosphorylates TFEB at S467 which increases its activity, and Akt 
inhibition can increase TFEB activity in an mTORC independent manner (Palmieri et al. 
2017). Furthermore, this Akt inhibition-driven TFEB upregulation can enhance clearance of 
aggregate proteins in neurodegeneration (Palmieri et al. 2017). 
TFEB is implicated in Aβ plaque pathology in AD by increasing autophagasome formation 
and lysosomal fusion; its expression can also increase the uptake, trafficking, and lysosomal 
degradation of Aβ42 in primary astrocytes (Xiao et al. 2014; Settembre et al. 2012; Martini- 
Stoica et al. 2016), and can also regulate several Tau species (Polito et al. 2014). Polito et 
al. (2014) reported that TFEB interacts with the PTEN gene through two Coordinated 
Lysosomal Expression and Regulation (CLEAR) -containing sequences in its promoter; 
CLEAR sequences exist in many genes in the lysosomal pathway and are bound by TFEB, 
with an effect of upregulating their transcription (Sardiello et al. 2009). TFEB expression 
increases PTEN expression in vitro and in vivo; as well as PTEN levels, TFEB levels 
correlated with reduced PHF1-positive Tau levels (Polito et al. 2014). As the availability of 
PTEN regulated the ability of TFEB to reduce certain phospho-Tau species, it was 
concluded that PTEN is targeted by TFEB, which is necessary for TFEB-mediated Tau 
clearance (Polito et al. 2014). This was also reflected in behavioural experiments in rTg4510 
Tauopathy mice; learning and memory outcomes were improved by TFEB expression shown 
in Morris water maze tests (Polito et al. 2014). PTEN KD reduced TFEB-mediated alleviation 
of pTau, suggesting PTEN is critical in TFEB’s ability to clear pTau (Polito et al. 2014).  
Polito et al. (2014) suggest that upregulation of TFEB may improve aggregate 
protein clearance by enhancing autophagasome clearance. 
Recently, it was discovered that TFEB overexpression can upregulate RNA and total protein 
levels of retromer components SNX27, VPS26 and VPS35 (Curnock et al. 2019). Therefore, 




I hypothesized that by indirectly upregulating TFEB via P-Akt suppression, PTEN could 
upregulate retromer components levels via TFEB, according to studies by Polito et al. 
(2014) and Curnock et al. (2019). In summary, PTEN is a target of TFEB, and also can 
indirectly cause its activation (Polito et al. 2014); this is relevant to neurodegeneration as 
TFEB has a role in aggregate protein clearance (Palmieri et al. 2017; Polito et al. 2014), 
and can even directly influence retromer components which are also involved in protein 
clearance (Curnock et al. 2019; Vagnozzi and Pratico 2019; Ansell-Schultz et al. 2018). 
 
6.1.6 GluT1 and ASCT2 as Model Retromer Cargoes in Cell Lines 
 
GluT1 trafficking is known to be influenced by PTEN (Shinde and Maddika, 2017); in 
addition, I tested the effect of PTEN of trafficking of another retromer cargo: Alanine, Serine, 
Cysteine Transporter 2 (ASCT2). GluT1 and ASCT2 are both regulated by both SNX27 and 
VPS35 (Steinberg et al. 2013; Scalise et al. 2018; Yang et al. 2018; Curnock et al. 2019) and 
can therefore be used as retromer model cargos to examine the effects of PTEN and PTEN 
SUMOylation on retromer in cell lines. 
ASCT2 surface localisation is necessary for glutamine influx and efflux, and has increased 
expression in proliferative cells (Console et al. 2015; Yang et al. 2018; Scalise et al. 2018; 
Bhutia and Ganapathy 2016). Previous research in ASCT2 trafficking has identified a role for 
SNX27 (Steinberg et al. 2013; Yang et al. 2018). Knockout (KO) of SNX27 in cell lines 
reduces surface ASCT2 levels, reducing glutamine uptake, which leads to restriction of 
cellular proliferation (Yang et al. 2018). Yang et al. (2018) suggest ASCT2-SNX27 
interactions through the SNX27 PDZ domain are important in rescuing ASCT2 from 
lysosomal degradation, reducing this interaction through SNX27 KO leads to increased 
ASCT2 degradation and downstream effects on autophagy due to mTORC1 dysregulation. 
VPS35 KO HeLa cells, ASCT2 is lost from the surface and colocalises with LAMP1-positive 
endosomes and lysosomes significantly more, suggesting enhanced lysosomal degradation 
during retromer depletion (Curnock et al. 2019). This effect was rescued by GFP-VPS35 
expression in the KO cells, which restored ASCT2 surface levels. ASCT2 is found to be 
upregulated in various types of cancer and is a pharmacological cancer target; since its 
inhibition can block cancer cell growth (van Geldermalsen et al. 2016; Wang et al. 2015; 
Jeon et al. 2015). ASCT2 activity is critical in growth of basal-like breast cancer cells in vitro 
(van Geldermalsen et al. 2016). Furthermore, in mice which had undergone xenograph of 
breast cancer HCC1806 cells, shRNA KD of ASCT2 in these cells was associated with 
enhanced survival and reduced tumour growth (van Geldermalsen et al. 2016). GluT1 is also 
relevant in cancer through its effect on glucose uptake regulation (Morani et al. 2014; Oh et 
al. 2017). 




PTEN’s role in trafficking of ASCT2 has not been examined, neither has the role of 
SUMOylation of PTEN in retromer mediated trafficking. Testing this will help to improve 
understanding of whether effects seen previously on GluT1 trafficking are restricted to this 
cargo, or whether PTEN affects retromer trafficking more widely, and if PTEN SUMOylation 
is involved. 






The purpose of this chapter is to assess the role of PTEN in retromer mediated trafficking, by 
testing which cargoes are involved and how PTEN may influence retromer components. I 
also wanted to compare PTEN-WT and PTEN-3KR in these contexts to establish whether 
PTEN SUMOylation and/or ubiquitination is involved. 
Specifically, my aims were 
 
• To establish how PTEN may influence retromer-mediated trafficking 
 
• To examine which retromer cargoes are influenced by PTEN 
 
• To establish whether SUMOylation and/or ubiquitination is are involved in 
retromer-mediated trafficking and regulation by comparing PTEN-WT and 
PTEN-3KR effects in these contexts 





6.3.1 PTEN-WT and PTEN-3KR Show Differential Binding to SNX27 
 
It has recently been shown that PTEN directly interacts with SNX27 and is able to sequester 
it and block retromer formation (Shinde and Maddika, 2017). To determine whether the 
enhanced SUMOylation or ubiquitination could influence this interaction I investigated the 
association of WT and PTEN-3KR with SNX27 (Figure 6.3.1.1). Therefore I probed for 
SNX27 on Western blots from the experiments shown in Figure 5.3.8, where I expressed 
either GFP, GFP-tagged WT-PTEN or 3KR-PTEN alongside Myc-PSD-95 in HEK cells, then 
carried out a GFP trap (see methods for full protocols). Compared to PTEN-WT, PTEN-3KR 
bound significantly less SNX27, suggesting SUMOylation and/or ubiquitination on PTEN 




Figure 6.3.1.1. PTEN-WT interacts with SNX27 significantly more strongly than 
PTEN-3KR. 
Representative blot showing immunoprecipitated endogenous SNX27 in HEK293T cells, 
probed on the same blots as in Figure 5.3.8. Cells were transfected with Myc-tagged PSD- 
95 along with GFP, PTEN-WT or PTEN-3KR and subject to immunoprecipitation and 
Western blot protocols as in Methods 3.4.1. Samples were blotted for SNX27 and GFP. 
SNX27 signal was normalised to GFP, PTEN-3KR was compared to WT set to 100 as a 
control. PTEN-3KR was then compared with WT which was set to a hypothetical value of 
100. A one sampled T-test was then used to establish significance (p=0.0372, N=3). Re- 
probe is of immunoprecipitation. 




6.3.2 Expression of WT or PTEN-3KR does not Alter SNX27-VPS26 Interaction 
 
Previous research shows that PTEN can sequester SNX27, blocking its association with 
VPS26 (Shinde and Madikka, 2017). As PTEN-3KR bound SNX27 less than WT (Figure 
6.3.1.1), I hypothesised that PTEN-3KR may interrupt SNX27/VPS26 association less than 
PTEN-WT. To test this, and whether overexpression would influence SNX27/VPS26 
association in my hands, I immunoprecipitated GFP-SNX27 and blotted for VPS26, 
alongside either TAP, TAP-PTEN-WT or TAP-PTEN-3KR in HEK293T cells (Figure 6.3.2.1). 
Although interpreted with caution due to N=2, no effect was seen of expression of WT or 
PTEN-3KR on the amount of VPS26 immunoprecipitated by SNX27, so overexpression of 
PTEN seems unlikely to affect VPS26-SNX27 interactions in this context. 
 
Representative blot of endogenous VPS26 immunoprecipitated by GFP-SNX27. HEK293T 
cells were transfected with either empty GFP plasmid or GFP-SNX27 plasmid, along with 
empty TAP plasmid, TAP-WT-PTEN or TAP-3KR-PTEN. Two days later, cells were lysed and 
immunoprecipitated with GFP beads. Samples were then subject to Western blot and blotted 





















Figure 6.3.2.1. Expression of PTEN-WT or PTEN-3KR does not alter SNX27-VPS26 
interaction in HEK cells. 




6.3.3 PTEN-WT Expression, but not PTEN-3KR, can Alter Retromer Component 
Levels 
 
After finding differential effects of PTEN-WT and PTEN-3KR in terms of SNX27 binding, I 
investigated whether levels of retromer components would change between KD, WT and 
PTEN-3KR conditions. SNX27 and VPS26 are vital components of the retromer complex; 
their individual or simultaneous knockdown causes a variety of proteins to be lost from the 
cell surface (Steinberg et al. 2013). I was therefore interested in whether PTEN could 
influence these proteins, given that PTEN can bind SNX27 (Shinde and Maddika, 2017). 
Furthermore, there is the potential for PTEN to influence total levels of SNX27, VPS26 and 
VPS35, through TFEB (see 6.1.5.1) (Polito et al. 2014; Curnock et al. 2019). 
I therefore blotted for SNX27, VPS26 and VPS35 in lysates from my PTEN HeLa cell lines 
(Figure 6.3.3.1), which I have previously characterised in terms of PTEN, p-Akt, Akt and p-
Erk expression (Figures 5.3.3-5.3.4). I saw that VPS26 and SNX27 were both significantly 
increased in cells expressing PTEN-WT compared to Scr, PTEN KD or PTEN-3KR. VPS35 
levels did not change significantly between conditions. These results suggest that VPS26 
and SNX27 are either being degraded more slowly, or that their transcription is upregulated 
in the PTEN-WT expressing HeLa cell lines compared to Scr, PTEN KD or PTEN-3KR 
expressing cells. This supports my hypothesis, that phosphatase active PTEN-WT can drive 
retromer component upregulation, possibly via TFEB (Polito et al. 2014; Curnock et al. 
2019). 







Figure 6.3.3.1. PTEN-WT overexpression, but not PTEN-3KR overexpression, significantly 
increases SNX27 and VPS26 levels in HeLa cells. 
Samples from HeLa cell lines shown in Figure 4.3.2 were subject to Western blot protocols 
and blotted for SNX27, VPS26 and VPS35 then stripped and blotted for GAPDH. A, C and E) 
show representative Western blots of SNX27, VPS26 and VPS35. B, D and F) show a 
quantification of each protein. SNX27 levels were normalised to GAPDH. KD, WT and PTEN- 
3KR were then normalised to Scr as a control. All experiments were individually normalised 
to mean of each experiment, then a one-way ANOVA with Tukey correction was used to 
analyse significance (SNX27 N=4, VSP26 N=3, VPS35 N=3; *=p ≤ 0.05, **=p ≤ 0.01). 




6.3.4 SNX27 Levels are not Altered in PTEN KD, WT or PTEN-3KR Expressing 
Neurons 
 
Due to evidence showing that the retromer complex is involved in AMPAR trafficking 
(Temkin et al. 2017), evidence showing that PTEN may disrupt retromer formation (Shinde 
and Maddika, 2017), and my data showing PTEN can affect SNX27 levels in HeLa cells 
(Figure 6.3.3.1), SNX27 levels were blotted in the total samples in Figure 5.3.9.1, where I 
expressed PTEN-KD, PTEN-WT and PTEN-3KR Lentivirus in neurons. There was no 
significant difference in SNX27 level between any of the conditions, suggesting any effects 




Figure 6.3.4.1. Lentiviral PTEN KD and overexpression of WT or PTEN-3KR do not 
significantly alter total SNX27 levels in neurons. 
A) Representative blot showing SNX27 levels in surface biotinylation total samples shown in 
Figure 5.3.9.1. Neurons were left for 6/7 days after being infected with Scr, PTEN KD , 
PTEN-WT or PTEN-3KR Lentivirus on DIV 14/15. B) Graph showing quantification of 
SNX27. SNX27 was normalised to GAPDH. Samples were normalised to Scr and all 
experiments were individually normalised to the mean of each experiment. One-way 
ANOVA analysis was then carried out with Tukey correction. There were no significant 
differences between any conditions (N=3). 




6.3.5 PTEN-3KR Can Influence GluT1 Trafficking 
 
PTEN can regulate GluT1 surface expression through binding with SNX27 (Shinde and 
Madikka, 2017). My results indicate that PTEN-3KR binds to SNX27 less than PTEN-WT 
(Figure 6.3.1.1.). Therefore, I next tested if PTEN-3KR expression would alter GluT1 surface 
levels compared to WT. I therefore surface biotinylated the Scr/PTEN-KD/PTEN-WT/PTEN- 
3KR HeLa cell lines (previously characterised for PTEN levels in Figure 6.3.5.1.), followed by 
Western blotting for GluT1 (Figure 6.3.5.1.A/B). 
GluT1 surface expression was significantly lower in PTEN-3KR expressing cells, compared 
with Scr. PTEN-3KR expression therefore seems to have a gain of function effect of 
reducing surface GluT1. PTEN KD, or PTEN-WT overexpression had no significant effect 
compared to Scr on surface GluT1 levels, in contrast to previous reports (Shinde and 
Maddika, 2017). It is noted that the PTEN-3KR and WT cells vastly overexpressed PTEN 
compared to the level of endogenous PTEN seen in Scr (Figure 6.3.5.1.). Total GluT1 levels 
were not significantly altered between any of the conditions. 
The results of the surface biotinylation are supported by preliminary evidence from confocal 
imaging carried out by Dr Ash Evans (Figure 6.3.5.1.C). Transfection of HeLa cells with 
GFP-tagged PTEN-WT and PTEN-3KR constructs, and subsequent staining for GLUT1, 
LAMP1 and PTEN, followed by confocal imaging shows GluT1 appears to be modestly 
reduced from cell surface in PTEN-3KR cells compared to WT. Furthermore, in PTEN-3KR 
cells, there appears to be more co-localisation between GluT1 and LAMP1, a lysosomal 
marker, suggesting GluT1 may not be being efficiently rescued from lysosomal sorting in this 
condition (although it is noted that total GluT1 levels do not differ significantly in the surface 









Figure 6.3.5.2. Surface GluT1 is Significantly Reduced in PTEN-3KR Expressing HeLa 
Cell Lines. 
A) Representative blot of surface biotinylation of HeLa stable cell lines. HeLa cells expressing 
Scr, PTEN KD, PTEN-WT and PTEN-3KR were plated into wells of a 6-well dish, the next day 
cells were subject to surface biotinylation and blotted for GluT1. B) Quantification of A. 
Graphs show surface GluT1, Total GluT1 (normalised to GAPDH) and surface/total GluT1. 
Signals within individual experiments were normalised to the mean of that experiment, and 
One-way ANOVA with Tukey correction was used for statistical analysis (N=5, *=p ≤ 0.05, 
**=p ≤ 0.01). C) Confocal imaging by Dr Ash Evans of HeLa cells transfected with GFP PTEN- 










6.3.6 PTEN is not involved in ASCT2 or TfR Trafficking 
 
To determine whether the PTEN-3KR effect of reducing surface GluT1 is specific for GluT1 
or affects other retromer cargoes, I repeated this experiment and blotted for another 
retromer cargo: Alanine, Serine, Cysteine Transporter 2 (ASCT2) (Yang et al. 2018) (Figure 
6.3.6.1). I also added an extra condition: PTEN-C124S mutant (cloned by Dr K Wilkinson), 
which is catalytically inactive against PIP₃ (Maehama and Dixon, 1998). I surface 
biotinylated another batch of the HeLa cell lines with the addition of cells expressing PTEN-
C124S. Samples were also blotted for Transferrin Receptor 1 (TRF1), which has not been 
reported as a retromer cargo. I reasoned that this would help determine whether the effect of 
PTEN-3KR is limited to retromer cargoes, or a more general effect on surface protein 
trafficking. 
There was no significant difference between surface levels of ASCT2 or TfR1 between 
conditions, although there was a modest but significant decrease in total ASCT2 levels 
between Scr and the PTEN-C124S mutant. Therefore, my data indicate that the effect of 
PTEN-3KR in reducing GluT1 surface levels is not a general effect on retromer cargoes, or 
on surface proteins in general, but may instead be specific to GluT1, or affect a restricted 
subset of retromer cargoes. 







Figure 6.3.6.1. Surface ASCT2 and Transferrin Receptor levels are not significantly 
altered in PTEN KD, WT and mutant cell lines. 
A) Blot showing level of PTEN expression in Scr, PTEN KD, PTEN-WT, PTEN-3KR and 
PTEN-C124S (CM) HeLa cell lines. B) Representative blot of surface biotinylation of HeLa 
cell lines. Cells were plated into wells of a 6-well dish, the next day, cells underwent surface 
biotinylation (see Methods 3.4.8) followed by Western blotting for ASCT2, Transferin receptor, 
and GAPDH. C/D) Quantification of surface and total signal of blot on the Left. Surface was 
normalised to total, and total was normalised to GAPDH. One-way ANOVA with Tukey 
correction was used to determine statistical significance (*=p ≤ 0.05, N=3). Signals within 
individual experiments were normalised to the mean signal from that experiment. 






In this chapter, I have shown that PTEN-3KR acts differently to PTEN-WT in: 
 
• binding with SNX27 in HEK293T cells 
 
• affecting expression of retromer components VPS26 and SNX27 in HeLa cells 
 
• regulating GluT1 surface expression in HeLa cells 
 
I have also shown that PTEN-WT or PTEN-3KR expression does not affect surface 
expression of another retromer cargo, ASCT2. 
 
 
6.4.1 PTEN-SNX27 and VPS26-SNX27 Binding 
 
PTEN-3KR bound significantly less than PTEN-WT to SNX27 (Figure 6.3.1.); it is not clear 
why this is, as PTEN is thought to bind SNX27 via its C-terminal PDZ binding motif (Shinde 
and Maddika, 2017), and mutations in PTEN-3KR are not near the PDZ ligand. As previous 
work has shown PTEN-SUMO site mutants localise differently (Huang et al. 2012), a 
possibility is that PTEN-3KR could localise differently and co-localise less with SNX27 than 
WT. Due to evidence that PTEN can sequester SNX27 and interrupt the SNX27-VPS26 
association (Shinde and Maddika, 2017), I wanted to test whether overexpression of PTEN 
could do this in my samples. I hypothesised that PTEN-WT overexpression may limit 
SNX27-VPS26 interaction, but PTEN-3KR may not, as it bound SNX27 less. However, no 
obvious effect was seen after overexpression WT or PTEN-3KR on the amount of VPS26 
immunoprecipitated by SNX27. It is noted the experiment was only carried out twice, 
although no obvious change was seen. It could be that lack of affect is an artefact of 
overexpression, in that increasing expression of both constructs increases binding to 
SNX27, and overshadows any difference in effect that could be seen at endogenous levels. 
Future experiments could include repeating the experiment at lower levels of PTEN 
expression. 
 
6.4.2 PTEN and Regulation of Retromer Components in HeLa Cells and Neurons 
 
The finding that PTEN-WT overexpression increases VPS26 and SNX27 levels is novel 
(Figure 6.3.3). PTEN can reportedly sequester SNX27 away from VPS26 (Shinde and 
Maddika 2017) and PTEN-3KR binds less to SNX27 less than PTEN-WT (Figure 6.3.1), so a 
possibility is that cells increase total levels of retromer components to compensate for 
SNX27 sequestration when PTEN-WT is expressed. 




Due to recent evidence that TFEB can enhance expression of these proteins (Curnock et al. 
2019), and that PTEN may indirectly upregulate TFEB through suppression of P-Akt (Polito 
et al. 2014), it could be that PTEN overexpression is causing this increase in retromer 
component levels through TFEB. Unlike PTEN-WT, PTEN-3KR does not increase SNX27 
and VPS26 levels, and PTEN-3KR also lacks ability to supress P-Akt (Figure 6.3.3.1). This 
supports the notion that PTEN’s phosphatase activity against P-Akt could upregulate 
retromer levels though TFEB activation (Figure 6.4.1.1). It is noted that components don’t go 
down under PTEN-3KR conditions; this could be because the regulation of retromer 
components by PTEN is “off” under normal conditions, and only switched on when PTEN 
has higher expression or activation. 
It is of interest that PTEN levels are reduced and P-Akt is increased in AD brains (Griffin et 
al. 2005). PTEN-driven upregulation of TFEB activity enhances clearance of AD related 
protein aggregates such as P-Tau, and subsequently upregulates PTEN (Polito et al. 2014). 
Taking these together, it could be that in AD, loss of PTEN blocks enhancement of TFEB 
activity through the PTEN-P-Akt-TFEB feedback loop, reducing the ability of cells to clear 
aggregate proteins (Polito et al. 2014). The retromer complex could also be involved, as it is 
suggested to enable protein clearance and be dysregulated in neurodegeneration (Mecozzi 
et al. 2014; Ansell-Schultz et al. 2018). 
SNX27 levels were unchanged in Scr/ PTEN-KD/ PTEN-WT/ PTEN-3KR expressing 
neurons (Figure 6.3.4). This suggests SNX27 total levels are not involved in the changes to 
AMPAR trafficking observed upon perturbing PTEN levels (Figures 5.3.7.1. and 5.3.10.1). 
However, more experiments are needed to establish if PTEN-SNX27 binding occurs in 
neurons, and whether this is relevant to neuronal processes, or if other retromer components 
such as VPS26 are being influenced by PTEN in neurons. 







Figure 6.4.2.1. Schematic showing Regulation of Retromer Components SNX27 and 
VPS26 by PTEN. 
This schematic shows that through dephosphorylation of PIP₃, PTEN-WT supresses P-Akt, 
which activates TFEB and upregulates VPS26 and SNX27. PTEN-3KR is unable to supress 
P-Akt, so TFEB activity is supressed and SNX27 and VPS26 are not increased. This model 
is based on work by Curnock et al. (2019) who demonstrated TFEB can upregulate 
retromer components, and Polito et al. (2014) who suggest PTEN can upregulate TFEB 
through suppression of P-Akt, which in turn upregulates PTEN. PTEN’s effect of negatively 
regulating P-Akt through dephosphorylation of PIP₃ is well characterised (Maehama and 
Dixon 1998; Stambolic et al. 1998; Myers et al. 1998; Myers et al. 1997). Created in 
Biorender.com with premade shapes. 
 
6.4.3 PTEN Effects on GluT1 and ASCT2 Trafficking 
 
From results published by Shinde and Maddika (2017), I expected that surface GluT1 would 
be increased under PTEN KD and decreased under WT overexpression, given that PTEN 
sequesters SNX27 and limits GluT1 recycling. Correspondingly, given that PTEN-3KR binds 
less to SNX27 than PTEN-WT, I also expected surface GluT1 to be increased in PTEN-3KR 
expressing cells compared to PTEN-WT cells. However, no effect on surface GluT1 was 
seen in KD or PTEN-WT conditions compared to Scr, and surprisingly, PTEN-3KR reduced 
surface GluT1. PTEN-3KR therefore appears to have a gain of function effect of reducing 
GluT1 surface expression. This is not due to downregulation of SNX27 or VPS26 levels, 
however, when PTEN-WT is overexpressed, VPS26 and SNX27 are increased, which could 
compensate for the increase in PTEN-WT sequestration of SNX27. As retromer components 




are not increased by PTEN-3KR, it’s possible that reduced surface GluT1 is due to lack of 
this compensation. 
These experiments suggest PTEN-3KR differs from PTEN-WT in regulation of GluT1 surface 
expression, regulation of retromer components and regulation of PTEN-SNX27 binding, 
possibly through enhanced levels of SUMOylation and/or ubiquitination. An important 
potential confounding issue is that PTEN-3KR lacks phosphatase activity against P-Akt 
(Figure 6.3.3). Therefore, it is difficult to ascertain whether its differences in activity 
compared to WT are due to enhanced SUMOylation and/or ubiquitination, or a lack of 
phosphatase activity. Regarding ASCT2, PTEN did not have an influence on surface levels 
(Figure 6.3.5.). This suggests that PTEN does not have the same effects across all retromer 
cargoes. It may be that in the case of GluT1, PTEN-SNX27 binding can disrupt forward 
trafficking through disruption of retromer formation (Shinde and Maddika et al. 2017), but this 




In short, this chapter suggests that PTEN-3KR differs to PTEN-WT in its ability to regulate 
GluT1 trafficking, retromer component levels and in its binding to SNX27. It is possible that 
these effects are due to enhanced SUMOylation and/or ubiquitination of PTEN-3KR seen in 
Chapter 4, however, more research is needed to establish whether it is in fact SUMOylation 
or ubiquitination that is having this effect, or whether it is due to another mechanism acting 
on the PTEN-3KR. SUMOylation aside, these experiments suggest that PTEN regulates 
retromer function via increases in VPS26 and SNX27 (Figure 6.3.3), possibly through an 
indirect effect of PTEN in enhancing TFEB activity (Polito et al. 2014), as TFEB has been 
show to regulate VPS26 and SNX27 levels (Curnock et al. 2019). 
 
6.6 Future Directions 
 
• Compare VPS35 and VPS26 levels in PTEN HeLa cell lines after treatment with WT 
versus catalytically dead SENP, to establish if PTEN-3KR effects on these proteins 
are due to enhanced SUMOylation of PTEN. This could also be carried out with a 
DUB to investigate the effect of PTEN ubiquitination in this setting. 
• Surface biotinylate PTEN HeLa cell lines after PI3K inhibitor treatment and examine 
surface GluT1. This will help to establish whether PTEN-3KR has its effects on 
surface GluT1 through deficits in Akt pathway regulation. 




• Mass spectrometry of surface fraction of PTEN cell lines to establish if other surface 
proteins are affected by PTEN modulation. Further modulation of retromer 
components can then be used to establish if retromer is involved in this. 
• Blotting TFEB and dephosphorylated (activated) TFEB to confirm if TFEB is activated 
by PTEN overexpression in the HeLa cell lines. RT-PCR could be used to establish if 
SNX27 and VPS26 are transcriptionally upregulated. Also, repeat blotting for SNX27 
and VPS26 in cell lines with TFEB KD/inactivation to confirm a TFEB-Dependent role 


















7 General Discussion 
7.1 Context and Summary of Findings 
7.1.1 PTEN, SUMO and Receptor Trafficking 
 
The goal of this thesis was to further characterise the role of SUMOylation in PTEN 
regulation. I also aimed to understand the role of PTEN and PTEN-SUMOylation in cell- 
surface protein trafficking, a process fundamental to synaptic plasticity and relevant in AD 
(Chang et al. 2006; Shi et al. 2001; Passafaro et al. 2001). The finding that mutation of 
K254/K266/K289 to arginine (PTEN-3KR) increases SUMOylation and ubiquitination was 
novel, and contrasts with reports showing that single/ individual mutation of these sites 
reduces SUMOylation (Gonzales-Santamaria et al. 2012; Bawa-Khalfe et al. 2016). An 
important difference is that all of these studies examined tagged, recombinant SUMO2 or 
SUMO 2/3 except Bawa-Khalfe et al. (2016), while my work has tested endogenous 
SUMO2/3. Testing SUMOylation of target proteins with endogenous SUMO is valuable due 
to the possibility of confounding issues of increased SUMOylation when tagged recombinant 
SUMO is used (Eifler and Vertegaal, 2015). 
I next examined how PTEN can influence AMPARs in neurons, again with the overall aim of 
exploring the relevance of PTEN to synaptic transmission dysregulation in Alzheimer’s 
disease (Chang et al. 2006). My results suggest that PTEN positively regulates surface 
GluA2. My work so far did not reveal a clear mechanism behind this but it may be through 
PTEN’s phosphatase action against CaMK2, or through its effects on PIP₃ sensing proteins 
such as SNX27 or PHLDB2, which will be outlined in this chapter (Xie et al. 2019; Arendt et 
al. 2010; Cai et al. 2001; Song and Huganir 2002; Qin et al. 2005). Interestingly, PTEN-3KR 
was also defective in Akt pathway regulation, supporting evidence that SUMOylation or 
ubiquitination may also play a role in controlling PTEN phosphatase activity (Huang et al. 
2012). 
 
I then tested how PTEN can influence retromer mediated trafficking, a process known to be 
disrupted in AD, which can also regulate GluA2 trafficking (Tian et al. 2015; Bhalla et al. 
2012; Vagnozzi and Praticò, 2019; Ansell-Schultz et al. 2018). I created HeLa cell lines with 
modulations of PTEN to examine PTEN-mediated regulation of retromer cargo trafficking, 
and how PTEN effects retromer proteins. I discovered that PTEN-WT overexpression can 
upregulate SNX27 and VPS26 protein levels and PTEN-3KR expression can downregulate 
surface GluT1. This builds on reports that PTEN can influence retromer-mediated trafficking 
(Shinde and Maddika, 2017). The differential role of PTEN-3KR from PTEN-WT in both of 






clarify this. I will now outline how I have fulfilled the aims outlined at the start of this thesis, 
then discuss my main findings. 
1) To create and test tools to study PTEN SUMOylation/ ubiquitination 
 
While I aimed to make a “non-SUMOylatable” PTEN mutant, PTEN-3KR has been a useful 
tool to examine enhanced SUMOylation (and ubiquitination). Creation of GFP-WT and GFP- 
PTEN-3KR has enabled me to detect endogenous SUMOylation and ubiquitination, which 
avoids potential confounding effects of overexpression. 
2) To characterise these tools and examine how to changes to PTEN SUMOylation regulate 
its function 
I have characterised aspects of PTEN-3KR function and properties including its ability to 
regulate phospho-Akt levels, dimerization and degradation. Notably, PTEN-3KR is defective 
in phospho-Akt regulation. 
3) To test cross-regulation of SUMO and Ubiquitin on PTEN 
 
My interpretation of my data leads me to tentatively suggest that SUMO can outcompete 
ubiquitin for modification on PTEN; overexpression of SUMO2 reduced ubiquitination of 
PTEN (although this result was just under the threshold for statistical significance 
(P=0.0541)). Although it is noted that this may be an artefact of overexpression, however, my 
results are in line with Wang et al. (2014) who report SUMOylation of PTEN can limit 
ubiquitination. My preliminary result using in vitro treatment with the de-SUMOylating enzyme 
SENP1 suggests that removal of SUMO with SENP1 treatment does not influence PTEN 
ubiquitination, suggesting ubiquitin is not forming chains on SUMO on PTEN. 
4) To test the role of PTEN and PTEN SUMOylation/ ubiquitination in AMPAR trafficking 
 
By examining both PTEN KD and overexpression, I have revealed a bidirectional effect of 
PTEN in regulating surface GluA2 levels. While the effect of PTEN KD in reducing surface 
GluA2 was not robust, possibly due to variability between batches of neurons, taken together 
they are suggestive of a role for PTEN in AMPAR trafficking. However, by comparing PTEN- 
WT and PTEN-3KR on GluA2 surface expression in surface biotinylation experiments, I 
observed no significant difference, suggesting that the increased SUMOylation status of 
PTEN does not play a role in this process. 
5) To examine how PTEN affects retromer in terms of its trafficking ability and regulation of 






My experiments revealed that WT, but not PTEN-3KR overexpression can upregulate SNX27 
and VPS26 levels in HeLa cells. PTEN-3KR bound SNX27 significantly less than WT, and 
also reduced surface expression of the glucose transporter GluT1, which was surprising 
given that PTEN can sequester SNX27 and interrupt GluT1 forward trafficking (Shinde and 
Maddika, 2017). In contrast, PTEN KD or WT overexpression had no significant effect on 
surface GluT1, in contrast to previous work (Shinde and Maddika, 2017). This points to a 
possible role of PTEN SUMOylation in regulating GluT1 expression, but more experiments 
are needed to clarify whether it is SUMOylation or another quality of PTEN-3KR that is 
responsible for this effect. These experiments also suggest that the role of PTEN in GluT1 




7.2 Discussion of the Main Findings 
7.2.1 PTEN-3KR is More SUMOylated than WT 
 
I used PTEN-3KR to examine SUMOylation, which according to the literature would be non- 
SUMOylatable due to mutation of three lysines which are reported SUMO sites (Huang et al. 
2012; Gonzalez-Santamaria et al. 2012; Bassi et al. 2013). Unexpectedly, in my 
experiments, PTEN-3KR is significantly more SUMOylated by endogenous SUMO2/3 than 
WT, and preliminary results suggest it may also be more SUMOylated by SUMO1. However, 
conversely, when I tested tagged, recombinant SUMO2, PTEN-WT was significantly more 
SUMOylated than PTEN-3KR, which is congruent with the literature showing single or double 
mutations of the three SUMO sites reduce PTEN SUMOylation by overexpressed SUMO. My 
experiments therefore suggest that tagged, recombinant SUMO may behave differently to 
endogenous SUMO. Eifler and Vertegaal (2015) point out that expression of exogenous 
SUMO can lead to increased SUMOylation of target proteins, and artefacts can occur 
through overexpression. According to this, the reduced SUMOylation of PTEN-3KR (and 
possibly other PTEN mutants in the literature) seen with tagged, recombinant SUMO are 
possibly an artefact, and assessing SUMOylation by endogenous SUMO as in Figure 4.3.4 
may be more reliable. 
Overexpression of SUMO can lead to artefacts in target protein SUMOylation if not controlled 
(Eifler and Vertegaal 2015). It is possible that WT is more SUMOylated in recombinant 
SUMO conditions, where SUMO is potentially being ‘pushed’ onto non-physiologically 
relevant sites, simply because it has more available lysines to modify. Therefore, 






are mutated and unavailable for SUMO to attach to on PTEN-3KR. Eifler and Vertegaal 
(2015) suggest that target protein identification should also be confirmed by examining 
endogenous SUMO after exogenous SUMO is used; my experiments in this thesis and 
Bawa-Khalfe et al. (2016) are the only current examples of this strategy for PTEN. This is 
important considering many of the conclusions drawn about the role of PTEN SUMOylation 
are based on the premise that the previously used lysine mutants are less SUMOylated, 
such as work on phosphatase activity (Huang et al. 2012). 
 
7.2.2 Possible mechanistic explanations for how PTEN-3KR is more SUMOylated 
than WT 
 
As outlined above, there is currently no clear explanation for how PTEN-3KR would have 
enhanced endogenous SUMOylation compared to WT. Possible reasons and approaches to 
resolve this issue include: 
• A change of structure or conformation of PTEN-3KR leading to more exposed 
SUMOylatable lysines. This could be tested by the immunoprecipitation experiment 
suggested in 4.6., whereby tagged mutants of the PTEN C-tail and the rest of WT or 
PTEN-3KR can be immunoprecipitated (Odriozola et al. 2007; Rahdar et al. 2009). If 
PTEN-3KR was able to immunoprecipitate more C-tail fragment than WT, this would 
imply it exists more in the “closed” conformation, due to enhanced ability to form 
intramolecular interactions between the C-tail and PTEN-3KR. PTEN-3KR and PTEN- 
WT appear to dimerise with PTEN-WT to the same extent, suggesting there is not 
likely to be major changes to structure/conformation. 
 
• Removal of lysines in PTEN-3KR that are modified by SUMO or other PTM’s, 
which may be blocking SUMOylation at other sites; Huang et al. (2012) suggest 
concomitant SUMOylation at K254 and K266 is impossible due to the large size 
of SUMO. Therefore, removal of these lysines and their modifications may allow 
more space for modifications at other potential SUMO sites which could increase total 
PTEN SUMOylation. Testing the level of endogenous SUMOylation of individual 
mutants, using the same experimental procedure used here, would help to narrow 
down whether one, or a combination of mutations in PTEN-3KR are causing the 
increase. 
 
• Removal of lysines mutated in PTEN-3KR may increase the interaction of SUMO 






SUMO closer to other potential SUMO sites which it could modify, increasing 
SUMOylation (Wang and Dasso 2009). Bawa-Khalfe et al. (2016) have identified two 
potential SIM sites in PTEN: amino acids 98-101 and 317-320. Removal of lysines in 
PTEN-3KR may potentially enhance the availability of these SIM sites, increasing 
SUMOylation. A co-immunoprecipitation under native conditions would help to detect 
non-covalent binding of SUMO to SIM sites on PTEN. This could be carried out with 
non-conjugatable SUMO, which lacks the C-terminal diglycine motif necessary for 
SUMOylation, so could only interact with PTEN non-covalently (Kantamneni et al. 
2011; Saether et al. 2011). Additionally, known SIM sites could be mutated to see if 
this affects SUMOylation of PTEN-3KR. 
 
 
7.2.3 PTEN, SUMO and Membrane Localisation 
 
Membrane localisation of PTEN is critical for its role in P-Akt regulation (Vazquez et al. 
2000). Huang et al. (2012) suggest that membrane localisation is the link between 
SUMOylation and PTEN phosphatase activity, and postulate that SUMOylation at K266 on 
PTEN facilitates electrostatic interactions between PTEN, SUMO and the membrane, driving 
phosphatase activity. Furthermore, Gonzales Santamaria et al. (2012) suggest SUMO 
modification of PTEN forces it into the “open” conformation by blocking interactions between 
the C-tail and C2 domain, facilitating membrane localisation and phosphatase activity. 
Consequently, the general consensus in the literature is that SUMOylation facilitates 
phosphatase activity of PTEN. 
In contrast, my results demonstrate that PTEN-3KR, exhibits significantly less ability to 
supress P-Akt than PTEN-WT, yet is more SUMOylated (Figures 5.3.3. and 4.3.4), these 
data are incongruent with the notion that SUMOylation increases PTEN “open” conformation 
and consequent membrane binding proposed by Gonzales-Santamaria (2012). This 
suggests that SUMO may not facilitate phosphatase activity through membrane binding, and 
is more in line with Shenoy et al. (2012), who argue SUMOylation of PTEN would be more 
likely to reduce membrane localisation. 
I note that it is not clear where on PTEN-3KR SUMOylation is occurring, and Gonzales- 
Santamaria et al. (2012) do not suggest which sites of SUMOylation keep PTEN “open”. It 
may be that SUMOylation of specific sites such as K266 facilitates the open conformation 
and membrane binding (Huang et al. 2012), but sites modified on PTEN-3KR have an 
inhibitory effect on membrane binding. Alternatively, it may be that additional SUMO on 






reduces phosphatase activity via another route, such as by obscuring the PIP₃ binding site. 
Another possibility is that since SUMOylation must be tightly regulated as it can have a 
strong influence on the function of target proteins (Schorova and Martin 2016), extremes of 
both hypo- and hyper- SUMOylation of PTEN may cause its dysregulation and lead to 
enhanced Akt phosphorylation. 
Shenoy et al. (2012) dispute the model proposed by Huang et al. They suggest that SUMO 
has the potential to be disruptive to membrane association according to molecular dynamics 
(MD) simulations, which can be used to simulate behaviour of proteins over time 
(Hollingsworth and Dror 2018). Considering that I have found mutations used by Huang et 
al. (2012) may actually increase endogenous PTEN SUMOylation, Shenoy’s conclusion 
seems more consistent with my findings. There are several, non-mutually exclusive 
possibilities which could explain the discrepancy between my results and those of Huang 
(2012) and Gonzales-Santamaria et al. (2012): 
1) Huang’s K266R mutant, like PTEN-3KR, is in fact more SUMOylated than PTEN-WT 
in the absence of overexpressed SUMO, and this actually inhibits PTEN phosphatase 
activity. 
2) PTEN’s SUMOylation level needs to be tightly controlled (Schorova and Martin, 
2016): both inhibition or enhancement of SUMOylation blocks P-Akt regulation. 
3) Discrepancies are a result of differences in methodology or cell type 
4) Additional SUMO on PTEN-3KR may not be directly involved in the reduction of 
PTEN phosphatase activity; other aspects of PTEN-3KR such as a change in 
conformation may be responsible. 
5) Effects of SUMOylation may be site specific; SUMOylation at K266 may aid 
membrane localisation, while SUMOylation at other sites may hinder it. 
 
In support of possibility 1), Shenoy et al. (2012) have suggested that Huang’s model 
whereby SUMO facilitates membrane binding electrostatically is unlikely, based on a few 
observations. Firstly, they point out that according to the model, K266 would be likely to be 
frequently mutated in cancer, but this has not been shown (Liu et al. 2019; Shenoy et al. 
2012). Huang et al. (2012) suggest that SUMO1 essentially sits at the side of PTEN and 
touches the membrane, and lysines K237, K263 and K31 in PTEN also touch the membrane. 
Shenoy et al. (2012) also state that in order for SUMO-PTEN to associate with the 
membrane and for SUMO1 to facilitate this by touching the membrane, PTEN would have to 
be in a different orientation to the one suggested by Lee et al. (1999), who made predictions 






to further test the original model, a technique which involves measuring reflected scattered 
neutrons that have been directed at a surface, which can be used to measure membrane 
structure (Shenoy et al. 2012; STFC (ISIS Neutron and Muon Source)). Their results are 
congruent with the orientation suggested by the original crystal structure experiments by 
Lee et al. (1999), and support a model whereby PTEN does not bind the membrane in the 
orientation suggested by Huang et al. (2012). Overall, my results support Shenoy’s 
conclusions, as they suggest SUMOylation of PTEN is more likely to have an inhibitory 
effect on membrane localisation, which would reduce phosphatase activity (Rahdar et al. 
2009; Vazquez et al. 
2006). This is line with PTEN-3KR, which has enhanced SUMOylation, and also displays 
reduced activity against P-Akt. Alternatively, it may be that K266 SUMOylation positively 
regulates membrane association and activity, but enhanced SUMOylation at other sites has 
the opposite effect. 
In summary, it seems possible that SUMO could hinder membrane association and activity 
against P-Akt, and differences seen in the SUMOylation level of mutants between this and 
previous work are most likely due to discrepancies between endogenous and tagged, 
recombinant SUMO. However, it cannot be ruled out that effects of SUMOylation on 
membrane localisation and activity are site specific. It may be that SUMO at K266 drives 
membrane association and Akt regulation (Huang et al. 2012), but additional SUMO at other 
sites has the opposite effect. 
 
7.2.4 PTEN-3KR Ubiquitination 
 
As well as increased levels of SUMOylation, PTEN-3KR was also more ubiquitinated. It is 
possible that effects seen when comparing PTEN-3KR to PTEN-WT could also be due to this 
additional ubiquitin, rather than SUMO (or both). SUMO-ubiquitin hybrid chains can act as a 
signal at DNA damage sites to promote DNA repair (Guzzo et al. 2012). However, while 
interpreted with caution due to lack of repeats, in vitro treatment with SENP1 enzyme 
removed SUMO2/3 from PTEN immunoprecipitated from HEK293T cells, but did not alter 
ubiquitination of PTEN, suggesting ubiquitin is not attaching to PTEN via SUMO. 
Ubiquitination can often act as a signal for degradation, as well as induction of signalling 
cascades (Kawadler and Yang, 2006; Tatham et al. 2008). PTEN K289 polyubiquitination is 
associated with proteasome-mediated degradation (Wang et al. 2003), however I found that 
PTEN-WT and PTEN-3KR were degraded to a similar extent after 24-hour cycloheximide 
treatment (Figure 5.3.1.1.). This suggests that the additional ubiquitin on PTEN-3KR is likely 











chain- specific ubiquitin antibodies would help to validate this, and establish which other 
ubiquitin chain linkage is preferentially modifying PTEN-3KR. For example, it could be that 
the additional ubiquitin is Lys63 linked, which can induce signal cascade activation (Kawadler 
and Yang, 2006). 
 
7.2.5 PTEN and Retromer Component Upregulation 
 
While few studies have examined the role of PTEN on retromer, there is evidence that PTEN 
can inhibit retromer formation through sequestration of SNX27 (Shinde and Maddika, 2017). I 
wanted to further examine this, due to evidence that retromer is critically involved in 
plasticity, and may be dysregulated in AD (Temkin et al. 2017; Tian et al. 2015; Munsie et al. 
2014; Li et al. 2019; Choy et al. 2014; Wang et al. 2012). Furthermore, as GluA2 is a 
retromer cargo (Tian et al. 2015), I wondered if PTEN was positively influencing surface 
GluA2 via retromer. I therefore created HeLa cell lines with PTEN modulations as a model 
system to examine the effects of PTEN on retromer proteins and trafficking of model 
cargoes. 
PTEN-WT overexpression increased protein levels of the retromer components VPS26 and 
SNX27, an effect which has not previously been reported. A potential explanation for this 
comes from recent work on transcription factor TFEB, a transcription factor which 
upregulates transcription of many genes in the lysosomal pathway (Sardiello et al. 2009), 
and can upregulate expression of the retromer components SNX27, VPS26 and VPS35 
(Curnock et al. 2019). PTEN is a target of TFEB, and can also indirectly cause its activation 
through the proposed feedback loop whereby PTEN can block inhibitory TFEB 
phosphorylation by Akt (Palmieri et al. 2017; Palmieri, Pal, and Sardiello 2017; Polito et al. 
2014; Settembre et al. 2012). To more vigorously validate the role of TFEB in the PTEN- 
mediated upregulation of VPS26 and SNX27, expression of these proteins should be 
measured after TFEB removal by shRNA knockdown in control and PTEN overexpression 
conditions. RT-PCR could also be used to examine if SNX27 and VPS26 are being regulated 
at the transcriptional level under these conditions. 
Unlike PTEN-WT, PTEN-3KR did not upregulate SNX27 and VPS26 levels (Figure 6.3.3.1. 
and Schematic 6.4.1.). As PTEN-3KR has reduced activity against P-Akt, this suggests the 
ability of PTEN to upregulate SNX27 and VPS26 may be dependent on its phosphatase 
activity. This further suggests the involvement of TFEB, as PTEN-3KR is less able to supress 
P-Akt, which is reported to have an inhibitory effect on TFEB (Polito et al. 2014; Palmieri et 
al. 2017). It also suggests a possible role for SUMOylation in PTEN’s influence over these 






modulate SUMOylation, for example SENP overexpression conditions, to confirm the 
involvement of SUMO. 
TFEB is relevant in AD pathology as its expression can also increase the uptake and 
lysosomal degradation of Aβ42 in primary astrocytes in APP/PS1 mice (Xiao et al. 2014; 
Martini-Stoica et al. 2016). Furthermore, TFEB activation via PTEN can clear Tau in AD 
mouse model rTg4510 brains; lipid phosphatase activity of PTEN is critical in Tau clearance 
(Polito et al. 2014). TFEB activation can also reduce neurodegeneration in the form of 
aberrant hippocampal volume and neuroinflammation, and can increase neuronal survival 
(Polito et al. 2014). TFEB upregulation can increase 1A/1B-light chain 3 (LC3-2)-positive 
autophagosome clearance, which is a proposed mechanism of p-Tau clearance (Poltito et al. 
2014). Retromer is also implicated in protein aggregate clearance via autophagy (Cui et al. 
2019; Carosi et al. 2020). 
 
Therefore, it is plausible that PTEN, through TFEB-mediated control of retromer, could alter 
the autophagy-lysosomal pathway (Polito et al. 2014; Cui et al. 2019). More work in 
therefore needed to clarify whether the role of PTEN in TFEB-mediated regulation of 
autophagic proteins shown in these studies could involve retromer. A starting point for this 
could be examining whether the ability of PTEN-WT overexpression to upregulate VPS26 in 
HeLa cells is also observed in neurons, and whether PTEN-mediated aggregate clearance 
via TFEB also involves VPS26 (Polito et al. 2014). 
 
7.2.6 PTEN and SNX27 Binding 
 
Another potential explanation for the increase in SNX27 when PTEN is overexpressed is that 
PTEN can sequester SNX27 (Shinde and Maddika, 2017). Thus, SNX27 could be 
upregulated to compensate for this. As PTEN-3KR binds SNX27 significantly less than 
PTEN-WT, this could explain why SNX27 is not upregulated by PTEN-3KR expression. 
While PTEN overexpression did not increase SNX27 in neurons, it should be examined 
whether PTEN attenuation is able to change the localisation of PIP₃-sensing SNX27 through 
modulation of PIP₃ levels (Cullen 2008; Ghai et al. 2015; Cai et al. 2011). This may have an 
effect on APP trafficking and Aβ generation as SNX27 interacts with γ-secretase complex 
subunit Presenilin 1 (PS1), disrupting stability of the γ-secretase complex and limiting Aβ 
generation (Wang et al. 2014). 
Furthermore, as the PTEN PDZ binding motif can bind SNX27 via its PDZ domain and 
sequester it (Shinde and Madikka, 2017), and SNX27 PDZ domain interacts with PS1, its 






examine whether the SNX27 sequestration by PTEN seen by Shinde and Maddika (2017) 
can disrupt the role of SNX27 in limiting stability of PS1, which could enhance Aβ generation 
(Wang et al. 2014). As PTEN-3KR was less able to bind SNX27, its possible that 
SUMOylation and/or ubiquitination could play a role in this. 
The finding that PTEN-3KR bound SNX27 less than WT, may have implications for various 
neuronal receptors trafficked by SNX27 such as NRC2, given that PTEN can sequester 
SNX27 and block forward trafficking of other cell surface proteins such as GluT1 (Cai et al. 
2011; Shinde and Maddika, 2017). Conducting surface biotinylation experiments to measure 
surface NRC2 in PTEN KD and overexpression conditions may provide more mechanistic 
insight into how PTEN phosphatase activity plays a critical role in NMDAR-mediated 
plasticity (Jurado et al. 2010). More work is also needed to establish whether PTEN can 
sequester SNX27 in neurons and block retromer formation (Shinde and Maddika et al. 2017), 
and if differential binding between WT and PTEN-3KR exists in neurons and influences 
trafficking. 
 
7.2.7 PTEN and Retromer - GluT1 and ASCT2 Trafficking 
 
Due to previous work showing that PTEN can bind SNX27 and limit forward GluT1 trafficking, 
I explored the role of PTEN SUMOylation in this by testing PTEN-3KR alongside PTEN-WT 
and PTEN KD conditions in surface biotinylation assays. Unexpectedly, PTEN-3KR, which 
bound SNX27 less than WT, also significantly reduced GluT1 on the surface, while WT and 
KD had no significant effect. Thus, since only PTEN-3KR had an effect, it seems that PTEN- 
3KR had a gain of function in reducing surface GluT1. 
I do not currently have a clear explanation for why PTEN-3KR would limit GluT1 surface 
expression more than PTEN-WT, indeed this is even more surprising given the lack of 
activity of PTEN-3KR against P-Akt, and the observations that PI3K pathway inhibition can 
reduce surface GluT1, and Akt activation is associated with increased surface GluT1 
(Wieman, Wofford, and Rathmell 2007). To establish if the lack of P-Akt suppression from 
PTEN-3KR is relevant to its effect of surface GluT1, PTEN-3KR could be compared with a 
catalytically dead mutant. If this mutant also reduces surface GluT1, it is likely that the effect 
seen for PTEN-3KR is due to a lack of activity against P-Akt. This could be tested further with 
Akt inhibitors, or by PIP₃ synthesis inhibition using a PI3K inhibitor in PTEN-3KR and WT 
conditions, to examine whether it is an increase of PIP₃ or Akt activation that is causing the 
effect. The experiment could also be repeated with the addition of SENP and a DUB, in order 
to remove the additional SUMO/ ubiquitin from PTEN and examine whether this is influencing 






expression, suggesting PTEN-3KR does not influence all retromer cargos in HeLa cells 
(Scalise et al. 2018). 
 
7.2.8 PTEN and GluA2 Trafficking – PIP₃ and AMPAR Regulation 
 
While the initial finding that PTEN KD reduces surface expression of GluA2 in neurons was 
not robust, taken with the finding that PTEN over expression increases surface GluA2, these 
experiments suggests that PTEN can positively regulate surface GluA2 levels. This was 
slightly unexpected given that PTEN inhibition has been linked to increased surface AMPAR 
expression (Liu et al. 2013; Moult et al. 2010), although GluA2 levels after PTEN KD have 
not previously been examined. 
Despite a lack of clear link between PTEN and GluA2 surface levels and the fact that 
knowledge of PTEN function in neurons in limited, a possible explanation for PTEN’s role in 
GluA2 trafficking is though PIP₃ regulation. Phosphoinositide dephosphorylation in regulation 
of the membrane plays an important role in AMPAR trafficking (Parkinson and Hanley 2018); 
Arendt et al. (2010) report that PIP₃ depletion causes reduction of AMPARs at the synaptic 
membrane, and depression of AMPAR-mediated transmission. Although these mechanisms 
are not well characterised, PIP₃ may regulate AMPAR clustering at the membrane through 
modulation of the PSD-95 synaptic complex, specifically by enabling PSD-95 accumulation in 
spines (Arendt et al. 2010; Elias et al. 2006; Bats et al. 2007). Therefore PTEN, through lipid 
phosphatase activity against PIP₃, may influence the ability of PSD-95 to anchor AMPARs at 
synapses, reducing their clustering at the membrane (Arendt et al. 2010; Maehama and 
Dixon, 1999; Bats et al. 2007). 
PIP₃ may also play a role in AMPAR phosphorylation; phosphorylation of GluA1 at S831 is 
driven by signalling through the Ras–Pi3K–Akt pathway, which facilitates GluA1 insertion into 
synapses (Qin et al. 2005). Qin et al. (2005) suggest that rather than phosphorylating GluA1 
directly, Akt activates calcium/calmodulin-dependent protein kinase 2 (CaMKII) which could 
phosphorylate GluA1 (Song and Huganir, 2002). This implicates the PI3K/Akt pathway in 
AMPAR trafficking; it’s possible that this pathway could be influenced by PTEN. Indeed, in 
hippocampal neurons, reducing PTEN levels enhances Akt phosphorylation (Ning et al. 
2004), so potentially PTEN could influence AMPAR insertion through counteracting PI3K 
signalling and reducing AMPAR phosphorylation, which could limit AMPAR insertion into 
synapses (Qin et al. 2005). 
Although PTEN-mediated PI3K/Akt downregulation would likely reduce GluA1 






work has shown PTEN isoform PTENα can dephosphorylate CaMKII at T305/306, facilitating 
its activation (Wang et al. 2017). CaMKII also is necessary for GluA2 release from the 
endoplasmic reticulum (ER), which influences GluA2 synaptic delivery and surface 
expression (Lu, Khatri, and Ziff 2014). PTENα KO mice display CaMKII-mediated LTP and 
spatial learning deficits (Lu, Khatri, and Ziff 2014). CaMKII can also phosphorylate Stargazin, 
stabilizing it and enabling its binding to PSD-95, which can trap AMPARs at the synapse 
(Bats, Groc, and Choquet 2007; Opazo et al. 2010). 
With this in mind, it is possible that the increase in surface GluA2 levels seen under PTEN 
overexpression conditions is due to increased CaMKII activation, which could enhance 
GluA2 ER release and forward trafficking. Imaging of GluA2 with an ER marker under PTEN 
KD and overexpression conditions would reveal whether PTEN is able to regulate GluA2 ER 
release. If this was blocked by KD/inhibition of CaMKII, this would suggest PTEN is 
increasing forward trafficking of GluA2 via enhancing CaMKII activation (Lu et al. 2014). 
Future experiments could also involve examining the phosphorylation status of GluA1 and 
GluA2 in PTEN KD and overexpression conditions, to establish whether PTEN can regulate 
phosphorylation-mediated AMPAR insertion (Qin et al. 2005). It has not been reported that 
PTEN can directly dephosphorylate AMPARs, although it is also possible that PTEN may 
influence AMPAR phosphorylation indirectly for example via the Ras–Pi3K–Akt pathway (Qin 
et al. 2005). 
Similar to what has been presented here for AMPARs, PTEN levels have a positive effect on 
NMDAR surface expression (Ning et al. 2004). PTEN KD decreases NMDAR surface 
expression and currents, which is attributed to loss of PTEN phosphatase activity (Ning et al. 
2004). Surface NR1 levels were increased in G129E mutant PTEN (lipid-phosphatase 
inactive) expressing neurons, but reduced in neurons expressing C124A mutant (lipid and 
protein-phosphatase inactive) (Ning et al. 2004; Myers et al. 1998; Weng et al. 2001), 
suggesting both lipid and protein phosphatase activities of PTEN (outlined in 1.2.2 and 1.2.3) 
can have different effects of surface NMDAR expression. It also suggests that 
downregulation of PTEN protein phosphatase activity can reduce surface levels of NMDARs 
(Ning et al. 2004). The mechanism by which surface NMDARs are regulated by PTEN 
protein phosphatase activity is not clear, but it would be useful to examine whether the effect 
of increased surface AMPARs under PTEN overexpression conditions is also related to 
PTEN protein phosphatase activity. PTEN can associate with NMDARs, but it has not been 






Comparing PTEN-WT with a phospho-inactive mutant in future experiments may elucidate 
whether the phosphatase activity of PTEN is involved in surface GluA2 regulation. It would 
be useful to compare G129E mutant PTEN (lipid-phosphatase inactive) and C124A mutant 
(lipid and protein-phosphatase inactive) (Myers et al. 1998; Weng et al. 2001), to examine 
which aspect of phosphatase activity may influence AMPARs. 
 
7.2.9 PTEN and GluA2 Trafficking – PHLDB2 
 
Pleckstrin Homology Like Domain Family B Member 2 (PHLDB2), has a PIP₃-sensing 
Pleckstrin Homology (PH) domain, and can also interact with GluA1, GluA2 and PSD-95 
(Levi et al. 1993; Xie et al. 2019). Recently it has been shown that PHLDB2, through sensing 
PIP₃, can regulate plasticity and AMPAR and NMDAR localisation (Xie et al. 2019). PHLDB2 
localises in spines in neurons, and is highly sensitive to PIP₃ which plays a fundamental role 
in its localisation (Xie et al. 2019). Its localisation is also influence by Brain Derived 
Neurotrophic Factor (BDNF), which causes PHLDB2 translocation to spines (Xie et al. 2019). 
BDNF is an important regulator of LTP, by activating Tropomyosin Receptor Kinase B (Trkb); 
Trkb signalling can regulate spine growth and activity-Dependent remodelling (Xie et al. 
2019; Korte et al. 1995; Lai et al. 2012; De Vincenti et al. 2019). 
 
PHLDB2 interacts with and regulates PSD-95 turnover and localisation, and is critical in LTP. 
GluA2 was reduced at the plasma membrane in hippocampal neurons from PHLDB2 KO 
mice, shown in imaging experiments. Expression of GFP- PHLDB2 significantly restored this 
deficit. Rescue with a PHLDB2 mutant lacking the PH domain was not able to rescue plasma 
membrane GluA2, suggesting PHLDB2-PIP₃ interactions are important in regulating surface 
GluA2 (Xie et al. 2019). Furthermore, LY294002 treatment, used to inhibit PIP₃ synthesis, 
decreased GluA2 at the membrane in WT, but not PHLDB2 KO mice. It was suggested that 
PHLDB2 regulates AMPAR surface expression downstream of PIP₃ signalling (Xie et al. 
2019). In addition, NR1 was also reduced in PHLDB2 KO mice, which also exhibited a lack of 
CA1 LTP and deficits in reference memory. Xie et al. (2019) postulate that through PIP₃ 
sensing, PHLDB2 helps PSD-95 to accumulate in spine heads, which regulates NMDAR 
trafficking to the synapse, and stabilises NMDARs at the membrane. It was concluded that 
PHLDB2 is indispensable in plasticity, through its ability to sense membrane 
phosphoinositides (Xie et al. 2019). Considering this study, PTEN-mediated changes in PIP₃ 
levels could influence localisation of PHLDB2, which could have downstream effects on 
surface AMPARs and NMDARs. To test this, PHLDB2 could be imaged in neurons in PTEN 
KD and WT overexpression conditions to establish whether its localisation changes. The 






LY294002 as used by Xie et al. (2019). PHLDB2 could then be knocked out; if this ablates 
the effect of PTEN KD and WT overexpression, this would suggest a PTEN-mediated role of 
PHLDB2 in regulating surface GluA2 expression, and that PTEN may be influencing 
PHLDB2 localisation via regulation of PIP₃ levels. 
 
7.2.10 PTEN and GluA2 Trafficking – SNX27 
 
SNX27 is involved in trafficking of various neuronal cell-surface proteins including AMPARs, 
NMDARs, Neuroligin-2 and Transferrin receptor (Temkin et al. 2011; Cai et al. 2011; Halff et 
al. 2019; Hussain et al. 2014; Wang et al. 2013). In neurons, SNX27 is also localised to 
spines and the postsynapse (Loo et al. 2014). SNX27 overexpression can upregulate surface 
GluA1, GluA2 and NMDAR subunit NR1, and SNX27 KD has the opposite effect (Wang et al. 
2013). SNX27 overexpression can also increase AMPAR exocytosis during LTP, and SNX27 
KD can reduce surface AMPAR delivery, blocking LTP in mouse hippocampal slices (Loo et 
al. 2014). Although SNX27 is generally associated with endosome to membrane trafficking of 
membrane proteins (Shinde and Maddika, 2017; Hussain et al. 2014), KD of SNX27 has also 
been shown to increase surface levels of over 20 other cell surface proteins including 
Sodium- and Chloride-Dependent Creatine Transporter 1 and Ephrin B1 (Steinberg et al. 
2013). It is not clear exactly how SNX27 has this effect, but it has been found to regulate 
membrane endocytosis of NMDAR subunit NR2C (Cai et al. 2011). SNX27 physically 
interacts with NRC2 via its PDZ domain and cortical neurons from SNX27 knockout mice 
have increased surface NRC2 levels shown in imaging experiments, indicating reduced 
NRC2 endocytosis (Cai et al. 2011). SNX27 is also reported to facilitate Multidrug 
Resistance-associated Protein 4 (MRP4) endocytosis, negatively regulating its availability at 
the surface (Hayashi et al. 2012). It is thought that PDZ-interactions with MRP4 near the 
plasma membrane facilitate this process (Hayashi et al. 2012). SNX27 therefore has a role in 
endocytosis, which may be separate to its role in endosomal sorting and recycling (Burd and 
Cullen 2014; Cai et al. 2011; Hayashi et al. 2012; Shinde and Maddika 2017). 
Considering these studies, it is possible that in neurons, PTEN has influence over the role of 
SNX27 in reducing GluA2 endocytosis at the membrane. A role for SNX27 in AMPAR 
endocytosis has not yet been shown, but SNX27 is reported to regulate AMPAR exocytosis 
(Wang et al. 2013; Hussain et al. 2014). SNX27 levels did not change significantly under 
PTEN KD, WT KD-rescue or PTEN-3KR KD-rescue conditions in neurons, suggesting that 
PTEN is not having the same influence on SNX27 in neurons as in HeLa cells (Figures 6.3.4. 
and 6.3.3.), and suggesting PTEN is not upregulating surface GluA2 through increasing 






synapse or endosomes and reduce its ability to endocytose AMPARs via three potential 
mechanisms. Firstly, PTEN may influence SNX27 localisation and trafficking through 
modulation of PIP₃ levels, as PIP₃ can bind SNX27 at both at its Phox Homology (PX) 
domain and Four point one, Ezrin, Radixin, Moesin (FERM) domain, this can influence its 
localisation to early endosomes (Cullen 2008; Ghai et al. 2013; Ghai et al. 2015; Cai et al. 
2011). SNX27 can is also enriched in spines and at the post-synapse (Loo et al. 2014). The 
likely decreased PIP₃ levels under PTEN overexpression conditions could therefore influence 
SNX27 localisation at the post synapse or/ and endosomes and reduce its ability to 
endocytose receptors, given that PIP₃ levels are involved in SNX27 targeting to dendrites, 
the synapse and endosomes (Cullen, 2008; Loo et al. 2014; Hussain et al. 2014; Cai et al. 
2011; Ghai et al. 2015). It is not yet known whether the localisation of SNX27 at the post 
synapse is relevant to its ability to endocytose NRC2, but this would be interesting to test via 
imaging experiments (Cai et al. 2011; Loo et al. 2014). 
Secondly, sequestration of SNX27 by PTEN could block direct interactions with AMPARs 
(Shinde and Maddika, 2017; Hussain et al. 2014). The PDZ ligands of NRC2 and MRP4 can 
bind SNX27 and this is suggested to underpin SNX27-mediated NRC2 and MRP4 
endocytosis (Hayashi et al. 2012; Cai et al. 2011). It is possible that a similar mechanism 
could exist with AMPARs, which are also reported to bind the SNX27 PDZ domain (Hussain 
et al. 2014; Loo et al. 2014). SNX27 can also bind PTEN through its PDZ ligand, so PTEN 
could potentially block SNX27 binding with PDZ-containing proteins such as AMPARs, in the 
same way as it can block SNX27-VPS26 binding, which could compromise endocytosis/ 
trafficking of receptors (Hussain, et al. 2014; Shinde and Maddika, 2017). PTEN 
sequestration of SNX27 may also perturb its ability to bind the adaptor protein Leucine Rich 
Repeat and Fibronectin Type III Domain Containing 2 (LRFN2), which also associates with 
the SNX27 PDZ domain and can traffic AMPARs (McMillan et al. 2020). 
Lastly, SNX27 sequestration can block retromer formation, a process known to influence cell- 
surface protein trafficking (Shinde and Maddika, 2017). Enhanced levels of PTEN could 
therefore reduce the ability of SNX27 to endocytose AMPARs, through blocking retromer 
formation, rather than through blocking direct SNX27-AMPAR interactions (Figure 7.2.2.1). It 
may be that PTEN is blocking SNX27-VPS26 association, and this reduces AMPAR 
endocytosis. The increase in VPS26 seen under PTEN overexpression conditions (Figure 
6.3.3.) could be an attempt by the cell to compensate for this. Of note, VPS26 interaction 








Figure 7.2.10.1. PTEN may influence SNX27-mediated AMPAR endocytosis via 
modulation of PIP₃ levels. 
PTEN negatively regulates PIP₃ levels (Maehama and Dixon 1998). SNX27 is enriched at 
the postsynapse and early endosomes, however, changes in PTEN-mediated PIP₃ levels 
may alter the distribution of SNX27, due to the role of PIP₃ binding in its localisation (Cai et 
al. 2011; Wang et al. 2013; Loo et al. 2014). The likely PIP₃ level increase during PTEN KD 
could reroute SNX27 away from early endosomes, possibly reducing its ability to endocytose 
AMPARs. This is according to work showing that MRP4 and NRC2 endocytosis are 
regulated by SNX27 (Hayashi et al. 2012; Cai et al. 2011). This schematic is adapted from 










Figure 7.2.10.2. PTEN may influence SNX27-mediated AMPAR endocytosis via SNX27 
sequestration. 
Potentially enhanced SNX27 sequestration by PTEN in overexpression conditions may limit 
the availability of SNX27 at endosomes and the post-synapse (Ghai, 2015; Loo, et al. 2014; 
Shinde and Maddika, 2017). SNX27 depletion at these areas could reduce the ability of 
SNX27 to endocytose AMPARs, considering that SNX27 can endocytose NRC2 and MRP4 
(Hayashi et al. 2012; Cai et al. 2011). This could occur via sequestration of the PDZ domain 
of SNX27 blocking direct SNX27- AMPAR interactions, or block interactions with adapter 
protein LRFN2, processes both involved in AMPAR trafficking (Loo et al. 2014; Hussain et al. 
2014; McMillan et al. 2020). Alternatively, PTEN sequestration of SNX27 may block the 
ability of SNX27 to associate with VPS26, which may also disrupt trafficking of AMPARs due 
to evidence of the involvement of retromer in AMPAR trafficking (Shinde and Maddika, 2017; 
Temkin et al. 2017). During PTEN KD, there may be less SNX27 sequestration, and 
therefore more SNX27 available to endocytose AMPARs, leading to enhanced AMPAR 
endocytosis. Adapted from Sansal an Sellers (2004) and Shinde and Maddika (2017) and 
created in Biorender.com with premade shapes. 
 
 
Knocking down SNX27 and repeating PTEN KD/ overexpression surface biotinylations 
experiments to see if this changes the effect on GluA2 levels would confirm a role of SNX27. 
Comparing co-localisation of SNX27 with PIP₃ and synaptic and endosomal markers 
between PTEN conditions would then begin to elucidate whether PTEN effects synaptic or 
endosomal SNX27 localisation. It would also be useful to immunoprecipitate PTEN in 
neurons and blot for SNX27, to see if these associate in neurons as they do in cell lines 
(Shinde and Maddika, 2017). Comparing surface GluA2 levels between WT and phospho- 
dead PTEN conditions, using LY294002 to inhibit PI3K and block PIP₃ synthesis (Qin et al. 






regulation of surface GluA2. It would also be interesting to see if PTEN can influence VPS26 
or LRFN2 levels or activity in neurons and if this is relevant to GluA2 trafficking. This could 
be done by blotting and imaging of these proteins after expression of PTEN-WT or KD 
lentiviral constructs in neurons, to see if their expression or localisation changes. 
Additionally, VPS26 or LRFN2 could then be knocked down concomitantly with PTEN 
overexpression to see if this ablates the effect of PTEN on surface GluA2 levels. 
The lack of difference between WT and PTEN-3KR on surface GluA2 suggests that 
enhanced SUMOylation is not involved in PTEN-mediated GluA2 regulation. However, it is 
noted that both constructs were greatly overexpressed, which could negate differences 
between conditions. Ideally, this experiment should be repeated at endogenous expression 
levels. Although PTEN-3KR had reduce activity against P-Akt compared to PTEN-WT, vast 
overexpression of both constructs may negate potential differences between them. 
In summary, there are a variety of ways through which PTEN could regulate GluA2 
trafficking, but PIP₃-sensing proteins such as PHLDB2 or SNX27 may be involved (Cai et al. 
2011; Xie et al. 2019; Shinde and Maddika, 2017). Establishing whether PTEN phosphatase 
activity is involved will elucidate whether this mechanism is via PIP₃, or another mechanism 
such as sequestration through direct interactions (Shinde and Maddika, 2017). Taking these 
studies into account, there are a variety of routes by which PTEN, through modulation of 
PIP₃ levels, could influence AMPAR surface expression. PIP₃ plays an important role in 
NMDAR surface expression in LTP, and even under basal conditions can regulate surface 
AMPARs (Xie et al. 2019; Arendt et al. 2010). It also has the ability to regulate localisation of 
proteins involved in glutamate receptor trafficking including SNX27 and PHLDB2 (Xie et al. 






In this thesis, I have examined aspects of PTEN function relevant to AD including Akt 
pathway regulation, AMPAR trafficking and retromer regulation and trafficking (Kwak et al. 
2010; Rickle et al. 2004; Chang et al. 2006; Vagnozzi and Pratico 2019; Tian et al. 2015; 
Mecozzi et al. 2014; Bhalla et al. 2012). In addition, I have examined the involvement of 
SUMOylation and ubiquitination in these processes by characterising the novel PTEN-3KR 
mutant. PTEN-3KR is surprisingly is more SUMOylated and ubiquitinated than PTEN-WT by 
endogenous SUMO2/3 and ubiquitin. This has highlighted the importance of testing 






and Vertegaal (2015), as this method is less susceptible to confounding issues resulting from 
overexpression or tags. The work in this thesis has also given insight into how enhanced 
SUMOylation and ubiquitination might regulate PTEN function in terms of dimerization and 
ability to regulate the Akt pathway, although more work is needed to confirm the involvement 
of SUMO or ubiquitin. 
Experiments in this thesis have revealed a role for PTEN in positively regulating surface 
GluA2 levels in neurons; surface GluA2 after PTEN KD has not previously been examined. 
This is contrast to Liu et al. (2013), who found PTEN inhibition increases surface GluA2 in 
hippocampal neurons. However, my experiments involved PTEN KD for 6/7 days, while Liu 
et al. (2013) inhibited PTEN for 2 hours. The differences in effect may also be explained 
through the ability of PTEN to regulate PIP₃ levels at the membrane. Mechanistically, PTEN 
could influence PIP₃-sensing proteins involved in AMPAR trafficking such as SNX27 or 
PHLDB2 (Cai et al. 2011; Xie et al. 2019). Additionally, modulation of PIP₃ levels may 
influence AMPARs through regulation of PSD-95, which can stabilise AMPARs at the 
synapse (Arendt et al. 2010; Bats et al. 2007). Both WT and PTEN-3KR upregulate surface 
GluA2 levels, but only PTEN-3KR can downregulate surface GluT1, suggesting that these 
cell surface proteins are not regulated by PTEN via the same mechanism. As PTEN levels 
enhanced surface GluA2, GluA2 is not affected by SNX27 sequestration through PTEN in 
the same way as GluT1 (Shinde and Maddika, 2017). This could mean that either PTEN 
does not sequester SNX27 in neurons, or that potential sequestration could influence 
endocytosis rather than forward trafficking. PTEN-3KR did not have significantly different 
effects to PTEN-WT in GluA2 surface expression; while this may be due to the high level of 
overexpression of the PTEN constructs masking any subtle effects, this suggests enhanced 
SUMOylation of PTEN does not influence surface GluA2 levels. 
In summary, PTEN-3KR did have a differential role to WT in various aspects of cellular 
regulation relevant to cell surface protein trafficking including modulation of retromer 
component levels in HeLa cells, binding to SNX27, Akt pathway regulation, and surface 
GluT1 expression (Shinde and Maddika, 2017; Steinberg et al. 2013; Morani et al. 2014). 
While more research is needed to confirm the involvement of PTEN SUMO in effects of 
PTEN-3KR, this work is suggestive of a role for enhanced SUMOylation in influencing these 
processes. The addition of SENP1 in repeats of my experiments, either through recombinant 
expression in cells or treatment with the purified protein, would help elucidate this further. If 
the SENP1 treatment had no effect on the outcomes of the experiment(s), this would suggest 
that it is not enhanced SUMOylation that changes the activity of PTEN-3KR, and 






its effect. This could include the addition of a DUB to examine the involvement of 
ubiquitination. 
Nonetheless, the data presented here provide further insight into the regulation of PTEN by 
SUMOylation and ubiquitination, and highlight new roles for PTEN in protein trafficking in 
both cell lines and neurons. Building on these findings, further work will now be required to 
elucidate the mechanisms by which PTEN mediates glutamate receptor trafficking in 
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